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Summary 
Malignant melanoma remains the most deadly form of skin cancer due to its quick metastatic 
spread and the development of resistance to available treatment. The cause of melanoma is 
still under investigation but environmental factors, such as ultraviolet radiation, have been 
associated with the initiation of melanoma. Moreover, studies have revealed that the 
melanocytic lineage is predisposed to malignant transformation due to its developmental 
program. Melanocytes are derived from the embryonic neural crest, which utilizes processes 
such as the epithelial-to-mesenchymal transition (EMT) during their normal development to 
spatially migrate and complete terminal differentiation. Therefore, recent work in the field of 
melanoma has focused on investigating embryonic and neural crest-related genes since they 
may be reactivated during melanomagenesis and metastatic spread.  
To date, limited studies have suggested an important role of the embryonic stem cell marker, 
sex determining region Y-box 2 (SOX2), in melanoma; however a lack of detailed analyses 
and understanding of its function remains. In this study, SOX2 was found to be highly 
expressed in primary melanomas compared to melanocytic nevi. Additionally, using 
fluorescence in situ hybridization analysis, genomic SOX2 was found to be significantly 
amplified in both primary melanomas and metastatic melanomas compared to melanocytic 
nevi. Gain-of-function studies revealed that melanoma cells lost differentiation marker 
expression upon SOX2 overexpression in vitro. The dedifferentiated phenotype displayed 
can be in part explained by SOX2 binding to the promoter region of the microphthalmia-
associated transcription factor-M (MITF-M), thereby repressing its transcription. Additionally, 
SOX2 was shown to be required for melanoma cell migration and invasion in vitro. Invasion-
related EMT markers were upmodulated upon SOX2 overexpression and 
immunohistochemical analysis revealed high SOX2 expression in deep regions of primary 
melanomas and in stroma-infiltrating melanoma cells. In vitro enhanced SOX2 expression 
could be induced by TGF-β, indicating TGF-β signaling as an upstream regulator of SOX2 
expression in melanoma. 
This study proposes that TGF-β1 induces SOX2 expression, which may lead to melanoma 
progression by: i) SOX2 binding and repressing the MITF-M promoter, which may influence 
the dedifferentiation of human melanoma cells, and ii) SOX2 inducing high expression of 
ZEB1 and TWIST1, which promotes a mesenchymal phenotype. In line with the described 
phenotypic alterations, this work revealed that SOX2 enhances melanoma cell migration and 
invasion and depletion of this transcription factor results in loss of cellular motility. Therefore, 
I identified SOX2 as a key player in the complex molecular network that governs invasion-
related processes and I revealed a role for SOX2 as an invasion-related marker with 
potential clinical application.  
Zusammenfassung 
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Zusammenfassung 
Aufgrund der starken Metastasierung und der Entwicklung von Resistenzen gegen gängige 
Therapien ist das maligne Melanom eine der tödlichsten Hautkrebsarten. Obwohl 
Umwelteinflüsse wie Exposition durch ultraviolettes Licht mit der Entstehung des malignen 
Melanoms in Zusammenhang gebracht worden sind, ist die Ursache bisher nicht vollständig 
geklärt. Studien haben jedoch gezeigt, dass die Zellen der melanozytären Linie aufgrund 
ihres molekularen Entwicklungsprogramms besonders anfällig für eine maligne 
Transformation sind. Melanozyten entstehen aus den embryonalen Neuralleisten-Zellen, die 
während ihrer normalen Entwicklung einen sogenannten epithelial-mesenchymalen Wechsel 
durchlaufen. Basierend auf dieser Entdeckung haben sich mehrere Studien der letzten Jahre 
auf die Untersuchung verschiedener embryonaler und neuralleisten-assoziierter Gene 
spezialisiert, da diese womöglich während der malignen Transformation reaktiviert werden 
und dadurch zur Entstehung und zur Metastasierung des Melanoms beitragen können. 
Einige Studien haben in diesem Kontext dem Gen SOX2 (sex determining region Y-box 2) 
eine wichtige Rolle zugewiesen, es fehlen jedoch detaillierte Analysen, um dessen genaue 
Funktion bestimmen zu können. Die vorliegende Studie zeigt, dass SOX2 in primären 
Melanomen stärker exprimiert wird als in melanozytären Nävi. Zusätzlich wurde eine 
genomische Amplifikation von SOX2 sowohl in primären Melanomen als auch in Melanom-
Metastasen im Vergleich zu melanozytären Nävi festgestellt. Anhand humaner 
Melanomzelllinien wurde gezeigt, dass die Expression mehrerer Differenzierungsmarker 
verloren geht, wenn SOX2 überexprimiert wird. Dieser Phänotyp war zum Teil durch die 
Bindung von SOX2 an die Promoterregion des Mikrophthalmia-assoziierten 
Transkriptionsfaktors M (MITF-M) und der Repression dessen Transkription zu erklären. Des 
Weiteren wurde gezeigt, dass die Expression von SOX2 für die Invasionsfähigkeit der 
Melanomzellen in vitro erforderlich ist. Einige Marker für den epithelial-mesenchymalen 
Wechsel waren hochreguliert, wenn SOX2 überexprimiert wurde und eine 
immunhistochemische Analyse hat ergeben, dass SOX2 in tiefen Regionen primärer 
Melanome und in Stroma-infiltrierenden Zellen stärker exprimiert ist als in oberflächlichen 
Regionen primärer Melanome. Erhöhte SOX2 Expression konnte in vitro durch die 
Stimulierung humaner Melanomzelllinien mit TGF-β1 induziert werden, was darauf hinweist, 
dass sich TGF-β1-aktivierte Signalwege regulatorisch auf die SOX2 Expression im malignen 
Melanom auswirken. 
Zusammengefasst deuten die Ergebnisse der vorliegenden Studie darauf hin, dass TGF-β 
die Expression von SOX2 induziert und dass dies durch folgende Mechanismen zur 
Melanomentwicklung beitragen kann: erstens, indem SOX2 an den MITF-M Promoter bindet 
und dessen Transkription inhibiert, sodass es zu einer generellen De-Differenzierung der 
Zusammenfassung 
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Melanomzellen kommt, und zweitens, indem die Überexpression von SOX2 zu einer 
Hochregulierung der Expression von ZEB1 und TWIST1 führt, was zu einem 
mesenchymalen Phänotyp führt. In Einklang mit den phänotypischen Veränderungen bei 
starker SOX2 Expression, ist dieser Transkriptionsfaktor auch funktionell für erhöhte 
Invasionskapazität notwendig und seine Repression führt zu Motilitätsverlust in humanen 
Melanomzellen. 
Ich konnte daher in dieser Studie SOX2 als einen Schlüsselfaktor identifizieren, welcher in 
einem hoch komplexen Netzwerk für die aggressive Entwicklung des malignen Melanoms 
verantwortlich ist. Außerdem weist SOX2 Potential auf, um als invasionsassoziierter Marker 
in der klinischen Anwendung genutzt zu werden.  
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1 Introduction 
Development is a complex process orchestrated by the temporal and spatial control of 
specific genes. Unique to vertebrates, the development of the neural crest (NC) gives rise to 
various lineages including melanocytes. First discovered in 1868 by Wilhelm His, the neural 
crest was described as a band of cells in between the neural tube and ectoderm in chick 
embryos [1, 2]. Nearly two centuries later, the neural crest is a well-described cell population 
which undergoes a complex developmental process comprised of several key steps: 
induction, delamination and migration. Recently, some of these processes have been 
implicated in the pathogenesis of the deadly skin cancer: melanoma. Since melanocytes are 
derived from the neural crest, one hypothesis for malignant transformation suggests the 
reactivation of this developmental process. Therefore, understanding the neural crest and 
other embryonic-related systems and molecules coordinating them may help elucidate novel 
mechanisms controlling the transformation of malignant melanoma. 
1.1 The neural crest 
In a normal developing embryo, characteristic patterning of the nervous system and exterior 
structures requires the motility of the pluripotent population of cells known as the NC. Neural 
crest cells (NCCs) are formed along the vertebrate axis in the dorsal neural tube. These 
pluripotent cells give rise to various lineages, including bone, neurons and melanocytes. 
Here, I will only discuss the development of the trunk NC, where melanocytes are derived. 
1.1.1 Induction, delamination and migration of the neural crest 
The cells that form the NC are induced between the neural plate, which later develops into 
the central nervous system (CNS) and the non-neural ectoderm that builds the epidermis. 
The formation of the NC begins post-gastrulation, when the neural plate folds on itself to form 
the neural tube, the process where the neural folds from opposite ends of the ectoderm 
converge and eventually fuse (Figure 1a-c). Following fusion, NCCs leave the neural tube 
during or after neural tube closure, depending on the species, and migrate throughout the 
body [3]. The NCCs develop as the neural tube closes on day eight of gestation in mice and 
day 22 in humans [4]. From the dorsal neural tube, NCCs migrate into the surrounding 
tissue. This process gives rise to various tissue types, including bone and cartilage, 
pigmented cells, neurons and glial cells of the peripheral nervous system. NCC derivatives 
are specified via spatial and temporal patterning, migration patterns, lineage-specific markers 
and inherent cell characteristics [4, 5]; for an overview of NC developmental stages refer to 
Figure 1. 
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There are several models for the induction of the neural crest, namely neural default model, 
variation of the neural default model and the two signal model of neural crest induction. The 
models differ in the potential fates of the neural plate, as well as in the nature of inductive 
signals and neural crest specifiers leading to the induction of neural crest effector genes. The 
two signal model is the most accepted model and elucidates combinations of signaling that 
are capable of inducing the NC. Several second signals have been identified (wingless type 
(WNT), fibroblast growth factor (FGF) and/or retinoic acid) and, in combination with bone 
morphogenetic protein (BMP) inhibitors, are able to induce snail family zinc finger 2 (SNAI2 
or SLUG) expression and, in turn, NC induction [3, 6–8]. The induction of the NC potential is 
assayed by SNAI2 expression, a factor responsible for final emigration of NCCs. Many of the 
factors that are able to induce NC formation are found to be endogenously expressed in 
neighboring tissues at the appropriate stages during NC development. For example, the 
paraxial mesoderm, located adjacent to the neural tube, expresses the candidate induction 
signals eFGF, WNT8 and BMP4. Studies in vivo demonstrated, upon excision of the paraxial 
mesoderm from Xenopus embryos, SNAI2 expression was greatly reduced. The study 
proposed that the paraxial mesoderm and its corresponding signals are a possible 
requirement for NC induction [9, 10]. Additional NC-inducing signals may come from 
interactions between the epithelium and the neural plate [3]. Moreover, there are other 
potential signals that are able to induce the NC besides BMP and WNT, such as Notch/Delta 
signaling [11]. 
After the induction of the NC and formation of the neural tube, NC potential is maintained via 
BMP signaling [3, 12]. The next process to occur during NC development is delamination. 
Delamination is defined as the splitting of a tissue into separate populations, regardless of 
cellular mechanisms [13] (Figure 1d). Regarding the NC delamination, this process is 
triggered by BMP and canonical WNT signaling, accompanied by the expression of WNT1 
and WNT3 and paired box transcription factor (PAX3), BMP4 and Msh homeobox 1 (MSX-1) 
[13–15]. The BMP and WNT signaling cascades are crucial for the G1/S cell cycle transition 
in NC precursor cells, since NCCs are only capable of delamination in the S-phase. 
However, this prerequisite is not sufficient to initiate delamination or trigger onset of migration 
[13]. 
Additionally, the activation of the BMP/WNT1 signaling cascade activates downstream 
mediators like a disintegrin and metalloproteinase (ADAM)-10. ADAM10 is able to cleave the 
extracellular domain of N-cadherin (CDH2). Therefore, the expression of ADAM10 helps to 
reduce cell-cell adhesion not only between NCCs but also between NCCs and 
neuroepithelial cells [13]. N-cadherin is then degraded or the remaining domain is further 
cleaved into a cytoplasmic fragment (CTF2) and activates CCND1 (Cyclin-D1). While 
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CCND1 promotes cell cycle progression, it does not systematically promote the G1/S 
transition in the neural tube [16]. 
The control of cadherins during delamination is conserved across species and between NCC 
populations at different axial levels. Typically, NCCs switch from strong cadherin-based cell-
cell adhesion (N-cadherin) to a weaker type of cell-cell adhesions based on type II cadherins 
(Cadherin-6/6B/7/11) [13]. This process ensures the next stage in NC development: 
migration. Migration of individual NCCs occurs out of the neuroepithelium and into an area 
termed the migration staging area (MSA), located dorsally to the neural tube and underneath 
the ectoderm. At this stage, the premigratory NCCs are multipotent and begin to express 
SRY box-containing transcription factor 10 (SOX10) and SOX9 [4, 17, 18]. Studies have 
illustrated this by tracking the fate of individual cells and the rise of multiple lineages by 
injecting dye into the cells [19]. 
As migration occurs, the pattern of events involved in the epithelial-to-mesenchymal 
transition (EMT) differs among cells, but confers migration ability (Figure 1e). There are 
three major stages in the EMT process, which include the loss of cell polarity, changes in cell 
adhesions and increase in protease activity [20]. It is important to mention that the terms 
delamination and EMT are often interchangeably used in the NC field. However, it is 
essential to acknowledge that, while all NCCs must undergo EMT during development, the 
timing and completion of the EMT does not always correspond to the delamination phase. 
Here, I have separated the topics, but they can occur simultaneously or asynchronous from 
each other [13]. 
The first step in the EMT process is the loss of polarity or the switch from tight junctions to 
gap junctions between cells [20, 21]. The substitution of tight junctions with gap junctions 
during the first stage of the EMT process influences cell-cell interactions. The next stage, a 
key element in cell interactions during the EMT process, is cadherin-dependent cellular 
adhesion [20]. Changes in cadherins are essential, indicating the EMT process, and share an 
overlapping mechanism with the delamination process. As previously discussed, the shift 
from classical type I cadherins to type II cadherins strongly correlates to the gain of cellular 
motility [20, 22]. The major regulators of the cadherin switch are the members of the SNAIL 
gene family: SNAI1 (SNAIL) and SNAI2 (SLUG). Both were found to be expressed in the NC 
and are required for specification and migration of the NCCs [20, 23–25]. Gain and loss of 
function studies in chick embryos found that SNAI2 is an essential regulator of the EMT in 
the NC [26, 27]. 
The cadherin switch plays a key role in EMT progression in the NC but there are many 
migratory cells in which this step is not obligatory. However, a required and necessary step 
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for all cells to complete the EMT process is the ability to digest extracellular matrix (ECM). 
This enzymatic activity is carried out by proteins called matrix metalloproteases (MMPs). In 
the NC, MMPs play an important role in the last stage of development, migration. 
Interestingly, SNAI1 has been suggested to induce MMP expression [7]. In summary, the 
final step in NC development involves the initiation and completion of the EMT. The cells of 
the NC must lose polarity, switch from tight junctions to gap junctions, lose cell-cell adhesion 
and gain protease activity. The combination of these functions completes the EMT process 
and allows the migration of the NC cell population (Figure 1). 
The migratory route of these NCCs form segregated streams that emerge adjacent to 
specific locations along the vertebrate axis [28–31]. NCCs arise along the dorsal neural tube 
and avoid migrating in certain areas adjacent to the neural tube [32–35]. These cells travel 
either ventrally, following a path between somites and the neural tube and becoming the 
peripheral nervous system and endocrine cells, or dorsal-laterally away from the neural tube, 
following a path between dermamyotome and the ectoderm and ultimately forming 
melanocytes [4]. 
There are several theories regarding melanocyte precursor migration. The traditional view is 
that lineage specification occurs during the early stage of development. Progenitors of neural 
derivatives migrate ventrally and melanocyte precursor cells enter the MSA, located close to 
the neural tube, before migrating on a dorsolateral pathway underneath the ectoderm [36]. 
However, evidence has suggested an alternative migratory pathway for melanocyte 
precursor cells. Studies have revealed that a small portion of melanocytes arises ventrally 
along the pathway containing neural precursors [37]. Studies performed in zebrafish, mouse 
and chick embryos found that melanocyte precursors are capable of migrating both 
dorsolaterally and ventrally [38, 39]. In chick embryo studies, if the dorsal neural tube and the 
dorsal root ganglion (DRG) were ablated after the emergence of the initial melanocytes, the 
number of melanocytes in the skin was significantly reduced. However, if the dorsolateral 
skin surface containing the first melanocytes was removed, the complete melanocyte 
production was hardly affected. This suggests that a large majority of melanocytes in the skin 
are actually derived from nerve-associated precursors instead of dorsolaterally migrating 
NCCs [36, 38, 39]. Studies performed in mouse embryos using the Cre/loxP system revealed 
that nerve cells are able to produce cells with melanocytic features in vivo. This in vivo 
mapping analysis showed that a large majority of dermal melanocytes found in the trunk and 
limbs appear to be derived from cells previously associated with nerves [36, 38]. Moreover, 
recent work has elucidated that there is a prenatal capacity to form pigmented cells through 
the generation of a glial/melanocyte progenitor cells [40, 41]. 
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It is important to note that NC development is highly regulated by the presence of 
environmental cues at all stages. Several thorough studies have investigated the importance 
of intrinsic and local extrinsic signals from the microenvironment in the NC. These studies 
used tissue transplantation, cellular labeling and molecular analysis to show that the 
migratory streams of NCC are defined by a combination of intrinsic and extrinsic cues [42–
45]. In other words, there are several intrinsic and extrinsic modulators of NC development 
and early melanocyte fate determination. 
 
1.1.2 Melanoblasts and terminal differentiation of melanocytes 
Upon migrating away from the neural tube, some NCCs become specified into melanoblasts 
and continue migrating through the dermis and into the epidermis of the skin [4]. 
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Melanoblasts are the precursors of melanocytes and are highly migratory, proliferative and 
terminally differentiate en route to their final destination in the basal epidermis and hair 
follicles [46]. Melanoblasts are the descendants of the multipotent NCC population and there 
are two theories regarding when NCCs are specified into the melanocytic lineage [4]. 
The first theory states that melanocyte markers, such as microphthalmia-associated 
transcription factor (MITF) and the proto-oncogene KIT (also known as mast/stem cell growth 
factor receptor (SCFR) or CD117), are expressed during NC migration. The expression of 
dopachrome tautomerase (DCT), also known as tyrosinase-related protein 2 (TRP2), follows 
soon after [4]. This theory suggests that NCCs are predetermined to become melanocytes 
before they migrate along the dorsal-lateral pathway and the migratory path is therefore a 
consequence of these pre-specifications. 
The second theory acknowledges extrinsic factors in the environment which may influence 
the determination of the NCC population toward the melanocytic lineage. Therefore, 
migrating NCCs encounter factors which may have an overall impact on the terminal 
differentiation of the cells. To support this theory several studies found that expression of 
adhesion-related proteins, including extracellular matrix (ECM) proteins and cadherins, was 
reduced in melanoblasts upon migration initiation [8, 47–51]. The true mechanism may be a 
combination of both theories, where initiation of some melanocyte markers promotes initial 
migration and the additional expression of other genes, possibly externally induced, and 
further drives migration. 
There are several key players involved in melanoblast specification and securing the 
melanocytic lineage fate. MITF is regarded as key factor involved in melanocyte specification 
from NCCs [36]. The expression of MITF occurs shortly after NCCs emigrate from the neural 
tube and in the MSA. Fate mapping studies found melanoblast survival to depend on MITF 
expression [52]. Moreover, MITF is responsible for initiating transcription of important 
downstream targets, such as TRP2. However, MITF is not required for the migratory 
behavior of melanoblasts [53]. Therefore, MITF plays an important role in promoting cellular 
survival and development of melanoblasts. However, other factors are required in 
combination for complete specification [36]. 
SOX10 and PAX3 are two important genes in melanoblast specification and activators of 
MITF transcription. Studies reported that SOX10 and PAX3 synergistically activate the MITF 
promoter in vitro [54, 55]. Additional work investigated the specific role of both PAX3 and 
SOX10 independently from each other during early stages of melanocyte development. 
Mouse embryos homozygous for mutated PAX3 were found to still possess TRP2-
expressing migrating melanoblasts along the dorsolateral pathway [52]. In mouse embryos 
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negative for SOX10, the melanocytic markers TRP2 and MITF were virtually absent [54]. 
This analysis of both genes independent of one another suggests that PAX3 activity is not 
required for melanocyte specification, but is required for expansion of the melanocyte 
progenitor pool in early melanoblast stages. Studies have revealed that the WNT1 promoter 
possesses a PAX3 binding motif, allowing PAX3 to use these enhancer elements to activate 
WNT1. This suggests that PAX3 may be a direct regulator of WNT1 in the development of 
NC populations [56, 57]. Furthermore, TRP2 and MITF are direct transcriptional targets of 
SOX10 and are required for melanoblast specification [36, 54, 55]. 
Since SOX10 is crucial for melanocyte development, it is important to understand other 
factors that may be responsible for modulating its expression. Another member of the SOX 
family of transcription factors was found to be an antagonistic rather than synergistic 
interactor with SOX10. SOX5, a member of the SOXD subfamily, has little impact on 
melanocyte development alone [58]. Studies found that loss of SOX5 alone had little effect 
on melanocyte specification. However, when combined with SOX10 heterozygosity, the loss 
of SOX5 partially rescued impaired melanocyte development. This indicated that SOX10 
activity is being modulated, in part, by SOX5 [36, 58]. 
While SOX10 is an activator of MITF expression and acts as a specifier of the melanocytic 
lineage, the forkhead transcription factor (FOX) D3 plays an opposing role. FOXD3 
functionally represses MITF expression and melanogenesis [36]. In quail NCCs, FOXD3 
expression was found in all NCCs with the exception of late-emigrating cells pre-specified for 
the melanocytic lineage [59]. Additional studies in quail, where FOXD3 was overexpressed, 
demonstrated that FOXD3 repressed MITF expression, resulted in glial marker expression 
instead of melanocyte markers [60]. In summary, FOXD3 is involved in controlling 
melanocyte fate determination and migration, but represents only one factor in a complex 
network orchestrating melanocyte fate in NCCs. 
As described during NC induction, environmental cues are also responsible for regulating 
fate decision in the NC. These extrinsic signals are capable of directing NCCs towards a 
particular cell fate, which has been proven using clonal expansion studies. Many of these 
responsible factors have been identified for other lineages, including neurogenesis and 
gliogenesis, but inducers of the melanocytic fate remain to be discovered [36]. Nevertheless, 
there are several known growth factors that play a role during the melanocytic fate 
determination process. Among those growth factors are the members of the endothelin 
(EDN) family. Several studies have proven the EDN family to be important in determining the 
melanocytic fate. Upon exposure to EDN3 in quail NCCs, promotion and expansion of 
unipotent glial and melanocytic clones was observed. In addition, bipotent glial/melanocytic 
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clones were found [61]. Moreover, EDN3 was found to induce the generation of bipotent 
glial/melanocytic precursor cells from Schwann cells [40, 62]. In mouse NCCs cell cultures 
incubated in complex medium containing EDN, melanoblasts proliferated and successfully 
differentiated. However, upon the removal of EDN, melanoblast cells still emerged, 
suggesting that EDN signaling is not involved in melanocytic specification from NCCs [63]. 
Furthermore, continued migration of melanoblasts along the dorsolateral pathway requires 
EDN signaling. The absence of EDN signaling causes stalling of specified melanoblasts in 
the MSA [36, 64]. Lastly, mutations in the receptor or ligand of EDN signaling cause 
pigmentation defects. These defects were found to not be caused by a failure in melanocyte 
specification but, rather, in the later role of EDN signaling in melanocyte development [65]. 
Since the EDN pathway does not play a role in melanoblast survival and differentiation, this 
pathway is thought to be partially redundant with other pathways involved in melanocyte 
development.  
Another pathway required for melanocyte development is tyrosine kinase receptor KIT. KIT 
signaling has been well-studied and found to regulate melanoblast survival, proliferation but 
not late melanoblast migration. Upon injection of KIT antibodies into pregnant mice at varying 
developmental stages, three different patterns of melanocyte pigmentation and densities 
were observed in embryos and adult mice [66, 67]. Mutations found in the KIT also led to 
hypopigmentation defects. KIT signaling is involved in melanoblast proliferation, survival and 
dispersal along dorsolateral pathway. It also partly mediates the melanocytic differentiation 
program. However, melanocyte specification in the early stages of NCC fate determination 
occurs independently of KIT signaling [36].  
Canonical WNT/β-catenin signaling has been implicated in the early stages of melanocyte 
development [68]. The WNT ligand binds to its receptor, Frizzled, and β-catenin accumulates 
in the cytoplasm. β-catenin is translocated into the nucleus and subsequently interacts with 
the lymphoid enhancer-binding factor (LEF)-1/T-cell factor (TCF). This interaction modulates 
the transcription of several target genes, including MITF and CCND1 (Cyclin D1) [4]. In 
mouse studies, the directed gene transfer of WNT1 to NCCs resulted in the expansion and 
accelerated differentiation into pigmented cells [69]. Similarly, studies in quail NCCs 
demonstrated that signaling by WNT3A increased the number of melanocytes while 
simultaneously reducing the number of neural cells [70]. Finally, in zebrafish studies, in vivo 
overexpression of activated β-catenin promoted the formation of pigmented cells and 
repressed the generation of sensory neuronal and glial lineages [71]. When WNT signaling 
was inhibited via the injection of dominant negative WNT1, NCCs adopted a neural fate 
rather than a pigmented cell phenotype. β-catenin-deficient NCCs fail to express melanocytic 
markers such as MITF and TRP2. Therefore, canonical WNT/β-catenin signaling controls 
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expression of key melanocytic genes, MITF, and is important for melanocytic specification 
[36, 71, 72]. 
However, other studies suggest a more complex mechanism of Wnt/β-catenin signaling and 
melanocyte specification and development. For example, further studies in zebrafish 
observed that the inactivation of β-catenin inhibited the formation of both pigmented and 
neuronal cells [73]. Recent work tried to explain the inconsistent findings in Wnt/β-catenin 
signaling and melanocyte development. Using Cre cell lines, β-catenin was conditionally 
activated in NCCs at different developmental stages [74]. The activation of β-catenin in 
premigratory NCCs led to the formation of ectopic melanoblasts, while suppression of all 
other lineages was observed. Additionally, the activation of β-catenin in glial precursors or 
melanoblasts did not promote enhanced production of melanoblasts. This study 
demonstrated that NCC fate decisions in vivo are subject to strict temporal control by WNT/β-
catenin, where WNT/β-catenin responsiveness is highest during NCC migration [74]. 
As mentioned above, the migration of melanocyte precursors is possible through two routes: 
dorsolaterally (traditional view) and ventrally (new theory). Different extrinsic growth factors 
control progenitors traveling ventrally compared to those on the dorsolateral route. However, 
since this route was only recently described, many mechanisms remain poorly understood. A 
few mechanisms have been studied. The growth factor neuregulin-1 (NRG1) is a well-
established controller of axonal signaling in Schwann cells, regulating proliferation, migration 
and myelination. This signaling is mainly mediated by the ERBB2/3 heterodimer receptor. In 
mice lacking ERBB3, Schwann cells along nerves are completely abolished while 
melanoblast MITF expression significantly increases [38]. Other signaling mechanisms 
involved in regulating melanoblasts along nerves include platelet-derived growth factor 
(PDGF) and cytokines interleukin (IL) 3 and 5 [36]. Further investigations are required for a 
complete understanding of these mechanisms in regards to melanoblast formation and 
specification.  
Visualization of melanoblast migration has been achieved in mice using a lacZ transgene 
with the TRP2 promoter [75]. Melanocytes differentiate from the pluripotent NCC population 
at embryonic day (E) 8.5 before migrating along the dorsal-lateral pathway and ventrally 
through the dermis. However, it is now accepted that melanocytes precursors  migrate both 
dorsolaterally and ventrally and can be derived from nerve cells, where a dominant fraction of 
skin melanocytes is formed [36]. By E14.5 in mice, differentiated melanocytes populate the 
epidermis and developing hair follicles [46, 75].  
As melanoblasts migrate, they are constantly proliferating and, as the population expands, 
apoptosis is also inhibited. The melanoblast population is able to migrate vast distances 
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through the dermis, across the basement membrane, eventually settling in the epidermis [4]. 
Upon reaching their final destination in the epidermis, melanoblasts become fully 
differentiated melanocytes. 
1.1.3 Neural crest as a model system 
The NC is an important and crucial part of embryonic development in vertebrates. The NC is 
an excellent system for studying developmental processes [3]. For these reasons, many 
studies have tried to recreate NC development in vitro for further analysis.  
Earlier studies of the NC in vivo typically used embryos from avian, Xenopus or mouse 
species. For example, mouse embryos were used to examine melanocyte development in 
vivo and resulted in the discovery of the importance and dependence for the transcription 
factor MITF [76]. These studies used mouse embryos expressing wild-type (WT) MITF and 
MITF mutant embryos homozygous for the MITFv ga-9 or MITFmi-ew alleles, which encode non-
functional proteins. Moreover, these studies required neural tube explants obtained from 
embryos at E9.5 [76]. Though these studies laid the groundwork for NC and melanocyte 
development and identified crucial regulators in these processes, further advancement in 
biology has allowed for alternative ways of studying NC development. 
Recently, studies have successfully modeled the NC in vitro without the use of animal 
models. Authors developed a model using human embryonic stem cells (hESCs), where 
migratory cells undergo EMT to acquire properties of the NC [77]. The model used various 
culture conditions at different stages to promote propagation, segregation, gliogenesis and 
finally neurogenesis. With this model, the study identified another member of the SOX family, 
SOX2, involved in sensory neurogenesis [77]. This step-wise protocol was reproduced in 
another study as well [78]. Together, these studies gave insights into how modeling the NC 
will provide new perspectives without using animal models. However, the use of hESCs 
raises ethical concerns and is not an ideal model system. 
In particular, melanoblast model systems have also been established in vitro for further 
analysis into the melanocytic lineage. One study established a cell culture system to 
generate melanoblast-related cells (MBrc) [79]. This method was first described by Cook et 
al. [80]. The study demonstrated that the MBrc model is a reproducible system and may 
provide new insights into the role of melanoblast-related genes in melanoma progression. 
The most recent and groundbreaking research came with the discovery of induced 
pluripotent stem cells (iPSCs). Seminal research by Yamanaka and colleagues found that a 
terminally differentiated cell can be reprogrammed to its pluripotent state via the induction of 
four factors: SOX2, KLF4, OCT4 and NANOG [81]. This enabled further intensive research in 
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the field of development. The generation of iPSCs avoided ethical issues associated with 
hESCs and also provided research with better tools for development and disease modeling. 
In 2011, Ohta and colleagues successfully differentiated human iPSCs into melanocytes by 
supplementing culture medium with WNT3A, stem cell factor (SCF) and endothelin (ET)-3 
[82]. 
Recently, Studer and colleagues successfully modeled NC induction and the eventual 
specification of melanocytes using an in vitro system [83]. This work provided a complete 
model system from iPSC to NCCs to melanoblasts and finally ending with terminally 
differentiated melanocytes. Upon using timed exposure to WNT, BMP, and EDN3 and under 
dual-SMAD inhibition culture conditions, this triggered the sequential induction of NC and 
melanocyte precursor fates. Moreover, the global gene expression profile was analyzed 
throughout the model, giving new perspectives into NC and melanocyte fate determination 
[83]. In summary, the future of NC development and melanocyte progenitor research lies with 
in vitro modeling systems. These models allow for efficient analysis and new insights into 
development that were otherwise impossible due to constraints of animal models, ethics or 
limited resources. 
1.2 Melanocytes and their function in the skin 
The skin is the largest organ of the human body and plays one of the most important roles in 
protecting the body and its internal organs from external harm, such as microbes and 
environmental stress. Moreover, the skin maintains body temperature, prevents water loss, 
allows for the feeling of touch and protects against harmful ultraviolet (UV) radiation from the 
sun. The skin is composed of several layers of ectodermal tissue. The two primary layers in 
the skin are the epidermis and dermis. The epidermis is the outermost layer and contains 
melanocytes and keratinocytes. The epidermis is divided into five sublayers: stratum 
corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale. The 
dermis is where connective tissue, hair follicles, sweat glands, sebaceous glands and blood 
vessels are mainly located. The hypodermis is not a part of the skin but is located below the 
dermis and responsible for attaching the skin to muscle and bone [84]. 
Melanocytes are pigmented cells located in the stratum basale of the skin's epidermis. These 
cells populate the integument, inner ear and eyes of vertebrate organisms and arise from 
pluripotent NCCs [4]. These cells become fully differentiated upon reaching the basal 
membrane of the epidermis and their development and differentiation status are regulated by 
a complex network of genes. Additionally, melanocytes at hair follicles are produced by 
melanocyte stem cells. 
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1.2.1 MITF: master regulator of the melanocytic lineage 
MITF is the most critical regulator of the melanocytic lineage. This gene is not only 
responsible for melanin biosynthesis but also regulates cellular proliferation, survival, lineage 
determinacy and the replenishment of follicular melanocytes in adults [85, 86]. In vertebrates, 
MITF is expressed in melanoblasts and melanin-containing melanocytes and retinoid 
pigmented epithelia (RPE) cells [85]. Moreover, loss of MITF studies performed in mice and 
zebrafish showed a complete loss of melanocytes, further illustrating its key function in 
melanocyte biology [87]. Several isoforms (assigned A, B, C, D, E, H, M and Mc) of the MITF 
protein have been identified and characterized. They differ in their N-terminal region due to 
alternative promoters and first exons. It remains unclear whether the various isoforms have 
specific functions [86]. However, the MITF-M gene transcript has been found to be heavily 
involved in melanocytic lineage and is the only isoform that will be further discussed. 
The four main regulators of MITF-M transcription are CREB, SOX10, PAX3 and LEF1/TCF. 
Of several loci identified, the melanocortin-1 receptor (MC1R) has been found to be a major 
determinant of the pigmentation phenotype [46, 88]. MC1R encodes a seven-transmembrane 
domain G protein-coupled receptor. Once it has been bound by its agonist, typically α-
melanocyte stimulating hormone (α-MSH), it activates adenylate cyclase and induces cyclic 
AMP (cAMP) production [89]. This production leads to the phosphorylation of cAMP 
responsive-element-binding protein (CREB) which further transcriptionally activates 
numerous other genes, including MITF. 
Another crucial regulator of MITF and the melanocytic lineage is SOX10. SOX10 is also 
important and expressed in the NCC population [90]. Though SOX10 is not required for the 
development or early migration of NCCs, NCCs in mice lacking SOX10 undergo apoptosis 
before completing terminal differentiation [19]. Studies have shown that SOX10 is a direct 
regulator of MITF-M and therefore plays a crucial role in melanocyte differentiation [54, 55, 
91]. Moreover, the SOX10-mediated activation of MITF can be improved by the presence of 
PAX3, which suggests a synergy between SOX10 and PAX3 [54, 92].  
Other regulators of MITF-M transcription are the lymphoid enhancer binding factor LEF-
1/TCF HMG-domain transcription factors. These factors mediate their functions in canonical 
WNT signaling via interaction with β-catenin [93, 94]. The MITF-M promoter contains LEF-
1/TCF consensus binding sites and is directly regulated by WNT signaling when complexed 
with LEF-1 [68, 72]. Upon transcription, MITF is further regulated via post-translational 
modification by phosphorylation, which enhances the binding of MITF to the tyrosinase 
promoter [95–97]. 
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Perhaps, the most crucial role of MITF in melanocyte biology is its regulation of 
melanogenesis or pigmentation. The pigmentation process only occurs after complete 
differentiation from melanoblast precursors. Studies have demonstrated that MITF is capable 
of transactivating the promoters of three major pigmentation-related genes: TRP1, TRP2 and 
TYR. Downregulation of TYR and TRP1 was observed upon MITF inhibition [98]. Despite the 
evidence indicating a direct effect of MITF on pigmentation-related genes, overexpression of 
MITF in either mouse B16 melanoma cells or human melanocytes did not result in 
upregulation of TYR expression [99]. Lastly, MITF is also responsible for many other target 
genes crucial for the melanocytic lineage, including glycoprotein (GP)-100 (PMEL17) and 
melanoma antigen recognized by T cells (MART)-1 [100]. Taken together, MITF can drive 
the activation of target pigmentation-related genes. However, this might depend on further 
cooperation with additional proteins. 
1.2.2 SOX10: crucial regulator of melanocyte survival and specification 
SOX10 has proven its importance in NC specification and terminal differentiation of 
melanocytes. SOX10 is capable of controlling melanocyte development on two levels. First, 
SOX10 is crucial for the survival, maintenance, and proliferation of NCCs. This controls the 
overall size of the NCC population and indirectly influences the number of melanocytes. 
Second, SOX10 regulates melanocyte specification by modulating melanocyte differentiation 
factor MITF-M via directly binding to the proximal promoter and activating transcription [101]. 
In addition to these essential roles, SOX10 is also able to influence another important factor 
in melanogenesis, TRP2. Studies found that SOX10 is capable of binding to the TRP2 
promoter in a similar manner to that of MITF, thereby activating its transcription [102]. 
Moreover, SOX10-dependent activation of the TRP2 promoter could be synergistically 
increased by MITF [103]. The TRP2 promoter also contains CREB and β-catenin/LEF-1 
binding sites, though the function of these sites and the role of SOX10 may play in this 
pathway remains under investigation. 
1.2.3 Other important genes in melanocyte biology: PAX3, KIT and EDNs 
The expression of genes involved in melanoblast and late stages of melanocyte development 
are often found in fully differentiated melanocytes. These include MITF and SOX10 but also 
PAX3, KIT and EDNs. These genes remain important regulators of the melanocytic lineage 
throughout the lifespan of a melanocyte. 
Not only is PAX3 important for the regulation of MITF-M, it also plays a crucial role in 
proliferation, migration, resistance to apoptosis, lineage specificity and differentiation of 
melanocytes. PAX3 is important in NC and early melanocyte development and its expression 
continues to be essential in differentiated melanocytes for promoting and inhibiting 
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melanogenesis [56]. PAX3 also is capable of inhibiting TRP2 and blocking binding of MITF to 
the promoter of TRP2. PAX3 forms an inhibitor complex with LEF-1 and the groucho-related 
gene (GRG)-4. When β-catenin is present, LEF-1 switches partners, forming an activating 
complex composed of LEF-1, MITF, and β-catenin. This activating complex is able to 
displace PAX3 from the TRP2 enhancer and activate transcription [56]. PAX3 is also capable 
of influencing the melanocyte lineage via the binding to the promoter and driving expression 
of TRP1. Therefore, PAX3 is a crucial regulator of melanogenesis and is able to influence 
cellular proliferation and apoptosis.  
Another key NC marker and essential melanocyte development gene is KIT, a type III 
receptor tyrosine kinase [104]. The function of KIT remains of importance throughout the 
complete differentiation and life of a melanocyte. Detailed analyses of KIT mutants found that 
KIT and its corresponding ligand play a complex role in final melanocyte migration from the 
dermis to the epidermis as well as regulating cellular survival [47]. In differentiated 
melanocytes, KIT signaling remains important for melanocytic survival in the skin. The ligand 
of KIT receptor, SCF, is a paracrine factor synthesized by various other skin cells, including 
epidermal keratinocytes [105].  
In addition to c-KIT/SCF, there are other mechanisms likely to be involved in the late steps of 
melanocyte migration from the dermis into the epidermis, including the EDNs [46]. The 
endothelin-1 (ET1) peptide is a paracrine factor also synthesized by surrounding 
keratinocytes. The function of ET1 is primarily to bind and activate the endothelin-B receptor 
(ETBR). Upon ligand binding, a complex signaling network is activated, including the 
activation of protein kinase (PK) C [105]. This network, which is also important in 
melanoblast migration, is thought to play a role as a paracrine regulator of melanocytes, 
since ET1 is expressed by surrounding keratinocytes. 
1.2.4 Functions of melanocytes: pigmentation and ultraviolet radiation 
response 
Pigmentation in the skin is an essential defense mechanism against ultraviolet (UV) radiation 
of the sun. The pigment produced by melanocytes is termed melanin and is synthesized only 
by membrane surrounded organelles called melanosomes [100]. In the typical response to 
UV radiation, melanin-containing melanosomes are transferred to the periphery of 
melanocytes, where they are ultimately transported to keratinocytes [106]. The most 
important proteins involved in melanin catalysis include TRP1, TRP2 and TYR, whose genes 
are all activated by MITF-M. Another crucial protein which maintains the structural integrity of 
melanosomes is known as GP100, PMEL 17 or premelanosome protein (PMEL) [100]. 
Introduction 
15 
The biochemistry of melanin production in melanosomes by the catalytic enzyme tyrosinase 
has been well studied. Tyrosinase converts the amino acid tyrosine into melanin via several 
straightforward reactions. The initial and critical reaction involves the hydroxylation of 
tyrosine into 3, 4-dihydroxyphenylalanine (DOPA). After synthesis of DOPA, this byproduct 
can give rise to biopolymer melanin via extensive reactions, termed the Raper-Mason 
scheme [107–109]. In brief, these reactions are a series of oxidation reactions which form 
indole-quinone ring structures and permit the polymerization and quick configuration of 
pigmented biopolymers [110–112]. These biopolymers become different forms of melanin, 
depending on several external factors [46, 113]. 
After the production of melanin in the melanosomes, these organelles are transported for 
protective measures against environmental responses. Melanosome transport has been well-
studied in mice in which the pigmentation pathway has been altered or compromised. There 
are three major players in the transport of melanosomes through the cytoplasm to the 
periphery dendrites. These genes are Ras-related protein RAB27A, melanophilin, and 
myosin VA (MYO5A) [114–116]. On a molecular level, melanosomes become tethered to 
myosin motors which move the organelles through the cytoplasm. Upon reaching the 
periphery dendrites, the melanosomes are captured by actin filaments and remain there until 
they are delivered to keratinocytes by a process which remains poorly understood. However, 
recent studies have revealed that protease activated receptor 2 (PAR2) is involved in this 
process [117, 118]. After melanosomes reach the keratinocytes, they are distributed and, in 
response to UV radiation, positioned strategically over the ‘sun-exposed’ side of nuclei to 
form cap-like structures resembling umbrellas [46]. 
Melanocyte dendricity is not only important for the structure of the cell but also for the 
transfer of melanosomes to neighboring keratinocytes. Dendricity affects cell-to-cell 
communication, especially with keratinocytes, which stimulate melanocytes to proliferate and 
become more dendritic by secreting their own factors [119, 120]. Moreover, actin and 
RAC1/RHO have been shown to be important in the formation of dendrites. These can be 
externally regulated by physiological factors, such as MSH or UV radiation [121, 122]. 
UV radiation stimulates pigmentation in the skin by a process more commonly known as 
tanning. There are two main tanning processes in the skin. The first is called the immediate 
pigment darkening, where tanning occurs within minutes of the UV exposure. The second 
type of tanning process is known as delayed tanning, where the tanning response is only 
seen after several days [100]. The major regulator of the melanocytic lineage MITF tightly 
controls melanogenesis and the UV response mechanism. On a molecular level, MSH, which 
functions mainly through MC1R, controls the expression of MITF and its downstream targets 
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TYR, TRP1, TRP2, GP100 and MART1. Studies found, that regardless of racial background, 
similar increases in MITF expression were found within one day of exposure to UV radiation. 
Additionally, levels of TYR, TRP1, GP100 and MART1 were also similarly expressed 
between one and seven days, regardless of race [100].  
Aside from the many protective responses exerted by melanocytes, UV radiation has many 
adverse side effects in the skin, including the induction of DNA damage. Upon 
characterization of melanocytes and keratinocytes after UV radiation, there is an inverse 
relationship between melanin content and DNA damage induced in situ [100]. Moreover, 
between individuals, there is great variability in UV-induced DNA damage. UV-induced DNA 
damage can also cause mutations to occur in other key regulatory genes. 
1.3 Melanoma 
Melanoma is a dangerous form of skin cancer derived from the malignant transformation of 
melanocytes. Though malignant melanoma only accounts for four percent of all 
dermatological cancers, it remains the most lethal by far, accounting for 80 % of all skin 
cancer-related deaths [106]. Additionally, the incidence of melanoma has nearly doubled in 
westernized countries over the past 20 years [123]. According to the Skin Cancer 
Foundation, melanoma kills an estimated 9,710 people in the US annually. The American 
Cancer Society estimates that, to date, there are more than 120,000 new cases of melanoma 
in the US each year. In 2014, an estimated 76,100 of these will be invasive melanomas, with 
about 43,890 cases in males and 32,210 cases in women [124].  
If melanoma is recognized and treated early, it can be easily cured, typically by surgical 
resection. Approximately 80 % of melanomas are treated in this manner [123]. However, 
once the cancer has metastasized and spread to other regions of the body, therapy options 
become limited and poor prognosis is common, with a median survival rate of 6 months and 
5-year survival rate of less than 5 % [123, 125]. The development of immunotherapies and 
targeted therapy has improved the treatment and survival of melanoma patients. However, 
resistance to these treatments has now become the major obstacle in melanoma therapy. 
Once the melanoma has spread from its initiation site to distant organs it becomes difficult to 
treat. The major risk factors associated with melanoma include multiple benign or atypical 
nevi and a family history of melanoma. Other genetic predispositions or environmental risks 
include sun sensitivity, immunosuppression and exposure to UV radiation [106].  
The pathogenesis of melanoma was first characterized and classified in the 1970s by Clark 
[126]. This model describes different histological stages of melanoma, beginning from a 
benign melanocytic nevus to malignant melanoma via dysplastic nevus [127]. Although this 
model portrays linear progression, where each lesion is the immediate precursor to the next, 
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research has found that the pathways by which melanoma develops may vary [128]. 
Nevertheless, the model is still used and describes the first lesion type as a benign nevus or 
mole (small, well-defined). The next lesion is termed a dysplastic nevus, which is clinically 
defined as a nevus containing one or more features of melanoma, such as a larger size or 
irregular borders. The next phase is the radial growth-phase (RGP) of melanoma, where the 
lesion grows progressively but only ‘radially’. This phase occurs within the epidermis only. 
The last phase of the Clark model is the vertical growth-phase (VGP), where the melanoma 
forms large, distinct nodules in the dermis, indicating the potential for metastatic spread 
[128]. 
1.3.1 Origins of melanoma 
The deregulation of several pathways allows melanocytes to escape their tight regulation by 
keratinocytes and thereby facilitate malignant transformation. These transforming-promoting 
mechanisms include mutations in growth regulatory genes, production of autocrine growth 
factors and the loss of adhesion receptors [129]. Much research has been done to 
investigate the risk factors associated with melanoma initiation. One well-studied cause of 
malignant transformation in melanocytes is exposure to UV radiation. 
Exposure to UV light is the most well-known environmental risk factor associated with 
melanoma initiation. UV radiation causes mutations in skin cells, increases the production of 
growth factors, induces the formation of DNA-damaging reactive oxygen and affects 
cutaneous immune function [106]. Tanning of the skin is a natural defensive and protective 
measure taken by the skin against UV radiation. In response to UV radiation, keratinocytes 
excrete factors which control several functional processes of melanocytes, including the 
stimulation of melanin production [123].  
As seen with many other cancer types, genetic familial predisposition is also a cause of 
malignant melanoma in some cases. A family history of melanoma occurs in approximately 
10 % of melanoma patients and increases the risk of acquiring the disease by nearly two-fold 
[130]. Melanoma is often considered a genetic disease due to a range of heritable risk 
factors such as skin complexion and eye color. 
1.3.2 Familial mutations in melanoma 
Due to the familial link, it has been suggested that, in melanoma, there is an inheritance of 
melanoma susceptibility genes. To date there have been four different genes at three 
different loci identified to confer susceptibility in melanoma, the genes include: p16INK4a, 
p14ARF, CDK4 and TERT.  
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The cyclin-dependent kinase inhibitor 2A (CDKN2A) locus, located on chromosome 9p21, is 
unique because it encodes two different, unrelated protein products: p16INK4a and p14ARF 
[131]. These two transcripts can be altered simultaneously in both familial and sporadic 
melanoma cases. Inactivation of the CDKN2A locus is mainly caused by deletion, mutation 
or promoter silencing by hypermethylation (review in [132]). Mutations in this locus are 
strongly related to familial history, when three or more family members are affected, 35.5 % 
of patients developed melanoma, while only 8.2 % of those without any family history 
develop melanoma [133]. Both gene products impact cellular proliferation; however via 
separate mechanisms. p16INK4a protein blocks cell cycle progression inhibiting the activity of 
cyclin D1-dependent kinase 4 (CDK4). This inhibition blocks CDK4 from phosphorylating the 
retinoblastoma (RB) protein and induces cell cycle arrest at G1 phase. While p14ARF plays an 
important role in stabilizing p53 by inhibiting the ubiquitin ligase murine double minute 2 
(MDM2) protein responsible for degrading p53 [134]. Disrupting the degradation of p53 
promotes cellular growth, since p53 normally arrests cell division at G1 to either allow DNA 
repair or induce apoptosis in possibly transformed cells [132].  
Another melanoma susceptibility gene is CDK4, located at 12q13.6 and which encodes 
proteins that interact with p16INK4a.  Mutation in CDK4 is extremely rare but has been reported 
in the germline of melanoma-prone families. Typically, these mutations are observed at an 
arginine residue (Arg 24) and eliminate regulatory interactions with p16INK4a, leading to 
enhanced cell cycle progression (reviewed in [130]). It is important to note that the result of 
mutations in either p16INK4a or CDK4 seem to be functionally equivalent and both block the 
association between each other and hence impair the ability of p16INK4a to activate the RB 
family [135]. 
Recent studies identified a new melanoma susceptibility gene, the telomerase reverse 
transcriptase (TERT). Researchers investigated melanoma-prone families using linkage 
analysis and identified a germline mutation in the promoter of the gene that encodes the 
catalytic subunit of telomerase. This mutation is capable of creating a new binding motif 
which enhances its transcription two-fold [136]. Additionally, work identified that mutations in 
TERT can occur somatically in melanoma. The functions of TERT mutations in melanoma 
progression are currently being investigated [136, 137]. 
1.3.3 Somatic mutations in melanoma: BRAF, RAS, MITF, KIT and PTEN 
Somatic mutations, like in other cancer types, are a main driving force in melanoma initiation 
and progression. UV-induced DNA damage can cause the formation of somatic mutations 
and, when these mutations are induced in key regulatory genes or oncogenes, the result is 
carcinogenesis. Mutations which upregulate murine sarcoma viral oncogene homolog B 
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(BRAF) are most common mutations in melanoma, occurring in nearly 65 % of all melanoma 
cases. The most common somatic mutation in the BRAF gene is a missense mutation from 
valine to glutamic acid at amino acid 600 (BRAFV600E) in the ATP-binding region of the 
protein. This specific mutation comprises of nearly 90 % of all BRAF-mutated melanomas, 
while other variations, including BRAFV600K, are rare [138]. These mutations occur 
somatically, since wild-type forms of both genes are also found in normal tissue of melanoma 
patients [139]. In fact, there is a very low incidence of BRAF mutations found in melanomas 
arising from non-sun exposed skin, suggesting that UV exposure plays a crucial role in 
inducing BRAF mutations in cutaneous melanoma [135].  
Functionally, the BRAFV600E mutation causes a 10-12-fold increase in its activity, triggering 
the hyperactivation of the mitogen-activated protein kinase (MAPK) signaling cascade 
leading to cellular survival and proliferation [135]. Studies in immortalized mouse 
melanocytes showed this connection by expressing mutant BRAF and observing the 
induction of extracellular signal-regulated kinase (ERK) and the initiation of malignant 
transformation [140]. Moreover, upon treating human melanoma cell lines with BRAF 
mutations with mitogen-activated protein kinase kinase (MEK)-1/2 inhibitor U0126 the 
blockade of MAPK signaling and cell cycle progression was observed, but had no effect on 
melanoma cells harboring oncogenic neuroblastoma viral oncogene homolog (NRAS). 
Therefore, mutated BRAF can act as a potent oncogene in early stages of melanoma 
progression through activated MAPK signaling. However, mutated BRAF is not required for 
RAS-transformed melanocytes due to the innate redundancy within the pathway [140]. 
The BRAFV600E mutation is found in approximately 80 % of benign nevi. In zebrafish, 
expression of melanocyte-specific BRAF proteins induces ectopic proliferation of 
melanocytes, analogous to human nevi [141]. However, it is unknown why mutated BRAF 
leads to benign nevi formation and malignant formation. Multiple requirements are needed 
for transformation. A BRAF mutation alone is not sufficient to progress towards malignancy. 
In the zebrafish study described above, a combination of a BRAF mutation and inactivation 
of the tumor-suppressor gene p53 led to the malignant transformation of melanocytes [141]. 
Additionally, studies identified the association between mutant BRAFV600E and p16INK4a/p19ARF 
loss or mutations in p53 and PTEN leading to malignant transformation [142–144]. These 
studies provide an explanation for how BRAF mutations exist in nevi without directly inducing 
malignant transformation. 
The RAS family is also affected by somatic mutations in melanoma and functions as a 
transducer of extracellular growth factor signals in the cell. Among the RAS gene family, 
NRAS is the most commonly mutated and represents the second most common mutation 
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found in melanoma, comprising of nearly 20 % of mutations in the disease. This mutation is a 
point mutation of amino acid 61 from a glutamine to a lysine (NRASQ61K) or arginine 
(NRASQ61R), but there are many variations. Mutations also occur in other RAS family 
members but mutations in NRAS seem to be the most detrimental and oncogenic. Studies in 
mice investigated the different consequences of HRAS and NRAS in melanocytes. The 
hyperactivation of HRAS in combination with loss-of-function mutations in CDKN2A and/or 
p53 led to non-metastatic melanomas in mice. Activation of NRAS together with CDKN2A 
loss led to the production of melanomas with severe metastatic spread to both lymph nodes 
and distant organs in mice [135, 145, 146]. 
As described above, MITF plays a crucial role in melanocyte development and differentiation. 
The function of this gene in malignant transformation and melanoma progression has 
become important and remains not well understood. The role of MITF in differentiation and 
cell cycle arrest in normal melanocytes is known, but conversely MITF in melanoma cells 
does not possess the same function. A large study investigated genomic changes in 
melanocytes using analysis of high-density single-nucleotide polymorphisms (SNPs) and 
discovered an increased copy number of a region on chromosome 3 that included the MITF 
locus [147]. Moreover, this increase was accompanied by increased expression of the MITF 
protein. Upon the overexpression of both MITF and BRAF, primary human melanocyte 
cultures were malignantly transformed. The amplification of MITF correlates to poor 
prognosis and is associated with melanoma therapy resistance [147]. Taken together, these 
results suggest that MITF is an oncogene and a lineage-survival gene in melanoma [147–
149]. 
There are many other somatic mutations found in melanoma [136, 137, 150–153]. For 
example, another gene susceptible to somatic mutations is the KIT oncogene. Approximately 
1-2 % of all melanomas contain point mutations in the KIT receptor tyrosine kinase gene. 
Most of these mutations are found in mucosal and acral melanomas and also in constantly 
sun-damaged melanomas [138, 154]. An influential study observed that the MAPK signaling 
pathway was activated upon stimulating melanoma cells with the KIT ligand, SCF. This 
resulted in the phosphorylation of MITF and in the transactivation of the promoter of the 
pigmentation-related gene TYR [95]. This link between external signals transduced by KIT 
into gene regulation became an early indication for the importance of KIT in 
melanomagenesis. 
Another gene susceptible to somatic mutations in melanoma is the phosphatase and tensin 
homolog (PTEN) gene. Somatic mutations in PTEN are found in 40-60 % of melanoma cell 
lines and in approximately 10-20 % of primary melanomas, where the majority of the 
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mutations occur in the phosphatase domain (reviewed in [132], [155]). However, the contrast 
between low mutation frequency detection and a high level of gene silencing can be 
explained by other mechanisms important for the inactivation of PTEN, including epigenetic 
silencing and altered subcellular location of this protein [135]. Several methylation sites have 
been found within the PTEN promoter. Hypermethylation of these sites reduce PTEN 
expression in melanoma [132]. Moreover, genetic studies have found that deletions in 
chromosome 10q, including the PTEN locus, occur at high frequencies in BRAF-mutated 
melanoma, while deletions in this chromosome were less common in NRAS-mutated 
melanomas [156, 157]. This work suggests that BRAF and PTEN may cooperate in 
melanoma progression. PTEN is commonly regarded as a tumor suppressor because it acts 
as an antagonist of the phosphatidylionositol-3 kinase (PI3K) pathway and MAPK signaling, 
which will be discussed further in the following sections. 
1.3.4 Pathways affected by somatic mutations in melanoma: MAPK, PI3K-AKT 
and TGF-β signaling 
The complex signaling network which initiates, maintains and drives melanoma progression 
is well-studied. However, the depth of complexity leaves much left to uncover. In the next 
section, I will only highlight the key signaling pathways involved in melanomagenesis, 
including MAPK, PI3K-AKT and TGF-β signaling. 
The RAS/RAF/MEK/ERK signaling cascade, also known as MAPK pathway, is a serine-
threonine cascade involved in the regulation of cell growth, survival and differentiation. In 
melanocytes, this pathway drives melanogenesis by regulating cell proliferation and survival. 
In addition, the MAPK pathway has been meticulously studied in melanoma, since somatic 
mutations in BRAF and NRAS cause an overactivation of this pathway. First, the signaling 
cascade starts by the binding of a growth factor (e.g. SCF, EGF or PDGF) to its 
corresponding receptor (e.g. KIT, EGFR or PDGFR). This binding allows for RAS (a GTPase) 
to exchange its bound guanosine diphosphate (GDP) for guanosine-5'-triphosphate (GTP). 
This exchange initiates the recruitment and phosphorylation of membrane-bound RAF 
proteins. Lastly, activated RAF induces downstream signaling via phosphorylation of MEK 
and, subsequently, ERK. ERK phosphorylation results in its translocation to the nucleus 
where it controls expression of key survival, cell-cycle progression and differentiation-
associated genes [142, 158, 159]. 
The hyperactivation of the MAPK signaling is well-understood and strongly linked to the 
somatic mutation of BRAF. However, mutation of BRAF alone is not sufficient to induce 
malignant transformation. The MAPK signaling pathway is heavily involved in 
melanomagenesis by promoting cellular proliferation, inhibiting apoptosis and inducing tumor 
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invasion and metastasis. The overactivation of ERK controls cell proliferation by playing a 
role in the G1-phase to S-phase transition. The activation of ERK negatively regulates the 
p27/Kip1 inhibitor and upregulates c-MYC, leading to melanoma cell growth. Likewise, the 
inhibition of ERK leads to G1-phase cell cycle arrest mediated by the upregulation of cyclin-
dependent kinase (CDK) inhibitor p27/Kip1 and hypophosphorylation of the RB protein [160]. 
Additionally, ERK activation targets downstream transcription of POU domain, class 3, 
transcription factor 2 (POU3F2 or BRN2), which then leads to an increase in cell proliferation 
[135]. 
Inhibition of apoptosis is another important effect of the hyperactivation of the MAPK 
signaling pathway. The overactivation of ERK mediates melanoma-specific survival signaling 
by regulating ribosome S6 kinase (RSK)-mediated phosphorylation leading to inactivation of 
proapoptotic Bcl-2-associated death promoter (BAD) protein. Aside from controlling 
apoptosis, the MAPK pathway is also important for the acquisition of the invasive phenotype. 
ERK activation regulates MMP production, especially the production of MMP-1. Studies 
found that, upon blocking ERK activity, melanoma cell proliferation and collagen degradation 
was inhibited [161]. Additional functions of the MAPK signaling cascade lie in its induction by 
α-MSH and, therefore, cAMP levels. This cAMP-induced activation of ERK induces 
differentiation via inducing MITF expression, leading to the upregulation of the differentiation-
associated genes TRP1 and TRP2, though this activation is weak and transient [162]. 
In summary, the MAPK signaling cascade is an important pathway for maintaining 
melanocytic proliferation. However, the introduction of somatic mutations in RAS or RAF can 
cause the hyperactivation of this pathway and induce malignant transformation of 
melanocytes into melanoma. Although the hyperactivation of this pathway alone is not 
sufficient to induce transformation, the sustained activation of this pathway leads to cell 
proliferation, survival, inhibition of apoptosis and induction of cellular invasion. The weak and 
transient activation of this pathway via α-MSH and cAMP can also lead to cellular 
differentiation, further underscoring the complexity of melanomagenesis. 
The phosphatidylinositide 3-kinases (PI3K) is commonly dysregulated in melanoma, typically 
by mutation and silencing of the tumor suppressor gene phosphatase and tensin homolog 
(PTEN). PTEN encodes a phosphatase that inactivates the products of PI3K. The PI3K-AKT 
pathway functions by first activating PI3K, which then increases phosphatidylinositol 3, 4, 5-
triphosphate (PIP3) production. Conformational changes activate protein kinase B (also 
known as AKT), leading to cell cycle progression, survival and migration. However, PTEN 
antagonizes this pathway with two main biochemical functions: protein phosphatase and lipid 
phosphatase. The lipid phosphatase activity plays an anti-tumorigenic role by decreasing the 
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function of downstream AKT. PTEN dephosphorylates the cytosolic second messengers of 
the PI3K-AKT pathways, PIP3 and phosphatidylionositol 3, 4-bisphosphate (PIP2) [163, 164]. 
The loss of function of PTEN in tumor cells leads to the accumulation of these second 
messenger lipids and activates AKT and decreases apoptosis, while the reintroduction of 
PTEN into PTEN-null cells reverts this effect [130, 132, 135]. 
AKT activation induces many functional changes in the cell, including cell cycle progression, 
survival and migration. A main activating mechanism for AKT is DNA copy gain, which is 
found in 40-60 % of melanomas. Mutations in the catalytic subunit of PI3K also occur in 
melanoma but at a low frequency (5 %). Studies have found that activated AKT promotes 
cellular proliferation by downregulating cyclin-dependent inhibitor p27 and upregulating 
CDNN1 (Cyclin D1). Additionally, the activation of AKT suppresses apoptosis via several 
mechanisms, including inactivation of pro-apoptotic proteins such as BAD [132]. Lastly, AKT 
activation can promote tumor migration and invasion through the induction of MMP proteins, 
including MMP-2 and MMP-9. Studies proposed that AKT activation leads to NF-κB binding 
to the promoter of MMP promoting its transcription [165].  
Taken together, the PI3K-AKT pathway is extremely important in melanoma progression and 
survival. Mutation in the tumor suppressor PTEN enables the overactivation of AKT which 
further promotes cell cycle progression, inhibition of apoptosis and promotion of cellular 
migration and invasion. Moreover, there are activating mutations in AKT, which also lead to 
its overactivation in melanoma. 
There are several other important signaling pathways that are crucial for melanoma 
progression and metastatic spread. One of those pathways is the transformation growth 
factor (TGF)-β signaling pathway. The TGF-β signaling is involved in regulating development 
and cellular growth. The TGF-β ligand, TGF-β1, binds to membrane receptors, such as 
transforming growth factor beta receptor (TGFBR)-2, that contain a cytoplasmic 
serine/threonine kinase domain. Ligand binding induces assembly of a receptor complex 
which phosphorylates proteins of the mothers against decapentaplegic (SMAD) family [135, 
166]. Upon phosphorylation, SMAD proteins form heterodimers and they translocate into the 
nucleus, where they assemble complexes, bind DNA and regulate target gene transcription. 
Of note, there is substantial versatility in TGF-β responses. For example, there are countless 
combinations of interactions between the receptor and SMAD-interacting proteins, within the 
SMAD protein complexes and other sequence-specific transcription factors [167].  
To date, studies have revealed the importance of TGF-β signaling in melanoma 
pathogenesis. One of the first observations was that there is increased expression and 
secretion of the different TGF-β isoforms in melanoma cell lines when compared with normal 
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melanocytes (reviewed in [168]). TGF-β was found to suppress the growth of normal human 
melanocytes, while melanoma cell proliferation was only slightly inhibited by TGF-β. 
Therefore, melanoma, cells have developed a resistance mechanism to inhibit anti-
proliferative signals through TGF-β. A study found that melanoma cells express higher levels 
of SKI and SnoN in comparison to normal human melanocytes and that these molecules are 
capable of interfering with SMAD-dependent transcription of cell cycle regulator p21, 
therefore elucidating one possible mechanism used by melanoma cells to resist the anti-
proliferative signals from TGF-β signaling [169, 170]. 
Additionally, TGF-β signaling is involved in melanoma metastasis. One study found the 
blockade of SMAD7 inhibited 1205Lu melanoma cells from forming bone metastasis [168, 
171]. Moreover, tumor-stroma interactions where found to be important in melanoma, since 
the expression of TGF-β1 stimulated neighboring stoma cells via increased deposition and 
production of ECM proteins. This led to increased tumor cell survival and metastasis [172]. 
Taken together, TGF-β signaling plays an important yet complicated role in 
melanomagenesis and further work is required to fully understand the depth of its function in 
the context of this disease.  
1.3.5 Current targeted melanoma therapies 
The preferred treatment for melanoma is surgical resection. If detected early, melanomas 
can be removed surgically, with high progression-free survival. Therefore, early diagnosis 
remains crucial for improving clinical outcome of melanoma patients. However, once 
melanomas spread into the lymphatic or the circulatory system and home to distant organs, 
such as the liver, they become non-resectable and difficult to treat. The development of 
targeted therapies allows for the specific inhibition of factors responsible for the activation of 
mealnoma-driving pathways. To date, there are targeted therapies in melanoma inhibiting c-
KIT, BRAF, CRAF, MEK1/2, mTOR, AKT and CDK4 (reviewed in [138]). 
The BRAF kinase inhibitor vemurafenib was the first targeted therapy developed and shown 
to improve the clinical outcome of melanoma patients. Vemurafenib competes with 
adenosine-triphosphate (ATP) to bind the kinase domain of BRAF, leading to inhibition of 
BRAF-induced MEK activation [173]. Clinical trials found that, upon vemurafenib 
administration, patients displayed a response rate of 48 % and improved survival compared 
to dacarbazine, another chemotherapeutic agent [174]. This compound was approved by the 
Food and Drug Administration (FDA) and the European Medicines Regulatory Agency (EMA) 
in 2011. Soon after, a second BRAF inhibitor, dabrafenib, was developed and showed similar 
response rates but with different side effects [175]. The use of both of these compounds was 
not restricted to melanoma patients only possessing the V600E mutation. They were also 
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found to be effective in patients with other BRAF mutations, including V600K, V600R, 
p.T599del mutations and D594G [176]. Although the aforementioned compounds are 
generally tolerated well and considered safe, side effects associated with their use include, 
but are not limited to, fatigue, diarrhea and nausea [177, 178].  
Another strategy for targeting the MAPK signaling pathway is the inhibition of the 
downstream proteins MEK1 and MEK2. The first developed MEK1/2 inhibitor, trametinib, was 
shown to improve the progression-free survival of stage IV melanoma patients harboring a 
BRAFV600E or V600K mutation [179]. In 2013, this compound was approved by the FDA for the 
treatment of patients with BRAFV600E-mutated metastatic melanoma. Phase I trials showed 
that trametinib may also be used in combination with paclitaxel, a mitotic inhibitor used in 
cancer chemotherapy [180]. Another MEK1/2 inhibitor, selumetinib, was developed and 
displays similar clinical activity in BRAF-mutant melanoma. Moreover, in a phase II double-
blinded randomized clinical trial, this compound was tested in combination with dacarbazine 
in both BRAF-mutated and unknown primary melanoma, patients showed significantly 
improved progression-free survival compared with the control group receiving the placebo 
plus dacarbazine [181].  
In addition to BRAF inhibition, another common mutation, observed in approximately 20-
30 % of melanoma patients, is found in the NRAS gene. There are no current therapies 
which target NRAS directly; however, other treatments showing off-target effects on 
oncogenic NRAS are being used. For example, in patients harboring the NRAS mutation, 
treatment with MEK 1/2 inhibitors can lead to tumor regression. In a recent clinical trial, it was 
observed that 20 % of patients with NRAS-mutated melanoma had a partial response upon 
treatment with MEK inhibitor binimetinib (MEK162) [182]. Another strategy for targeting 
NRAS-mutated melanoma is via the simultaneous inhibition of MEK and CDK4/6. This is 
beneficial in NRAS-mutated melanoma patients because studies have revealed enhanced 
MAPK signaling and dysregulation of cell cycle checkpoints in NRAS-mutated melanoma 
[183]. Recent encouraging phase 1b/2 clinical trials showed that the combination of 
binimetinib (MEK162) and CDK4/6 inhibitor LEE011 resulted in partial responses in 43 % of 
patients [184]. 
Mutations in the oncogene KIT can lead to the overactivation of MAPK signaling and 
advance melanoma progression. Therefore, melanomas containing such regions were 
evaluated, leading to the development of the first targeted therapies against tyrosine kinase. 
One inhibitor, imatinib, showed an overall response rate of 16 %, with a response rate of 
23.3 % in patients harboring a KIT mutation [185]. Other KIT inhibitors currently being 
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investigated in clinical trials including dasatinib, which targets the L576P mutation in KIT, and 
nilotinib [138]. 
In addition to targeted therapy, another novel approach to treating melanoma is stimulation of 
the immune system, known as immunotherapy. One therapy, ipilimumab, is a human IgG1 
monoclonal antibody which blocks the cytotoxic T lymophocyte-associated antigen (CTLA-4). 
By inhibiting CTLA-4 activity, which normally is responsible for negatively regulating active T 
cells, results in an increase in proliferation of T cells. In clinical trials, patients with cutaneous 
melanoma showed an overall survival benefit when given ipilimumab [138, 154, 186]. 
Additionally, ipilimumab was used as adjuvant therapy in a placebo-controlled trial and 
showed significant improvement in recurrence-free survival in patients with stage III 
melanoma with a high risk of recurrence [187].  
Another immunotherapy option in melanoma treatment is a monoclonal antibody which 
targets the programmed death receptor (PD)-1. PD-1 is responsible for downregulating the 
initial T cell activation by binding the immunosuppressive ligand PD-L1. By blocking this 
interaction, T cell activation is halted, therefore PD-1 signaling stimulates an immune 
response. The anti-PD-1 antibody MK3475, pembrolizumab, was first examined in patients in 
advanced stages of melanoma and was found to extend progression-free survival for more 
than seven months and sustained tumor regression was observed [188]. In September 2014, 
pembrolizumab (MK3475) received accelerated approval by the FDA for the treatment of 
patients with either advanced or non-resectable melanoma. Similarly, another PD-1 inhibitor 
was developed, nivolumab, and demonstrated beneficial two- and three-year progression-
free survival rates [189]. In summary, the use of immunotherapy in treating melanoma has 
beneficial impact on overall survival and on tumor regression. 
1.3.6 Therapy resistance in melanoma 
The most prevalent issue with current melanoma therapy is the prompt acquisition of therapy 
resistance hypothesized in one theory to be acquired by selective pressure within the tumor. 
Typically, it is observed that the response to therapy, such as BRAF inhibitors, is transient. 
Therefore, mechanisms of resistance have been studied in detail. 
The effectiveness of targeted therapy is limited to cancer cells which lack the ability to confer 
resistance. There are several general and extremely complicated resistance mechanisms 
that cancer cells employ in order to evade treatment, including membrane transport systems 
that control drug entry/export/distribution, enzymatic mechanisms that metabolize the drugs, 
anti-apoptotic pathways that alter cell death programs and tumor physiology associated with 
its microenvironment [190]. The variety of mechanisms highlight the complexity associated 
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with acquired resistance. Next, I will briefly provide some examples of known mechanisms 
associated with melanoma therapy resistance, especially with BRAF and MEK inhibitors. 
The use of BRAF inhibitors showed much success in initial treatment, but the development of 
resistance is inevitable. Typically, resistance is acquired against targeted therapy by the 
development of secondary mutations. For example, resistance to KIT inhibitors, such as 
imatinib, may be caused by mechanisms induced by NRAS mutation and KIT copy number 
gain [154]. Conversely, instead of developing secondary gatekeeper mutations to reactivate 
BRAF, melanoma cells typically reactivate other members in the MAPK signaling cascade 
[191] upon BRAF inhibitor treatment. For example, patients that are resistant to BRAF 
inhibition have additional mutations in NRAS that reactivate the MAPK pathway (reviewed in 
[192, 193]). Moreover, BRAF activity is capable of being substituted by other paralogs of 
BRAF, such as CRAF and ARAF. Lastly, kinases that activate MAPK signaling are also 
involved in melanoma therapy resistance. One study identified the cobalt uptake protein 
(COT1) as an adaptive response mechanism to BRAF inhibition in melanoma cell lines. In 
the absence of activated BRAF, COT1 is able to stimulate the MAPK signaling pathway, 
leading to resistance [194]. Recently, work was done to better understand resistance 
mechanisms involved in BRAF and MEK inhibition in more detail. Studies found that 
suppression of SOX10 in melanoma induced the activation of TGF-β signaling, leading to the 
upregulation of epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor-β (PDGFRβ) responsible for resistance to BRAF and MEK inhibitors [195]. 
Moreover, this work suggests that EGFR-positive melanoma may benefit from re-treatment 
of BRAF inhibitors after structured treatment suspension. 
Due to the high occurrence of melanoma therapy resistance, many clinical trials have 
focused on combining already approved targeted therapy for synergistic and more potent 
effects in the clinic. Clinical studies have investigated selective BRAF inhibitors 
(vemurafenib, darafenib, encorafenib) in combination with selective MEK 1/2 inhibitors 
(trametinib, cobimetinib, binimetinib) [138]. One clinical trial investigated the effects of 
combining darafenib and trametinib as a first-line therapy option for patients with non-
resectable or metastatic BRAFV600E/K-mutated melanoma stage IIIC or stage IV. The trial 
observed an overall response rate of 67 % for the combination therapy compared to 51 % for 
darafenib only. Moreover, the progression-free survival rate was 93 % for the combination 
therapy compared to 85 % with darafenib only [196]. Correspondingly, another combinatorial 
phase III clinical trial found similar results when the combination of the BRAF inhibitor 
vemurafenib and the MEK inhibitor cobimetinib were used [197]. Lastly a recent clinical trial 
in metastatic melanoma patients, tested darafenib in combination with trametinib in 
comparison to vermurafenib monotherapy. Significantly improved overall survival was 
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observed in patients receiving combinatorial therapy compared to monotherapy after 12 
months, with progression-free survival rates of 72 % and 65 %, respectively [198].  
Another combinatorial tactic for avoiding the development of therapy resistance is the 
combination of immunotherapy and targeted therapy to treat melanoma. A phase I study 
investigated the use of ipilimumab, an anti-CTLA-4 antibody, in combination with different 
doses of BRAF inhibitor vemurafenib. However, there were several adverse side effects 
observed, including hepatotoxicity [199]. Another phase IB study investigated the 
combination of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma 
stages IIIB/C/IV. Peginterferon alfa-2b was initially approved for the treatment of hepatitis C 
and, in 2011, was approved for the treatment of melanoma. Peginterferon alfa-2b modulates 
the JAK-STAT pathway and controls the immune response by transcribing genes, including 
interleukin 4 (IL4), and subsequently inducing type 2 helper T cells, stimulating B cells 
amplifying the immune response [200]. Combinational therapy of peginterferon alfa-2b and 
ipilimumab led to a clinical benefit rate of 53.8 % and response rate of 42.3 % in 
unresectable stage IIIB/C/IV melanoma patient population [201]. Melanoma therapy 
resistance remains a major roadblock for the successful treatment of melanoma patients. 
However, there has been some progress in understanding the mechanisms by which 
melanoma cells become resistant and tackling resistance using combinatorial treatment 
strategies. 
1.3.7 Melanoma invasion, metastasis and plasticity 
Activating invasion and enabling metastasis is not only a hallmark of cancer in general but 
also causes most cancer-related deaths, especially in malignant melanoma [202]. Invasion 
and metastatic spreading are processes that alter tumor cell shape and their attachment to 
other cells and the ECM. Alterations in cadherin expression represent a well characterized 
feature of invasive cells [202] and the activation of the EMT process [202]. 
The EMT is driven by a network of embryonic EMT-inducing transcription factors from the 
following gene families: SNAIL, twist family bHLH transcription factors (TWIST) and zinc 
finger E-box binding homeobox (ZEB). In various cancer types, aberrant expression of these 
genes is a common occurrence and is correlated to poor prognosis and risk of metastatic 
spread. The EMT leads to the in the acquisition of stem cell-like qualities such as self-
renewal and reduced proliferation [203, 204]. Importantly, the EMT is flexible and transient 
which allows high tumor cell plasticity, driven primarily by microenvironment cues [205, 206]. 
In melanoma, tumor cell plasticity is mainly controlled by MITF. Unlike other epithelial 
tissues, melanocytes express EMT markers SNAI2 and ZEB2 and therefore one hypothesis 
claim this expression predisposes the lineage towards malignant transformation [207]. It is 
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important to note that since melanocytes do not belong to the epithelial lineage and the EMT 
cannot be fully attributed to malignant transformation, however melanocytes do express E-
cadherin to form close contacts to neighboring keratinocytes. Recently, the EMT 
transcriptional network in melanoma was revealed to undergo remodeling to favor expression 
of TWIST1 and ZEB1 upon NRAS/BRAF activation promoting an invasive phenotype [203]. 
The development of the NC during normal embryogenesis requires induction of the EMT and 
initiation of a migratory phenotype. Many of these phenotypes exhibited by NCCs, 
specifically during their migration phase, have also been implicated in cancer cell invasion 
and metastasis. For example, some of the overlapping mechanisms include the cadherin 
switch from E-cadherin to N-cadherin expression, expression of members of the SNAIL 
superfamily and the induction of MMP expression. For these reasons, studying the NC during 
normal development has been of significant interest to the field of cancer research, including 
melanoma. The current knowledge of processes underlying melanocyte specification and 
lineage determination are now becoming relevant in understanding melanoma initiation, 
progression and invasion. Overlapping pathways between the neural crest, melanocyte 
development and melanoma are summarized in Table 1.  
The melanocytic lineage has been heavily implicated in malignant transformation. Multiple 
behavioral and functional aspects important in NC development, including the cadherin 
switch and MMP expression and secretion, are also detected in melanoma (reviewed in 
[208]). Taken together, this indicates that the NC differentiation program can cooperate with 
oncogenic mutations and lead to malignant transformation. Further evidence linking the NC 
developmental program to malignant transformation in melanoma is provided in 
transplantation experiments, where melanoma cells and melanocytes were exposed to an 
embryonic environment. Upon transplantation into avian embryos, highly aggressive 
malignant melanoma cell lines were able to migrate along normal NCC routes, suggesting 
that melanoma cells are able to respond to environmental cues [209]. These migrating 
malignant melanoma cells downregulated pluripotency-associated genes while re-expressing 
early melanocytic and neuronal markers [210]. Interestingly, when these cells were implanted 
into non-NC regions, such as the embryonic optic cup, the cells gave rise to invasive 
malignant melanomas [211]. This data suggests that NC environmental cues are able to 
direct only NC-derived lineages [212]. However, these results only suggest that malignant 
melanoma can respond to NC-related extrinsic cues but does not implicate these cues in 
transformation itself. 
The aberrant regulation of NC developmental genes promotes plasticity and invasiveness in 
malignant melanoma [213]. This ability of melanoma cells to regain NCC migrative properties 
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and respond to embryonic environmental cues led to further investigation of these observed 
phenotypes. Expression profiling of metastatic melanoma found two distinct transcriptional 
signatures corresponding to either proliferative or invasive phenotypes [214]. Not only did 
melanoma cells possess one of the two phenotypes but were also capable of switching 
between the two states, termed the so-called phenotype switch. Moreover, melanoma cells 
could generate tumors, which contained both phenotypes independent of the initial 
phenotype [215]. In addition, NC-related genes were expressed in the non-invasive 
phenotype. Further work on the effects of the environment on the phenotype switch 
demonstrated when proliferative melanoma cells were subjected to hypoxic 
microenvironments in vivo and that this condition was sufficient to induce de-differentiation, 
resulting in the phenotype switch and therefore increased invasion by the melanoma cells 
[216].  
 
Mechanisms regulating the differentiation status of melanoma cells have also been under 
investigation, since this typically indicates the aggressiveness of the tumor and potential 
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induction of the phenotype switch. Dedifferentiation is a common indicator and route to 
metastasis in cancer. One theory suggest that melanoma dedifferentiates in order to activate 
the NC developmental program and trigger migration and invasion [217, 218]. However, the 
downregulation of MITF was found to lead to the re-expression of some pluripotency 
markers, OCT4 and NANOG. Moreover, these melanoma cells showed an increased 
invasive phenotype [219]. Similarly, another study found that a melanoma cell line could 
switch between low and high invasive phenotypes, depending on the expression levels of 
MITF [214]. 
Taken together, melanoma cells are masters of utilizing their developmental program for 
many facets of malignant transformation. Their ability to use NC migration-related genes and 
potentially pluripotency-related genes allows melanoma cells to easily acquire migratory and 
invasive capabilities. Moreover, the ability of melanoma cells to switch transcriptional 
signatures from proliferative to invasive phenotypes via several mechanisms, including 
environmental cues and dedifferentiation, further highlights the plasticity of melanoma cells in 
vivo. 
1.4 SOX proteins: Discovery, structure and function 
The SOX family of transcription factors consists of crucial regulators of several known and 
important processes in pluripotency, development and disease. Seminal research in 1990 
discovered the mammalian testis-determining factor. This gene was named SRY due to its 
specific location in the sex-determining region on the Y-chromosome [220, 221]. This gene 
received significant attention since it was found to be the sex-determining locus in mammals 
[222]. The SRY gene contains three major domains: N-terminal, high-mobility group (HMG) 
and transactivation. The HMG domain is crucial for DNA recognition and binding. In general, 
proteins that contain the HMG domain with amino acid similarity of 50 % or higher to the 
HMG domain of SRY are termed SRY-related HMG box (SOX) proteins [223–225]. These 
autosomal genes with similar DNA binding motifs are a part of a large family of 
developmentally relevant transcription factors termed the HMG superfamily [221, 226–228]. 
1.4.1 SOX family 
The SOX family is a subfamily of the large HMG superfamily. This superfamily was said to 
have emerged over 1 billion years ago before the divergence of plants and animals [227, 
229]. The commonality that constitutes the members of this superfamily is the essential HMG 
domain. The HMG domain is the fundamental domain in all members of the HMG 
superfamily, especially the SOX family, and is comprised of 79 amino acids, which permits 
DNA-SOX protein interactions [224, 230]. Nuclear magnetic resonance (NMR) analysis of the 
HMG domain in SOX proteins revealed that the structure and the sequence specificity of this 
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domain imposed restricted amino acid choices and positions for SOX proteins [224]. The 
HMG domain of the SOX proteins is highly homologous and recognizes only 6-7 base pairs 
of DNA sequence [231] in the minor groove of DNA [232, 233]. The consensus motif for SOX 
proteins was defined as the sequence 5 ’-(A/T)(A/T)CAA(A/T)G- 3’ [232]. Therefore a crucial 
commonality of the SOX protein family is that all family members are regulators of gene 
transcription.  
Initially, SOX proteins were classified by the deduced amino acid sequence of their HMG 
domain alone [221, 224]. To date, there are 20 orthologous pairs of SOX proteins between 
the mouse and human genome [234]. Of these 20 SOX proteins, they are further subdivided 
into groups according to sequence similarities and assembled into Groups A-G, where Group 
A is allocated to SRY [231, 235]. Within a group, the sequence similarity of the HMG domain 
is ≥ 90 % for most groups, but decreases to approximately 60 % between distant groups 
[231]. Evidence has shown that SOX family divergence already occurred before the base of 
the metazoan tree and the SOX groups SOXB, SOXE and SOXF are phylogenetically old. 
Additionally, the diversity of the SOX family members increased, especially in the SOXB 
group. The SOXB group further expanded its diversity in many animal groups. In mammals, 
there are five SOXB genes, which are further divided into the subgroups SOXB1 and SOXB2 
[223]. 
In 1994, the SOX2 gene, one of the SOX family members, was discovered and characterized 
in humans [236]. The SOX2 gene, located on chromosome 3q26.3–q27, is a member of the 
SOXB1 subgroup. SOX2 is comprised of three main domains: the N-terminal, the HMG and 
the transactivation domains (Figure 2a). To date, SOX2 research has heavily emphasized its 
crucial role in stem cell maintenance, lineage fate determination and as a necessary factor to 
reprogram somatic cells back towards pluripotency. 
1.4.2 SOX HMG domain structure and local architecture remodeling 
The structure of the SRY-type HMG domain has been described both on and off the DNA 
helix [237, 238]. The domain is comprised of three α-helices (I-III), like other HMG domains, 
which form a twisted L-shape. The overall structure of the domain is maintained by its 
hydrophobic core. These core amino acids remain highly conserved between SOX proteins 
and provide the base-specific DNA contacts. During DNA binding, the overall structure of the 
domain remains constant. However, a conformational change is induced on the target DNA. 
Therefore, the DNA bound by SRY or other SOX proteins displays a 70-85 ° bend [224, 239–
241]. The HMG domain-DNA interaction is crucial for successful gene transcription. 
However, the DNA structural changes in the target DNA induced by this binding are also 
necessary for efficient transcription. A study on one SOX family member, SOX2, illustrated 
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that SOX2 could not only induce DNA bending in a spatially precise manner but also that its 
transcription depends on it [242]. The investigation was done by creating mutations directed 
toward the HMG domain, resulting in differential geometric alterations of DNA bending and 
different activation of transcription by SOX2 on the FGF4 promoter. These studies prove that 
precise three-dimensional architecture is necessary for successful transcriptional activity in 
the SOX family of transcription factors [242]. 
The HMG domain of SOX proteins not only restructures DNA for transcriptional purposes but 
can also facilitate the formation of higher-order nucleoprotein complexes [243]. There are two 
mechanisms by which the HMG domain-induced DNA bend assists the formation of higher-
order protein-DNA structures. The first mechanism is the Compass model, where a protein 
regulates gene expression by bending the DNA helix to put side by side nonadjacent 
regulatory elements together. In this scheme, no interaction between other regulatory 
proteins is required for the nucleoprotein structure, since the single protein is capable of 
interacting with both nonadjacent sites due to the DNA bend [243]. The second mechanism 
is the Scaffold model (Figure 2b). This model occurs when DNA bending provides optimal 
scaffold structure for the assembly of additional proteins [243]. SOX proteins commonly act 
in this manner and create large nucleoprotein structures. However, these interactions do not 
automatically activate promoters or enhancer regions. There are two criteria which must be 
met before partner interaction and transcription of target genes occurs. First, both 
transcription factors must bind to their particular binding sequences and induce 
conformational changes in the DNA helix. Second, the induced conformational changes must 
facilitate proper spacing and angles between DNA-bound transcription factors to allow 
precise partner interaction to form highly potent activation complexes [244]. These 
interactions are highly regulated can lead to high activation of target gene transcription, For 
example, these conditions are impeccably met on the δ-crystallin DC5 enhancer, which 
contains a SOX2 binding site and PAX6 paired binding domain sites [245] and upon precise 
binding of both factors transcription is profoundly activated. 
1.4.3 SOX protein partners and function 
SOX proteins are found in all cell types but regulate distinct, variable, and cell type-
dependent target genes. This specific regulation lies in the precise interactions of SOX 
proteins with their protein partners. Not only do SOX proteins require additional transcription 
factors for successful and efficient gene activation, this interaction is also highly dependent 
on cell type [231]. The SOX-partner combination permits specific regulation of various cell 
functions, including cell specification and control of embryonic development [244]. These 
interactions typically occur between the HMG domain of SOX proteins and the DNA binding 
domain of other transcription factors [246]. SOX protein interactions with specific partners are 
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able to determine the cellular fate of many different lineages. For example, when SOX2 
partners with OCT3/4 or δEF3, the target genes FGF4 and UTF1 or CRYGD (δ-crystallin) are 
activated, respectively. Moreover, the partnership between SOX2 and OCT3/4 leads to the 
maintenance of embryonic stem cells and inner cell mass (ICM) cells, while its interaction 
with δEF3 is crucial for lens development [231].  
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1.4.4 Post-translational modifications of SOX proteins 
Post-translational modifications of proteins represent an additional level of regulation in the 
cell. These processes include altering or additional protein folding before the mature protein 
product is produced. Additionally, these modifications can be introduced chemically, with the 
addition of cofactors or in the presence of additional proteins and complexes. Some of these 
post-translational modifications that involve additional proteins include ubiquitination and 
SUMOylation. SUMOylation is the reversible covalent linkage to a small ubiquitin-related 
modifier (SUMO) protein (reviewed in [247]). 
The mechanism of SUMOylation is similar to that of ubiquitination, where the outcome is the 
formation of an isopeptide bond located between the C-terminal Gly residue of the modified 
protein and the ε-amino group of a Lys residue of the acceptor protein [247]. Though both 
pathways require the activation of enzymatic cascades, there is no overlap in enzymes 
utilized by each pathway. Before conjugation can occur in the SUMOylation process, the 
immature SUMO protein must be proteolytically processed by SUMO-specific isopeptidases 
sentrin-specific proteases (SENPs) to reveal its C-terminal Gly-Gly motif. Once processed, 
the SUMO protein is mature and ready for the attachment to substrates. The first step in the 
attachment of mature SUMO proteins to substrates is the activation of the C-terminus via the 
SUMO-specific E1-activating enzyme heterodimer A0S1-UBA2. Next, SUMO-AOS1-UBA2 is 
transferred to the E2-conjugating enzyme UBC9, where a thioester linkage is formed 
between the Cys residue of UBC9 and the C-terminal region of SUMO. Lastly, the UBC9 
transfers SUMO to its final substrate, facilitated by E3 ligases (including members of the 
protein inhibitor of activated STAT (PIAS) family), which catalyze the transfer of SUMO from 
UBC9 to the substrate [247]. This process is reversible and the substrate can be removed by 
SENPs. 
The molecular consequence of SUMOylation on its target protein is difficult to predict. 
SUMOylation can influence several aspects of its target proteins function in vivo, such as 
localization, stability, activity and interaction with protein partners [247]. Since SUMOylation 
alters the surface of its target protein, interactions with other protein partners can either be 
promoted, through the addition of interfaces, or destroyed, by masking of pre-existing binding 
sites. Moreover, protein-protein interactions can be altered upon SUMOylation due to 
conformational changes in the target protein which lead to the destruction or exposure of 
binding sites [247].  
In the SOX family, SUMOylation has been shown to be important for functional diversity in 
the SOXE subgroup. Studies found that in Xenopus, both SOX9 and SOX10 can be SUMO-
modified in vivo [248]. In this study, two phenotypes were compared. Xenopus embryos 
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either overexpressed WT SOXE (non-SUMOylatable SOXE mutant) or a SOXE-SUMO1-
fusion. The non-SUMOylatable SOXE promoted the expression of NC-related markers, while 
the SOXE-SUMO-1 fusion inhibited the expression of NC-related markers. Moreover, neither 
phenotype was able to completely reproduce the WT phenotype, which suggests that both 
unmodified and SUMOylated forms of SOXE proteins contribute to the WT SOXE activities in 
vivo [248, 249]. Additionally, another study observed that SUMOylation of SOX10 represses 
the transcriptional activity of its target genes, including MITF [250]. Recent work further 
investigated this topic and showed that the SUMOylation of SOXE proteins alters the 
recruitment of transcriptional cofactors. Specifically, SUMOylation caused the displacement 
of CREB-binding protein/p300 while promoting the recruitment of corepressor GRG4 [251]. In 
addition to the SOXE group, a study found that SOX2, when conjugated to SUMO-1, reduced 
its binding to the FGF4 enhancer [252]. 
Taken together, SOXE proteins can function as transcriptional repressors in a SUMO-
dependent manner in the NC. Moreover, SOX2 conjugated to SUMO-1 also functions as a 
transcriptional repressor. Therefore, the role of SUMOylation in the context of SOX proteins 
may be crucial in further understanding their regulation in development and disease. 
1.4.5 SOX2 and its role in embryonic development, disease and cancer 
SOX2 has been heavily studied in many aspects of normal human development but also in 
areas of disease and cancer. The first function of SOX2 was identified in embryonic 
development and now it’s well understood that SOX2 is a critical factor throughout 
embryogenesis.  
SOX2 was first discovered in embryogenesis and development and this remains a major field 
of study of this protein. It plays an important role in lineage specification, proliferation, 
morphogenesis and differentiation of various developing tissues in a fetus (reviewed in 
[225]). Here, I will briefly discuss the function of SOX2 in a developing embryo. 
SOX2 is initially present in both ICM and the trophectoderm (TE) but is later restricted to the 
ICM. Studies have shown that the zygotic deletion of SOX2 results in early embryonic 
lethality caused by the failure to form the pluripotent epiblast [253]. When both the maternal 
and zygotic SOX2 transcripts were depleted using RNAi, embryos underwent early arrest at 
the morula stage, leading to a complete failure of TE formation. These experiments suggest 
that SOX2 is required for the segregation of the TE and ICM [225, 253]. Therefore, SOX2 is 
critical for the maintenance of pluripotency in embryonic stem cells (ESCs). Expression 
levels of SOX2 heavily influence ESC self-renewal and differentiation in a dose-dependent 
manner. Moreover, SOX2 cooperates with other dosage-sensitive transcription factors, such 
as OCT4 and NANOG, to sustain the vital network responsible for self-renewal and 
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repression of differentiation programs in ESCs [254]. On a molecular level, SOX2 and OCT4 
interact and collaborate to efficiently bind DNA and recruit other factors to initiate or repress 
gene transcription. Additionally, many target genes contain OCT4/SOX2 consensus binding 
sequences, further indicating the importance of the interaction in regulating gene 
transcription.  
After gastrulation occurs in the embryo, SOX2 expression becomes largely restricted to the 
neuroectoderm, sensory placodes, branchial arches, primordial germ cells and gut endoderm 
[225]. In the ectoderm, SOX2 is expressed during the early stages of ESC differentiation 
towards the neural lineage, where SOX2 directly suppresses key regulators of the 
mesendodermal lineage, such as Brachyury [255]. Furthermore, SOX2 is important in the 
fate decision of bipotent axial stem cells into either paraxial mesoderm (dermis, skeletal 
muscle, and vertebral column) or the neural plate (central nervous system). SOX2 continues 
to be involved in the developing central and peripheral nervous system. Lastly, in the 
endoderm, SOX2 is responsible for organ specification, including the foregut [225]. In 
summary, SOX2 is heavily involved in key steps during embryonic development, from 
maintaining ESCs to fate decisions in the mesoderm and nervous system. 
Many of the key regulatory features of SOX2 mentioned above are not performed by SOX2 
alone. In fact, SOX2 regulates many aspects of embryogenesis in collaboration with a protein 
partner. The interaction of SOX2 and OCT4 is crucial for the activation of key embryonic 
genes responsible for ICM and ESC maintenance. Additionally, SOX2 is known to form 
heterodimers with transcription factor BRN2, which creates a positive feedback loop and 
transcribes SOX2 as well as the target gene NESTIN to maintain neural progenitor identity 
[244]. Another well-described interaction partner of SOX2 during lens development is PAX6. 
This interaction creates a positive feedback loop of both SOX2 and PAX6 transcription while 
also targeting the transcription of CRYGD (δ-crystallin) (Figure 2c). Recent work has tried to 
identify new interacting partners of SOX2 using proteomic analysis. However, the candidates 
need to be validated and investigated in a developmental context [256, 257].  
Since SOX proteins play a crucial role in development and cell regulation, the mutation or 
deletion of SOX proteins often leads to congenital disease or developmental defects in 
humans [224]. For example, a heterozygous mutation of SOX2 results in an abnormal 
development of ectodermal and endodermal tissues, known as anophthalmia-esophageal-
genital (AEG) syndrome. Individuals with anophthalmia are typically born with small eyes 
(microphthalmia) or even completely without eyes [258]. These patients also suffer from 
symptoms such as brain anomalies, hearing loss, esophageal atresia, genital abnormalities, 
pituitary defects and delayed motor skill development [258–260]. An interesting study in 2011 
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set out to further investigated SOX2 regulation in neural stem cells. Instead, they identified 
CHD7 as a SOX2 transcriptional co-factor [261], and revealed that SOX2 and CHD7 have 
overlapping genome-wide binding sites. Therefore, they are capable of regulating a common 
set of target genes: JAG1, GLI3 and MYCN. These genes are typically mutated in the 
genetic diseases Alagille, Pallister-Hall and Feingold syndromes [261]. This research further 
implicated SOX2 in human disease. 
Current research on SOX2 has expanded focus from embryonic development to its 
implications in disease and cancer. SOX2 has been shown to play various roles in several 
cancer types and have important associations to the clinic [262, 263]. The function of SOX2 
in cancer has illuminated its multifaceted capabilities in the cell. It has been shown to 
influence many pathways, from cellular proliferation to cancer cell invasion and metastasis 
(reviewed in [262]).  
SOX2 amplification is induced by the multiplication of the 3q26.3 gene locus [264, 265]. 
Which occurs in esophageal squamous cell carcinoma (SCC), glioblastoma, oral SCC, 
sinonasal cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 
lung SCC [264, 266–271]. A large study determined the copy number from 40 esophageal 
SCC DNA samples and 47 primary lung SCC DNA samples and found that the most 
significant amplification peak was located on chromosome 3q26.33 [266]. Moreover, 
researchers found that SOX2 was not only amplified, but that its expression was required for 
proliferation and anchorage-independent growth of both lung and esophageal cancer cell 
lines. This study identified SOX2 as a lineage-dependent oncogene in lung and esophageal 
SCC [266].  
SOX2 has not only been shown to be amplified in some cancer types. Much work has been 
put into understanding how it functions in multiple cancer types. Generally, SOX2 has been 
shown to influence cellular migration, invasion, proliferation and self-renewal of cancer stem 
cells, tumorigenicity, autophagy and metastasis. This illustrates the molecular complexity of 
SOX2’s role in cancer and further proves that SOX2 is of great importance in oncology. 
SOX2 typically plays differential roles, depending on the cancer type, further highlighting its 
intricacy in oncology. Though a few examples of SOX2’s involvement in cancer are 
described here, the field is immense and was recently reviewed in [262]. 
The regulation of cellular proliferation by SOX2 was observed in various types of cancer, 
including breast, colorectal and pancreatic cancer. For instance, functionally inhibited SOX2 
via cellular transfection with a tetracycline-inducible C-terminally-truncated version of SOX2, 
dnSOX2. Although lacking the transactivation domain, dnSOX2 could bind SOX2 recognition 
sites on DNA and compete with WT SOX2. This inhibition led to a decrease in cellular 
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proliferation in AZ-521 gastric cancer cells [272]. Numerous gain and loss of function studies 
in several cancer types (gastric cancer, ovarian cancer and hepatocellular carcinoma) 
enforced the link between SOX2 and cellular invasion and migration (reviewed in [262]). For 
example, the overexpression of SOX2 in the SOX2-negative glioma cell line U-87 resulted in 
a significant increase in the number of migratory and invasive cells [273]. Recently, SOX2’s 
involvement in promoting invasion and migration was demonstrated in laryngeal cancer cells 
through the induction of MMP-2 and the PI3K/AKT/mTOR pathway [274]. 
SOX2 induces these functional changes in cancer by being heavily involved in various 
oncogenic signaling pathways. In breast and prostate cancer cells, SOX2 has shown to 
promote metastasis via the EMT through WNT/β-catenin signaling. In chromatin 
immunoprecipitation (ChIP) studies, SOX2 was found to bind to the promoter region of β-
catenin, which further implicates a role for SOX2 in this signaling pathway [275]. Another 
study revealed that SOX2 was induced upon TGF-β stimulation in glioma-initiating cells. 
Furthermore, ChIP studies elucidated SOX4 as a direct regulator of SOX2 upon TGF-β 
stimulation by binding to the promoter region of SOX2 [276].  
The ability to improve reliability of diagnosis and prognosis for a cancer patient can have 
immense impact on patient survival and contribute to overall improved responses to 
therapies. Since SOX2 has great influence on cancer pathogenesis, research has aimed to 
understand the impact of SOX2 in clinical settings. In one study, 162 esophageal squamous 
cancer patients were analyzed for SOX2 and OCT3/4 expression. High expression of both 
markers was associated with a higher histological grade or stage (p < 0.001 for both factors). 
Furthermore, a significant correlation between high SOX2 expression and decreasing patient 
survival was observed (p < 0.001) [277]. However, it is important to note that SOX2 does not 
correlate with poor prognosis or decreased progression free survival in all cancer types. In 
fact, it has been shown to correlate with a favorable prognosis in lung cancer [262, 278]. 
To date, little is known about SOX2 and its function in melanoma. As mentioned above, SOX 
proteins play a critical role during early development and the NC and only recently has been 
associated with melanoma progression [195, 279, 280]. Since studies have shown that the 
melanocytic developmental program may predispose the lineage to malignant 
transformation, SOX2 has raise great interest in the field of melanoma [207] Initial studies 
found that SOX2 was highly expressed in primary melanoma (67 %) and metastatic 
melanomas (80 %) compared to nevi (14 %) [281, 282]. Moreover, SOX2 expression was 
associated to dermal invasion, which was determined by increased tumor thickness [281]. A 
bioinformatic study that used the database Oncomine to investigate stem cell markers in 40 
different cancer types found that SOX2 was significantly overexpressed in melanoma 
Introduction 
40 
metastasis patients who died after three years compared to those patients who remained 
alive after three years [283]. This study hinted towards SOX2 playing a role in melanoma 
pathogenesis. 
A study in 2011 began to further investigate SOX2 in melanoma and how this protein may be 
functionally affecting melanoma cells [284]. Upon examining patient melanoma samples and 
melanoma xenografts, SOX2 was found to be highly expressed in cells which bordered and 
infiltrated dermal stroma. Subsequently, gain and loss of function studies were performed in 
melanoma cell lines and changes in invasion capacity were observed. An RT-PCR screen 
revealed MMP-3 to be a potential mediator of the SOX2-induced invasive phenotype of 
human melanoma cells [284]. In addition, one study suggested that SOX2 is able to 
modulate MITF in normal human melanocytes and melanoma cell lines in vitro, but the exact 
mechanism remains to be elucidated [285]. 
Recently, work has implicated SOX2 in the regulation of self-renewal and tumorigenicity of 
melanoma-initiating cells [286]. This study investigated SOX2 in melanoma-initiating cells 
and Hedgehog-GLI (HH-GLI) signaling and functionally revealed that the ectopic expression 
of SOX2 in vitro caused enhanced self-renewal capacity in melanoma cells. Moreover, GLI1 
and GLI2, downstream transcription factors of HH-GLI signaling, were able to bind to the 
proximal promoter of SOX2 in primary melanoma cells in ChIP studies. These data indicate 
that SOX2 is regulated by HH signaling [286]. In summary, SOX2 is a critical regulator of 
embryonic development and is also responsible for oncogenic functionalities in various 
cancer types. The further understanding of SOX2 in the context of cancer will provide more 
insights into cancer pathogenesis and potentially be beneficial in the clinic. 
Taken together, melanocytes are derived from the pluripotent stem cell population of cells 
known as the neural crest. The neural crest consists of several well-described stages 
including: induction, delamination and migration. Understanding the neural crest using in vitro 
models will aid in understanding development in depth but also becomes relevant in disease. 
Malignant melanoma originates from the neural crest-derived melanocytes. To date, 
overlapping mechanisms between the developmental neural crest and malignant melanoma, 
such as the role of BMP [287] and WNT signaling [288, 289] and initiation of the EMT [203], 
have given rise to the hypothesis that melanoma reactivates its developmental program to 
assist in malignant transformation (Table 1). For these reasons, studying neural crest and 
embryonic-related markers may reveal novel mechanisms that are also being reactivated in 
malignant melanoma. 
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2 Aim of study 
The plasticity of melanoma cells makes them capable of switching between highly 
proliferative and highly invasive phenotypes depending on environmental cues, stage of 
disease or evasion of therapy [215]. To date, neural crest-related genes have been heavily 
implicated in melanoma suggesting that the melanocytic developmental program may 
predispose the lineage to malignant transformation [207, 283, 290]. Therefore, there is an 
urgency to analyze genes, which are involved in stem cell and/or neural crest processes in 
order to elucidate those that may be reactivated during melanoma pathogenesis. Taken 
together, this study aims to address the following questions:  
1. Do any of the stem cell-associated genes, OCT4, SOX2 and NANOG, play a distinct 
role during directed melanocyte differentiation from hiPSCs?  
 
2. Are any of the stem cell-associated genes, which are involved in directed melanocyte 
differentiation from hiPSCs, also linked to melanoma pathogenesis? If so, what 
functional roles do these genes play?  
By first investigating stem cell-markers during directed melanocyte differentiation from 
hiPSCs, the study may identify critical genes that are reactivated during melanoma 
pathogenesis and melanoma plasticity. This method is a general ectodermal lineage 
differentiation method and therefore provides a favorable tool for identifying genes 
universally involved in ectodermal differentiation. Therefore, we are likely to elucidate novel 
genes associated with the ectodermal lineage that may be switched back on during 
malignant melanoma transformation. The identification of genes linked to melanoma 
plasticity would provide novel markers with possible clinical relevance for anti-melanoma 
therapy. 
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3 Materials 
All reagents not listed below are commercially available analytical reagents or laboratory-
grade materials. 
3.1 Reagents 
Product Description Company Branch 
Agarose NEEO Ultra Qualität Carl Roth Karlsruhe, Germany 
alamarBlue® Invitrogen Darmstadt, Germany 
APS Carl Roth Karlsruhe, Germany 
Dimethylsulfoxide (DMSO) Carl Roth Karlsruhe, Germany 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche Mannheim, Germany 
Rotiphorese® gel 30 Carl Roth Karlsruhe, Germany 
Skim milk powder Fluka Analytical Steinheim, Germany 
TMED(C6H16N2) Carl Roth Karlsruhe, Germany 
Tween® 20 Applichem Darmstadt, Germany 
X-treme GENE®  Roche Mannheim, Germany 
 
3.2 Materials 
Product Description Company Branch 
DAPI Roche Mannheim, Germany 
High performance 
chemiluminescence film 
GE Healthcare Buckinghamshire, UK 
ibidi® 30 µ-Dish Culture Insert 
(35mm high) 
ibidi Munich, Germany 
Immobilon-P Transfer 
Membrane Pore size: 0.45uM 
Millipore Schwalbach, Germany 
Mini Trans-Blot® Cell Bio-Rad Munich, Germany 
Parafilm Sigma-Aldrich Steinheim, Germany 
Whatman chromatography 
paper 
GE Healthcare Buckinghamshire, UK 
 
3.3 Antibodies 
Product Description Company Branch 
Rabbit anti-c-Jun (N) Santa Cruz Biotechnology Heidelberg, Germany 
Mouse anti-MITF (C5) Abcam Cambridge, UK 
Rabbit anti-SMAD2 Cell Signaling Technology Cell Signaling Technology 
Europe, B.V. 
Rabbit anti-SMAD3 Cell Signaling Technology Cell Signaling Technology 
Europe, B.V. 
Rabbit anti-SOX10 Abcam Cambridge, UK 
Goat anti-SOX2 R & D Systems Wiesbaden, Germany 
Rabbit anti-SOX2 Abcam Cambridge, UK 
Rabbit anti-TGFβ RII (C16) Santa Cruz Biotechnology Heidelberg, Germany 
Mouse anti-TRP1 Abcam Cambridge, UK 
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Mouse anti-TRP2 Santa Cruz Biotechnology Heidelberg, Germany 
Mouse anti-α-actinin Santa Cruz Biotechnology Heidelberg, Germany 
Mouse anti-GP100 Abcam Cambridge, UK 
Anti-rabbit HRP-linked 2°Ab New England BioLabs Frankfurt, Germany 
Anti-mouse HRP-linked 2°Ab New England BioLabs Frankfurt, Germany 
Anti-goat HRP-linked 2°Ab New England BioLabs Frankfurt, Germany 
Cy2-donkey anti-mouse Dianova Hamburg, Germany 
Cy2-donkey anti-rabbit Dianova Hamburg, Germany 
Cy3-goat anti-mouse Dianova Hamburg, Germany 
Cy3-goat anti-rabbit Dianova Hamburg, Germany 
 
3.4 Small molecule inhibitors 
Product Description Company Branch 
SB 431542 Selleckchem Munich, Germany 
 
3.5 Human cell lines 
Cell Line Source Authentication Disease Mutation (BRAF or NRAS) 
A375 ATCC Multiplexion 
Heidelberg Germany 
Malignant 
Melanoma 
BRAF V600E 
C32 ATCC Multiplexion 
Heidelberg Germany 
Melanoma, 
amelanotic 
BRAF V600E 
HT144 ATCC DSMZ 
Heidelberg Germany 
Malignant 
Melanoma 
BRAF V600E 
Mel 501 Ballotti lab, Nice N/A Melanoma BRAF V600E 
Mel STV CNIO Madrid IDEXX 
Ludwigsburg, Germany 
Melanocytic 
cell line  
N/A 
MeWo Ballotti lab, Nice Multiplexion 
Heidelberg Germany 
Malignant 
Melanoma 
WT/WT 
MZ-7 Thomas Tüting  Multiplexion 
Heidelberg Germany 
Melanoma BRAF V600E 
RPMI7951 ATCC  Multiplexion 
Heidelberg Germany 
Melanoma BRAF V600E 
SK Mel 103 CNIO Madrid Multiplexion 
Heidelberg Germany 
Melanoma NRAS Q61R 
SK Mel 147 CNIO Madrid Multiplexion 
Heidelberg Germany 
Melanoma NRAS Q61R 
SK Mel 173 CNIO Madrid IDEXX 
Ludwigsburg, Germany 
Melanoma WT/WT 
SK Mel 23 Cornelia Mauch Multiplexion, 
Heidelberg Germany 
Melanoma WT/WT 
SK Mel 28 ATCC Multiplexion 
Heidelberg Germany 
Malignant 
Melanoma 
BRAF V600E 
SK Mel 30 DKMZ Leibniz 
Institute 
Multiplexion 
Heidelberg Germany 
Melanoma NRAS Q61R 
WM2664 ATCC Multiplexion 
Heidelberg Germany 
Melanoma BRAF V600D 
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3.6 Cell culture 
Product Description Company Branch 
2-Mercaptoethanol Gibco® Life Technologies Darmstadt, Germany 
Adenine Sigma-Aldrich Steinheim, Germany 
Ascorbic acid Sigma-Aldrich Steinheim, Germany 
Bone morphogenic protein 4 
(BMP4) 
Promokine Heidelberg, Germany 
Cholera Toxin Sigma-Aldrich Steinheim, Germany 
DMEM AQmedia Sigma-Aldrich Steinheim, Germany 
Doxycyline Sigma-Aldrich Steinheim, Germany 
Endothelin 3 (EDN3)  Millipore Schwalbach, Germany 
Epidermal Growth Factor (EGF) Promokine Heidelberg, Germany 
Fetal Calf Serum (FCS) Biochrom Berlin, Germany 
Gelatine Sigma-Aldrich Steinheim, Germany 
Glutamax DMEM Sigma-Aldrich Steinheim, Germany 
Glutamax DMEM -glucose Sigma-Aldrich Steinheim, Germany 
HAM’s F12+ DMEM Gibco® Life Technologies Darmstadt, Germany 
Human melanocyte growth 
supplement (HMGS) 100x 
Gibco® Life Technologies Darmstadt, Germany 
Human stem cell factor (hSCF) PeproTech Rocky Hill, NJ USA 
Hydrocortisone Sigma-Aldrich Steinheim, Germany 
Hydroxyurea Sigma-Aldrich Steinheim, Germany 
Insulin Sigma-Aldrich Steinheim, Germany 
Matrigel® Corning Amsterdam, Netherlands 
Medium 254 Gibco® Life Technologies Darmstadt, Germany 
Mitomycin C Carl Roth Karlsruhe, Germany 
mTeSR™  stem cell medium Stemcell Technologies Colonge, Germany 
mTeSR™ 1 stem cell medium 
supplement 
Stemcell Technologies Colonge, Germany 
Neomycin (G418) Sigma-Aldrich Steinheim, Germany 
Normocin Invivogen Toulouse, France 
Non-essential amino acids Sigma-Aldrich Steinheim, Germany 
Penicillin streptomycin Sigma-Aldrich Steinheim, Germany 
Puromycin Sigma-Aldrich Steinheim, Germany 
Recombinant human TGFβ-1 PeproTech Rocky Hill, NJ USA 
Rock inhibitor Stemgent Bergisch Gladbach, Germany 
Sodium pyruvate Sigma-Aldrich Steinheim, Germany 
Triiodothyronine Sigma-Aldrich Steinheim, Germany 
Trypan blue solution Sigma-Aldrich Steinheim, Germany 
Trypsin Sigma-Aldrich Steinheim, Germany 
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3.7 Buffers and gels 
Transfer buffer (pH 8.3)  Running buffer (pH 8.3)  10 X TBS (pH 7.6) 
25 mM Glycine  25 mM Glycine  150 mM NaCl 
190 mM Tris  190 mM Tris  50 mM Tris 
20 % SDS  0.1 % SDS  dH2O 
20 % methanol  dH2O   
dH2O     
     
Washing buffer (TBST)  Washing buffer (PBST)  Blocking buffer (milk) 
0.02 % Tween® 20  0.02 % Tween® 20  5 % Skim milk powder 
1 x TBS   PBS  Washing buffer (PBS or TBS) 
     
Cell lysis buffer for protein isolation  Primary antibody (BSA) 
1 x PhosphoStop  1 x TBS 
1 x cOmplete mini protease inhibitor cocktail  0.1 % Tween® 20 
1 % Triton-X in TBS  5 % BSA 
   
10 % SDS separating gel  10 % SDS stacking gel 
dH2O  dH2O 
30 % Acryl (Rotiphorese®)  30 % Acryl (Rotiphorese®) 
1.5 M Tris (pH 8.8)  1 M Tris (pH 6.8) 
10 % SDS  10 % SDS 
10 % APS  10 % APS 
TEMED  TEMED 
 
3.8 Kits 
Product Description Company Branch 
ARCTURUS PicoPure RNA 
Isolation Kit 
Life Technologies Darmstadt, Germany 
Cultrex® 96 Well BME Cell 
Invasion Assay 
R & D Systems Wiesbaden, Germany 
Cytoselect™ invasion assay 
(Basement membrane, 
Fluorometric Format)  
Cell Biolabs Heidelberg, Germany 
ECL Prime western blotting 
detection reagent 
GE Healthcare Buckinghamshire, UK 
Pierce BCA protein assay kit ThermoScientific Karlsruhe, Germany 
RevertAid RT Kit ThermoScientific Karlsruhe, Germany 
RNase-free DNase set Qiagen Hilden, Germany 
RNeasy Mini Kit Qiagen Hilden, Germany 
Sybr®Green PCR mastermix Applied Biosciences Warrington, UK 
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3.9 Devices 
Product Description Company Branch 
AB 7500 Real-Time PCR 
machine 
Applied Biosciences Darmstadt, Germany 
Classic E.O.S. Developer AGFA Mortsel, Belgium 
Nanodrop Spectophotometer 
ND-1000 
Peqlab Biotechnologie GmbH Erlangen, Germany 
Nikon Eclipse Ti Fluorescence 
microscope 
Nikon Düsseldorf, Germany 
Nikon Eclipse TS100 Nikon Düsseldorf, Germany 
Tecan infinite F200 PRO Tecan Crailsheim, Germany 
 
3.10 Software 
Product Description Source 
7500 Software Applied Biosciences 
ApE Department of Biology, University of Utah 
Chipster Chipster Open source 
DOG 2.0 University of Science & Technology of China 
GENE-E Broad Institute 
Graphpad Prism Graphpad Prism 
ImageJ NIH 
Ingenuity (IPA) Qiagen 
Mendeley Mendeley 
NIS-Elements Nikon 
R www.r-project.org 
T-scratch ETH Zürich 
 
3.11 Online databases 
Name Website 
Cancer Cell Line Encyclopedia http://www.broadinstitute.org/ccle 
GPS-SUMO http://sumosp.biocuckoo.org/online.php 
JASPAR http://jaspar.genereg.net/ 
Protein Atlas http://www.proteinatlas.org/ 
Uniprot http://www.uniprot.org/ 
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4 Methods 
4.1 Cell culture 
All human melanoma cell lines and NIH 3T3 feeder cells were cultured in DMEM 
supplemented with 10 % FCS, 1 % penicillin (100 units/ mL) and streptomycin (100 µg/ mL), 
1 % mL non-essential amino acids solution (10 mM) and 0.75 % ß-mercaptoethanol, 
hereafter referred to as MEF medium.  
Normal human melanocyte cell lines and melanocytes differentiated from hiPSCs were 
cultured in Medium 254 (Gibco® Life Technologies) and supplemented with human 
melanocyte growth supplement (HMGS), 100 x (Gibco® Life Technologies). 
All cell lines were cultured in a humidified incubator with 5 % CO2 and 95 % air. 
4.2 Human induced pluripotent stem cell culture 
Stables clones of human induced pluripotent stem cells (hiPSCs) were generated from 
primary human fibroblasts in the Utikal lab following the protocol from Sommer et al. [291] 
using a lentiviral vector system. The hiPSCs were cultivated under xeno-free cell culture on a 
synthetic surface matrix. Matrigel plates were prepared one day prior to use (Section 4.2.1). 
Human iPSCs were washed in PBS and undifferentiated parts were manually dissociated 
into small cell clusters of 50-100 cells. These aggregates were transferred to Matrigel-coated 
plates and cultured in mTeSR1 medium containing 20 % (v/v) mTeSR1 supplements 
(Stemcell Technologies) and 50 µg/mL normocin. Human iPSCs were maintained by 
manually removing differentiated areas using a pipette tip to ensure clean colonies. 
4.2.1 Matrigel® preparation 
Matrigel® plates were prepared before seeding hiPSCs. Matrigel® was thawed on ice for 1-
2 h. Next, 25 mL of DMEM+F12 medium were transferred to a 50 mL falcon. Matrigel® was 
added to medium and 1 mL of the mixture was transferred to each well of a 6-well plate or 
6 cm dish. Plates incubated for 1 h at RT and were then ready for use. For storage up to two 
weeks, plates were not aspirated and wrapped with parafilm and placed at 4 °C. 
4.3 Melanocyte differentiation protocol 
Melanocytes were differentiated from hiPSCs by following the protocol described in Nissan et 
al. [292]. In preparation for the differentiation experiment, 6 cm cell culture dishes were pre-
coated with 0.2 % gelatin and left to set for 15 min at RT. 3T3 NIH feeder cells 
(Section 4.3.1) were thawed and counted. Cells were seeded at a density of 660,000 
cells/6 cm dish. Feeder cells were cultured overnight in normal MEF medium. The next day, 
hiPSCs were manually picked (about 3 colonies per 6 cm dish) using a pipette. Cells were 
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centrifuged for 5 min at 900 rpm to remove excess hiPSC medium. The medium was 
aspirated and cells were gently resuspended in differentiation medium and placed on top of 
NIH 3T3 feeder cells in 10 cm cell culture dishes and supplemented with ascorbic acid 
(0.3 mM) and BMP4 (20 pM) (Table 2). By day 60, pigmented areas of the dish were 
manually removed using a pipette and placed into an uncoated 10 cm cell culture dish. Cells 
were cultured in melanocyte-specific medium 254 supplemented with human melanocyte 
growth supplement. Selected cells were allowed to grow and were differentially trypsinized to 
isolate a pure population of melanocytes derived from hiPSCs, referred to as Mel D1. 
 
4.3.1 NIH 3T3 feeder cell preparation 
NIH 3T3 murine fibroblasts were trysinized and seeded in cell culture dishes in MEF medium. 
The following day the fibroblasts were treated with 8 µg/mL Mitomycin C in MEF medium for 
4-5 h in humidified incubator. This treatment places the cells in a postmitotic state. The cells 
were washed in PBS (Ca/Mg) and seeded for use as postmitotic feeder cells. 
4.4 Lentiviral particle production and transduction 
To produce infectious lentiviral particles, HEK293T cells were transfected with the target 
vector in combination with the packaging plasmids VSVG and Δ8.9 using X-tremeGENE® 
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Transfection Reagent (Roche) according to the manufacturer’s protocol. Supernatant was 
discarded 12 h after transduction. Viral supernatant was harvested 24, 36 and 48 h after 
transfection and directly used for transductions of target cells or centrifuged at 13500 rpm for 
5 h at 4 °C and stored as concentrated virus, stocks. 
4.5 Overexpression of SOX2 in human melanoma cell lines 
Gain-of-function experiments were performed using both an inducible FU-Tet-O human 
SOX2 construct selectable with G418, together with a lentiviral vector encoding the M2 
reverse tetracycline transactivator (kindly provided by K. Hochedlinger) (M2-rtTA, for 
construct design of FU-Tet-O human SOX2 and M2-rtTA see vector maps provided in 
Figure S1). As a negative control cells were transduced both constructs without doxycycline 
administration in order to exclude that observed effects were due to the expression of the 
constructs or the presence of doxycycline.  
The cloning of FU-TetO-hSOX2 neomycin was performed as follows. A resistance cassette 
comprising the neomycin-kanamycin phosphotransferase type II under the control of the 
murine PGK promoter was cut with EcoRI from the MIR Neomycin vector (provided by Dr. 
Daniel Novak) and blunted with the Phusion proofreading polymerase. In parallel, the FU-
Tet-O-hSox2 vector (kindly provided by K. Hochedlinger) was linearized with XhoI and 
blunted with the Phusion proofreading polymerase. Subsequently, the resistance cassette 
was inserted via blunt-end ligation into the linearized vector. The selection of the FU-TetO-
hSOX2 construct was performed using geneticin, G418, since resistance to G418 is 
conferred by the neomycin resistance gene. 
Lentiviral particles were produced following the protocol above (Section 4.4) and cells were 
transduced with supernatant containing lentiviral particles of SOX2 and M2 under S2 
conditions. Cells were seeded in 6-well plates and transferred to the S2 laboratory. Cells 
were infected with 500 µL of each virus for each corresponding condition. Cells were 
incubated overnight. The next day cells were superinfected with both constructs with the 
same amount of virus supernatant. The following day, cells were washed three times with 
PBS and transferred to the S1 laboratory. Cells were then induced with 1 µg/mL doxycycline 
for three days before selected with G418 for one week. Table 3 indicates the antibacterial 
selection concentration used for various melanoma cell lines.  
4.6 Knockdown of SOX2 and SOX10 in human melanoma cell lines 
shRNA constructs targeted against SOX2 were purchased from Genecopoeia 
(cat. #HSH017628-LvH1). Four different shRNA clones and a scrambled control 
(cat. #CSHCTR001-LvH1) were provided and clone 1 was used in experiments. shRNA 
constructs were selectable with puromycin and contained an eGFP reporter gene. Lentiviral 
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particles were produced as described above and transduction in human melanoma cell line 
SK Mel 103 was performed as described in Section 4.4. Transduced cells were selected 
using 1 µg/mL puromycin for three days (Table 3).  
shRNA constructs targeted against SOX10 were purchased from Genecopoeia 
(cat. #HSH017636-LVRH1GP). Four different shRNA clones and a scrambled control 
(cat. #CSHCTR001-LVRH1GP) were provided and clone 2 was used in experiments. shRNA 
constructs were prepared and used for transduction in human melanoma cell line C32 was 
performed as described in Section 4.4. Also cells were selected using puromycin at 1 µg/mL 
for three days (Table 3). 
4.7 Antibiotic selection 
Cells infected with a plasmid containing a neomycin cassette, conferring G418 resistance, 
(SOX2 overexpression construct) were selected with defined G418 concentrations optimized 
for each cell line (Table 3). For optimization, infected cells were seeded in 12-well plates at 
50 % confluence. G418 was added in six different concentrations, including a negative 
control without G418 (50, 5, 0.5, 0.05 and 0 µg/ml). The optimized selection concentration 
was defined as the minimal concentration killing all cells after one week of selection (kill 
curve). For long-term culture, the G418 concentration was reduced to 50 % of the optimized 
selection concentration. The same procedure was used to determine the antibiotic selection 
concentration for cells infected with a plasmid containing puromycin (SOX2 and SOX10 
shRNA constructs). As described above, a kill curve was determined for the C32 and SK Mel 
103 cell lines. The optimized selection concentration was defined as the concentration killing 
all cells after three days of selection. Optimized selection concentration was defined as the 
concentration killing all cells after three days of selection and the concentrations for 
puromycin tested were 10, 1, 0.1 and 0 µg/mL. For long-term culture, the culture medium 
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was supplemented with puromycin every 10 days at 50 % of the optimal selection 
concentration.  
4.8 Quantitative polymerase chain reaction 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) or the ARCTURUS PicoPure 
RNA Isolation Kit (Life Technology) according to the manufacturer’s protocol. Briefly, cells 
were lysed and RNA was purified using a column-based system. After washing and on-
column DNAse treatment, RNA was eluted from the column using nuclease-free water. 
Concentration and integrity were measured using a Nanodrop Spectophotometer ND-1000. 
Complementary DNA (cDNA) was generated from 500 ng RNA using the First Strand cDNA 
Synthesis Kit according to the manufacturer’s protocol. For all experiments, oligo-dT primers 
were used for cDNA synthesis, including the optional incubation step at 65 °C. cDNA was 
diluted 1:10 in nuclease-free water use in quantitative PCR (qPCR). 
qPCR was performed using SYBR Green in combination with the Applied Biosystems® 7500 
Real-Time PCR System (Life Technologies) according to manufacturer’s protocols. Primer 
sequences used are listed in Table 4. Expression of target genes was normalized to the 
housekeeping gene HPRT, 18S or both after testing all cells for low inter-sample variance of 
housekeeping gene expression (<3 cycles). All primers were validated; primers with 
amplification efficiencies between 80 – 120 % were defined as functional. All samples were 
analyzed in triplicate and data was processed using the 7500 Software and the delta (delta 
(Ct)) method, including the efficiency of each primer pair. Graphs were generated using 
GraphPad Prism software. Error bars show variance as 95 % confidence intervals calculated 
by the 7500 software. 
4.9 Immunoblotting 
Proteins were extracted using radioimmunoprecipitation assay (RIPA) buffer (Invitrogen) 
containing complete protease inhibitor cocktail (Roche). Protein yield was measured using 
the bicinchoninic acid (BCA) method (ThermoScientific) prior to protein separation on self-
made 10 % Tris/glycine SDS-polyacrylamide gels (Section 3.7) at 70 V for 30 min through 
stacking gel and then at 100 V for one h or until desired separation was obtained. Proteins 
were transferred onto methanol-activated polyvinylidene fluoride membranes for 70 min at 
100 V. Unspecific binding was blocked for 1 h using 5 % BSA in PBS or milk depending on 
antibody used, according to manufactures protocol. After overnight incubation with primary 
antibodies at 4 °C and washing three times with TBST or PBST washing buffer (at least for 
10 min each), depending on antibody used, the membrane was incubated with secondary 
antibodies against either mouse or rabbit IgG labeled with horseradish peroxidase for 1-2 h 
at RT. After washing three times with TBST or PBST, signals were visualized using ECL™ 
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Western Blotting Detection Reagents (GE Healthcare) according to the manufacturer’s 
protocol and imaging was performed using Classic E.O.S. Developer. Protein quantification 
was performed using ImageJ.  
 
4.10 Immunocytochemistry 
Seeded cells were washed with PBS and fixed for 30 min using 4 % PFA. After several 
washing steps with PBS, unspecific binding sites were blocked with 2.5 % bovine serum 
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albumin (BSA) in PBS before the cells were incubated with primary antibody. For primary 
antibodies that were not directly labelled, additional washing with PBS and incubation with a 
fluorescence-labeled secondary antibody was performed. Cells were washed with PBS and 
nuclei were stained with PBS containing 1 µg/mL of DAPI for 3 min. After mounting samples 
with DAKO mounting medium, cells were analyzed using a fluorescence microscope (Nikon). 
4.11 Immunohistochemistry 
Tumor tissues provided by UMM and prepared with support from our technician, Sayran Arif-
Said. The tissues were embedded in paraffin. Paraffin-embedded tissues were stained with 
hematoxylin and eosin (H&E) and additional indirect staining against SOX2 (1:100, ab97959 
Abcam) was performed as indicated in figure legends. Using biotinylated secondary 
antibody, expression could be analyzed by light microscopy. 
4.12 Tissue microarray analysis 
All analyses involving human melanoma tissue were carried out in accordance with the 
ethical committee II of the University of Heidelberg. 37 nevi and 26 primary melanomas were 
included in the tissue microarray (TMA) used in this study. TMA was generated at the core 
facility of the National Center for Tumor Diseases (NCT), Department of Pathology, 
University of Heidelberg. TMA-slides were prepared with support from our technician, Sayran 
Arif-Said. TMA-slides were stained for SOX2 with anti-SOX2 (1:100, ab97959 Abcam) 
overnight and after washing with TBST, slides were incubated with secondary, anti-rabbit 
antibody (Dako EnVisionTM + System-HRP; AEC K4009) for 60 min. After 15 min incubation 
with AEC according to the manufacturer’s protocol and additional washing steps, samples 
were counterstained with H&E and stabilized with mounting medium (Dako S3025) for 
storage and analysis. Each sample was included in duplicates to the TMA and control 
staining against S100B was performed to visualized tumor cells. Two blinded individuals 
applying a quantity/intensity- based IHC scoring system, which is displayed in Figure S2, 
performed scoring of tissue microarrays. 
4.13 Migration (scratch) assay 
Migration assay was performed in a manner similar to a scratch assay. However, cells were 
seeded using ibidi® chambers to achieve a precise 500 µm gap. The ibidi® chambers were 
removed from the slides, placed into a 6-well cell culture plate and allowed to adhere for at 
least 30 min. Next, cells were seeded at an optimized density of 70,000 cells per ibidi® side 
for each condition. Cells were allowed to attach for 4-5 h. The medium was then aspirated 
and replaced with MEF medium supplemented with 5 µM hydroxyurea (proliferation inhibitor) 
into the chambers. Cells were incubated overnight. The next day, the ibidi® chambers were 
removed very carefully. Cells were washed twice in pre-warmed medium and 2 mL of MEF 
Methods 
54 
medium supplemented with 5 µM hydroxyurea were added to each well. Cells and scratch 
were imaged using a fluorescence microscope at the following time points: 0, 6, 12, 24, and 
48 h. T-scratch software (ETH Zürich) was used to analyze images and quantify migration-
covered area. 
4.14 Invasion assays 
The Cytoselect™ invasion assay (basement membrane, Cell Biolabs) was used according to 
the manufacturer’s protocol to measure the invasive potential of cells. In brief, the basement 
membrane was rehydrated and 200,000 cells were seeded per well in serum-free medium. 
Next, 150 µL of media containing 10 % fetal bovine serum were added to corresponding 
wells of the feeder tray (bottom). The plate was covered and transferred to an incubator for 
24 h. After 24 h, medium was removed and replaced with cell dissociation solution. Cells 
were incubated for 30 min. Next, 4 x Lysis Buffer/CyQuant® GR dye solution was added to 
each well and allowed to incubate for 20 min at RT. Lastly, the mixture was transferred to a 
96-well plate suitable for fluorescence measurement. Fluorescence was measured at 
480 nm/520 nm. Relative invasion potential was determined by comparing relative 
fluorescent units (RFUs).  
A second assay used to determine the migration and invasion potential was the Cultrex® 96 
Well BME Cell Invasion Assay (©2008, Trevigen Inc.), applied according to the 
manufacturer’s protocol. Briefly, cells were starved in serum-free MEF-medium and transwell 
chambers were coated with 0.1 x basal membrane equivalent (BME) coating solution. After 
24 h, cells were seeded at a density of 50,000 cells/well in coated (invasion) and non-coated 
(migration) wells. Cells that migrated into the bottom chamber within a 24 h-period were 
lysed and stained with a fluorescent dye. Fluorescence was measured at 485 nm (excitation) 
and 520 nm (emission). Relative migratory and invasive potential was determined by 
comparing RFUs. 
4.15 alamarBlue® assay 
Cells were seeded in triplicate into black 96-well plates and growth capacity was analyzed 
after 72 h. Medium was carefully removed, 10 % alamarBlue® REDOX indicator dye 
(Invitrogen) in medium was applied and fluorescence was measured after indicated time with 
an excitation wavelength of 530-560 nm and emission wavelength of 590 nm using the 
Tecan Infinite® 200 PRO plate reader. Fluorescence intensity was normalized to wells 
containing 10 % alamarBlue® REDOX indicator dye in medium only. Percentage of celluar 
metabolism was determined by normalizing fluorescence emission to non-treated control 
cells. 
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4.16 TGF-β stimulation experiments 
Cells were seeded at 30 % confluence and allowed to attach overnight. The next day, cells 
were stimulated for up to one week with either TGF-β1, 10 pM, 100 pM, or 1 nM 
(PeproTech), or SB431542, 100 nM, 1 µM, or 10 µM of SB431542 (Selleckchem) cultured in 
MEF medium. SB431542 was dissolved in DMSO to a stock concentration of 10 mM, 
according to manufacturer’s protocol. Aliquots of the inhibitors solutions were stored at -20°C 
and applied at the indicated concentrations. Cells were also seeded as control cells and 
incubated in MEF medium with 0.1 % DMSO. 
4.17 Gene expressing profiling 
Total RNA extracted using the RNeasy Kit (Qiagen) was submitted to the microarray unit of 
the DKFZ Genomics and Proteomics Core Facility. Illumina expression profiling was 
performed using whole genome Illumina® arrays (Human-HT12V4). 
4.18 Statistical analysis 
Tests for all data except microarray data were performed using GraphPad Prism version 5.00 
(2007) with the appropriate tests. Significance in two-tailed t-tests was assumed for p-values 
< 0.05 (*), < 0.01 (**) or < 0.001 (***). 
For all expression array data, significantly deregulated gene expression was determined 
using Chipster v2.12.0. After quantile normalization of raw data using Illumina normalization 
in Chipster, genes which were differentially regulated in two selected groups were extracted 
using the empirical bayes two-group test with Benjamini and Hochberg (BH) as the chosen p-
value adjustment method [293]. A p-value cutoff of 0.05 was chosen, if not otherwise 
indicated.  
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5 Results 
5.1 Establishment and validation of a protocol for the differentiation of 
melanocytes derived from human induced pluripotent stem cells 
To date, there are several well-established models of the neural crest (NC) that allow for the 
critical investigation of different developmental stages such as: induced pluripotent stem cells 
(iPSCs), NC, melanoblast and terminally differentiated melanocytes. The human iPSCs were 
generated in the lab following the protocol from Sommer et al. [291]. The generated human 
iPSCs were used in the melanocyte differentiation protocol, which was first established by 
Nissan and colleagues [292]. In brief, hiPSCs were seeded on mitomycin C-treated, 
postmitotic NIH 3T3 fibroblasts in stem cell medium. After three days the medium was 
switched to differentiation medium supplemented with ascorbic acid and BMP4. For a 
complete list of medium components see Table 2. Pigmentation was observed by day 30 
(Figure 3), however only after day 60 were there large enough pigmented colonies available 
to be manually picked and cultured in melanocyte specific medium (Figure 3). 
 
Upon successfully establishing the melanocyte differentiation protocol the melanocytes 
derived from hiPSCs, termed Mel D1, were characterized.  
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Common pluripotency markers were investigated to evaluate the differentiation protocol. For 
example, the expression of pluripotency markers OCT4 and LIN28 were downregulated with 
increasing time of differentiation (Figure 4a), while differentiation markers, MITF and TRP2, 
were upregulated with increasing time of differentiation (Figure 4b). The pigmentation of the 
Mel D1 cells was comparable to that of normal human melanocytes (NHMs) (Figure 4c). 
Additionally, the morphology of the Mel D1 was similar to that of NHMs as both melanocyte 
populations showed at least two dendritic processes per cells, which is a hallmark in 
melanocyte-specific morphology (Figure 4d). Next, expression of additional differentiation 
markers was investigated on protein-level using immunofluorescence. MITF, GP100 
(PMEL17), TRP2 and TRP1 were detected in Mel D1 cells at levels comparable to NHMs 
(Figure 4e). 
Mel D1 cells were further characterized using electron microscopy (EM) with the help of the 
DKFZ electron microscopy core facility. Mel D1 cells were seeded on special disc punches 
and allowed to attach and grow before they were subjected to electron microscopy (method 
describe in Supplemental section 8.1.2.1). Melanosome development was examined and 
the four stages were found in both the Mel D1 cells and NHMs (Figure 5). Melanosomes in 
premelanosome stage I are characterized by their spherical shape, as clearly seen in the 
upper panel of both the Mel D1 and NHMs (Figure 5, upper left panels). Those in 
premelanosome stage II are ellipsoidal in shape and contain perpendicular filaments; but 
have no notable pigmentation present. During stage III, the organelle starts to become 
partially pigmented or melanized. This partially melanized melanosome organelle was 
successfully identified in both Mel D1 and NHMs (Figure 5, upper middle panels). Lastly, at 
stage IV, the melanization process is completed and the organelle appears completely 
pigmented and therefore black in color [294] (Figure 5, upper right panels). These 
experiments provided substantial evidence that Mel D1 cells represent a population of 
successfully differentiated melanocytes with functionally essential features, i.e. melanosome 
development (Figure 4-5). 
Mel D1 cells were further validated and characterized using whole genome expression 
analysis. Three independently generated Mel D1 populations were subjected to a whole 
genome gene expression microarray and global gene expression patterns were compared 
between hiPSCs, neural crest cells (characterization not shown, method described in 
Supplemental section 8.1.1.2), Mel D1 and NHMs (Figure 6a). Heatmap presentation 
illustrates the differentially up- and down- regulated genes determined by several groups 
testing with each row representing one gene and each column a sample (yellow indicates 
upregulation and blue downregulation).  
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Pearson distance shows that Mel D1 cells have strong similarities to NHMs in contrast to 
their derivative hiPSCs. Upon hierarchical clustering, Mel D1 and NHMs cluster closely 
together and exhibit similar genome-wide expression patterns (Figure 6a).  
Moreover, comparable analyses were performed for Mel D1 vs. hiPSCs (group A) and NHMs 
vs. hiPSCs (group B). First, gene expression values for pluripotency-related markers and 
differentiation-related markers were extracted using Chipster software (Figure 6b). All 
pluripotency markers were similarly downregulated in both comparison groups, whereas 
differentiation markers were upregulated in both groups, shown as log2 [fold change]. 
Notably, expression of TRP2 detected by microarray analysis was higher in NHMs compared 
to expression in Mel D1, which is in contrast to expression analysis using qPCR (Figure 4b), 
where higher TRP2 levels were observed in Mel D1 cells. This pattern was also observed for 
MITF expression with higher expression levels in Mel D1 cells detected by qPCR (Figure 4b) 
but higher expression levels in NHMs using the gene expression microarray (Figure 6b). 
Ingenuity analysis (IPA) revealed that most pathways enriched in differentially expressed 
genes (Figure 6c, +2≤ fold change ≤-2) were similarly deregulated between Mel D1 vs. 
hiPSCs and NHMs vs. hiPSCs. However, a difference was observed in the pathway 
‘transcriptional regulatory network in embryonic stem cells’ between the two groups with a 
stronger enrichment in differentially expressed genes in NHMs compared to Mel D1 cells. If 
this has any significant meaning remains under investigation, but it is not surprising that 
differentiating hiPSCs towards the melanocytic lineage would utilize slightly different 
canonical pathways.  
More detailed analysis of the canonical pathway ‘melanocyte development and pigmentation 
signaling’ using IPA revealed that genes involved in the melanocyte pigmentation pathway 
were specifically differentially regulated when comparing Mel D1 vs. hiPSCs and NHMs vs. 
hiSPCs (Figure 6d). Nearly all genes that were upregulated in Mel D1 vs. hiPSCs were also 
upregulated when NHMs were compared to hiPSCs. In general, NHMs vs. hiPSCs 
pigmentation pathway was more highly upregulated compared to Mel D1 vs. hiPSCs. For 
example, TRP2 was slightly upregulated 2.35 and highly upregulated 6.6 fold in Mel D1 vs. 
hiPSCs and NHMs vs. hiPSCs respectively. Strikingly, genes essential for the melanin 
production in melanocytes, TRP1, TRP2 and TYR, were strongly upregulated in both NHMs 
and Mel D1 cells compared to hiPSCs confirming data from electron microscopy that the 
pigmented organelles were present in both melanocytic populations (Figure 6d).  
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Based on these results, I conclude that I was able to successfully differentiate hiPSCs into 
melanocytes. For this work, the functionality of these melanocytes was not tested, for 
example, in an in vitro model of reconstituted melanized epidermis or organotypic skin 
reconstruction. However, this should be investigated in the future.  
5.2 Role of SOX2 and SOX10 during melanocyte differentiation from human 
induced pluripotent stem cells 
Detailed investigation of specific pluripotency genes during the established melanocyte 
differentiation protocol revealed a complete loss of OCT4 during the melanocyte 
differentiation protocol (Figure 4a). In addition, NANOG expression was diminished 
throughout the early days of differentiation (day 11-15) by day 15 (Figure 7a). However, 
SOX2 remained moderately expressed compared to hiPSCs (Figure 7a). This hinted that 
SOX2 may play a role not only in regulating pluripotency but also in further stages of 
ectodermal lineage development. Therefore SOX2 expression was analyzed in comparison 
to the neural crest marker SOX10 throughout all days of differentiation (Figure 7b). SOX10 
expression was highest at day 20 followed by a steady decrease at the later days of 
differentiation (Figure 7b). Similarly, SOX2 expression followed the same pattern with 
highest expression at day 20; however relative expression was lower than SOX10 
expression. 
Investigating the expression of SOX2 in a NC cell population generated from Dr. Lionel 
Larribere from our laboratory, which was specifically enriched for neural crest cells via cell 
sorting for HNK1 and p75 (NGFR/CD271) (method described in Supplemental 
section 8.1.1.2) , revealed that SOX2 was highly expressed in the NC cell population 
compared to hiPSCs (Figure 7c). Taken together, SOX2 seems to play an important role 
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during melanocyte development and its regulation is important for the switch into the 
melanocytic lineage.  
 
5.3 Mutation-independent SOX2 function in melanoma 
To date, several research groups found SOX2 to be relevant in melanoma [282, 284, 286, 
295], but a detailed understanding of SOX2’s role in melanoma remains unknown. First, 
SOX2 expression was investigated in a panel of melanoma cell lines (n=9) and 67 % of cell 
lines highly expressed SOX2 on mRNA-level independent of mutational status compared to 
NHMs (Figure 8a). This was also confirmed on protein-level using immunoblotting 
(Figure 8b). 
To understand whether or not upregulation of SOX2 in melanoma is independent on the 
mutational status of BRAF, 63 melanoma cell lines were examined using the online Cancer 
Cell Line Encyclopedia (CCLE). BRAF-mutated melanoma cell lines (n=32) and NRAS-
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mutated melanoma cell lines (n=7) were separated and relative mRNA expression of SOX2 
compared to all BRAF/NRAS WT melanoma cell lines available regardless of any other 
mutational status (n=24). No significant difference in SOX2 expression between BRAF- or 
NRAS-mutated cell lines were found compared to the remaining melanoma cell lines 
(Figure 8c). This suggests that the upregulation of SOX2 in melanoma is independent of the 
mutational status.  
Next, SOX2 expression was investigated on protein-level in melanocytic nevi, primary and 
metastatic melanoma samples using immunohistochemistry (IHC) (Figure 8d). A skin section 
containing a melanocytic nevus revealed that SOX2 was not expressed in nevus cells but in 
a sebaceous gland (Figure 8d, upper panel,* indicates location of dermal nevus cells). In a 
superficial primary melanoma, SOX2 was slightly expressed, whereas in metastatic 
melanoma tissue stronger staining was observed (Figure 8d, middle and lower panel). This 
indicated that SOX2 is highly expressed in both primary melanoma and melanoma 
metastases. 
Lastly, fluorescence in situ hybridization (FISH) was performed with the help of Elias Orouji 
from our laboratory (method described in Supplemental section 8.1.1.1) to investigate if the 
SOX2 gene locus is amplified in human melanoma patient tissue (Figure 8e). Similar to the 
results observed in IHC, SOX2 was amplified in primary and metastatic tissue samples 
compared to melanocytic nevi, with only intact FISH signals in non-overlapping nuclei were 
counted (n=100). Control hybridizations were performed on metaphase spreads of euploid 
cells. The total number of SOX2 gene copies in relation to the reference probe copy number 
is indicated as SOX2 FISH ratio. Amplification of SOX2 was defined as a calculated FISH 
ratio > 1.3. A ratio less than 1 was considered no amplification. These values were 
empirically determined using Hothorn and Lausen method and could vary under different 
conditions [296]. Representative images of FISH analysis are shown in Figure 8f.  
To further confirm the mutation-independent effect of SOX2 in melanoma and to understand 
the functional effects of SOX2 in melanoma, gain-of-function studies in the BRAF-and NRAS-
WT melanoma cell line SK Mel 173 and the NRASQ61R-mutated cell line SK Mel 30 were 
performed. In addition, the melanocytic cell line Mel STV was transduced with the same 
overexpression construct. All cells were transduced using a lentiviral vector encoding for 
human SOX2 under the control of a tetracycline-inducible promoter in combination with a 
constitutively expressed neomycin selection cassette. In addition, cells were transduced with 
a lentiviral vector encoding for the constitutively active M2-rt-TA under the control of the 
human ubiquitin C promoter (Figure 9a, vector maps refer to Figure S1). Expression of 
SOX2 was induced by administration of doxycycline for three days before cells were selected 
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using G418 for one week. The cells were validated for their SOX2 overexpression on RNA-
level using qPCR (Figure 9b). A 5-, 4- and 17-fold increase in SOX2 expression was 
observed in SK Mel 30, SK Mel 173 and Mel STV, respectively, when normalized to the 
corresponding melanoma cell line in the absence of doxycycline. Furthermore, SOX2 protein 
overexpression was confirmed using immunoblotting (Figure 9b) and stronger SOX2 bands  
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were detected in doxycycline-treated cells. The morphology of the SOX2-overexpressing 
cells was assessed and few differences were noted (Figure 9c). In general, doxycycline-
induced SOX2-overexpressing cells showed more dendritic-like protrusions and had a 
tendency to grow in smaller colonies rather than in larger clusters, (Figure 9c, black 
arrowheads).  
Dedifferentiation in melanoma has been well studied in recent years and since SOX2 is a 
known pluripotency marker the differentiation status of the SOX2-overexpressing cells was 
assessed. First, qPCR analysis was performed and expression of the differentiation markers 
MITF and TRP2 was determined (Figure 9d). A reduction in expression of both 
differentiation markers was observed in all three SOX2-overexpressing cell lines. This loss of 
MITF was further verified on protein-level using immunoblotting in the SOX2-overexpressing 
cell line SK Mel 30 (Figure 9f). No difference in MITF reduction was observed upon G418 
administration in the absence of doxycycline, indicating that the observed downregulation of 
MITF on protein-level was caused by the overexpression of SOX2 and not a side effect of 
selection (not shown). Band intensities revealed a 50 % loss of MITF protein (Figure 9f). 
The strong repression of MITF on protein-level upon SOX2 overexpression led to further 
investigation of these two molecules. The relationship between MITF and SOX2 has been 
investigated by researchers in a short letter, which indicated that SOX2 may be possibly 
modulating MITF expression in NHMs and melanoma cells [285]. In 2012, interactions 
between SOX2 and MITF were investigated heavily in mouse, specifically in the cranial 
neural crest [297]. Authors found that not only can SOX2 bind to the proximal promoter of 
MITF in mouse, but was able to repress MITF-transcription in B16-F10 murine melanoma 
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cells. Therefore, it was of interest whether this mechanism held true in human and may partly 
explain the dedifferentiated phenotype observed in the gain-of-function studies in human 
melanoma cell lines.  
In silico analysis confirmed that in human; SOX2 is capable of binding the MITF promoter. 
Using JASPAR, an online predictive binding site modeling database, six predicted binding 
sites for human SOX2 were identified on the human proximal promoter of MITF (Figure 9e). 
The database allows for manual setting of the threshold by increasing or decreasing the 
stringency. By setting the threshold to 85 % one particular binding site with a much higher 
score compared to the others was found (Figure 9e, red box). This site was not only the 
most likely predicted site by JASPAR but also matched one of the binding sites found via 
ChIP experiments in a previous publication [297, 298]. These results indicate that SOX2 is 
able to bind to the human MITF promoter close to the transcriptional start site. Sequence 
conservation of the putative SOX binding site in the MITF promoter regions between three 
species, Homo sapiens, Mus musculus and Bos Taurus, revealed nearly 100 % conservation 
(Figure 9h) [299]. A schematic of the proximal MITF promoter is shown in Figure 9i. 
Interestingly, the confirmed binding site for SOX2 in the MITF promoter is also the identical 
site where SOX10 binds and activates MITF transcription. Therefore, not only does this 
SOX2 binding site explain a possible mechanism for SOX2-mediated repression of MITF 
transcription and in turn dedifferentiated melanoma cells, but also may be important in the 
regulation between SOX2 and SOX10. 
Next, the functional effect of SOX2 on the human MITF promoter was investigated in 
collaboration with Dr. Corine Bertolotto’s laboratory. SK Mel 30 cells overexpressing SOX2 
and non-induced control cells were transfected with MITF reporter and to control transfection 
efficiency pCMV Gal was used and assayed for luciferase and β-galactosidase activities. 
Transfections were performed in technical triplicates in at least three individual experiments 
[300] (method described in Supplemental section 8.1.2.4) An approximate repression of the 
MITF promoter of approximately 20 % was detected upon overexpression of SOX2 in the 
human melanoma cell line SK Mel 30 (Figure 9g).  
These data suggest that SOX2 is able to induce a more dedifferentiated phenotype and a 
mechanism, by which SOX2 may be regulating this, is via repressing the MITF promoter. 
Previous work has described that tumor dedifferentiation in melanoma, in general, is a crucial 
step towards tumor cell invasion [301]. It is understood that metastatic melanoma cells 
display a dedifferentiated phenotype with high plasticity, which allows them to invade into 
various microenvironments [213]. Here, the role of SOX2 was further investigated in order to 
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determine whether its overexpression leads to functional migrative or invasive changes in 
melanoma cells.  
First, an improved version of the scratch assay was performed using SK Mel 30 cells 
overexpressing SOX2 (hereafter referred to as SK Mel 30 SOX2-OE). Cells were seeded in 
ibidi® chambers and cultured in medium supplemented with 5 µM hydroxyurea as a 
proliferation inhibitor [302]. Chambers were removed resulting in a defined 500 µm gap for 
measuring migration. The scratch for both, SK Mel 30 SOX2-OE cells and non-induced 
control cells, was imaged after 6, 12, 24 and 48 h. After 48 h, the gap was still not closed
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completely. For quantification, images were analyzed using the open software T-scratch and 
a significant increase in the migration capacity in the SK Mel 30 SOX2 OE cells compared to 
non-induced control cells was observed (Figure 10a). 
After detection of enhanced migratory capacity when overexpressing SOX2 in melanoma 
cells, the invasive potential of these cells was assessed. A transwell chamber system was 
used to determine the invasive capacity of both SK Mel 30 and SK Mel 173 SOX2-OE cells 
through an artificial basal membrane equivalent. SK Mel 30 SOX2-OE cells demonstrated a 
significant increase in invasive capacity and same tendency was observed for SK Mel 173 
SOX2-OE cells; however this was not significant (Figure 10c). This further confirmed that 
SOX2 is plays a role in migratory and invasive capacity of melanoma cells in vitro.  
The epithelial-to-mesenchymal transition (EMT) is a process strongly related to migration and 
invasion in both NC development and cancer. Melanoma studies found that upregulation of 
TWIST1 and ZEB1 indicated EMT restructuring towards a more dedifferentiated, invasive 
phenotype [203]. For these reasons, these EMT-related markers were investigated in SK Mel 
30 SOX2-OE cells and an upmodulation of ZEB1 and TWIST1 was observed, while ZEB2 
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and SNAI2 expression was decreased (Figure 10b). Next, this SOX2-related invasive 
phenotype observed in vitro was further evaluated in primary melanoma patient samples. 
Moderate expression of SOX2 was observed at superficial regions of primary melanomas 
(Figure 10e, upper panel); however extremely high levels of SOX2 expression were detected 
in deeper regions of the same tumor (Figure 10e, lower panel). Next, SOX2 positive cells 
were observed, which invaded through the dermis and extracellular matrix supporting 
functional in vitro data (Figure 10f). Moreover, strong positivity was detected near an 
invasive border of a primary melanoma close to a nerve cell (Figure 10g). The nerve cell 
served as a positive control for SOX2 staining in IHC since SOX2 is highly expressed in this 
cell type (reviewed in [303]).  
Melanoma research has highlighted the unique, so-called phenotype switch phenomenon, 
where melanoma cells oscillate between highly proliferative and non-invasive or highly 
invasive and low proliferative states [304]. Since a highly invasive phenotype was observed 
upon SOX2 overexpression, the metabolic activity of these cells was investigated to further 
confirm that SOX2 plays a role in the induction of the phenotype switch. The alamarBlue® 
assay was used to determine metabolic activity of the cells, which correlates with cellular 
viability and proliferation. Both SOX2-overexpressing cell lines, SK Mel 30 and SK Mel 173, 
were seeded into black 96-well plates. alamarBlue® was applied, three days after seeding 
and its conversion was measured using a fluorescence plate reader after three hours. A 
significant decrease in cellular metabolism in SK Mel 30 SOX2-OE cells was observed 
compared to the corresponding non-induced control cells (Figure 10d). However, only a 
slight decrease in cellular metabolism was detected in the SK Mel 173 SOX2-OE cells.  
Next, SOX2-knockdown studies were performed in the human melanoma cell line NRASQ61R-
mutated SK Mel 103. SK Mel 103 was chosen due to its high expression of SOX2 on RNA 
and protein-level (Figure 8a-b). The cells were transduced with shRNA targeting human 
SOX2 gene or with vectors encoding for a scrambled control that were selectable using 
puromycin (Table 3). Upon selection for three days, knockdown of SOX2 was validated for 
RNA expression by qPCR analysis and on protein-level by immunoblotting (Figure 11a). 
60 % reduction of SOX2 was observed in SK Mel 103 knockdown cells and no morphological 
changed were evident when compared to control cells (Figure 11a, g). Subsequently, SOX2 
knockdown (KD) cells were evaluated regarding the expression of NC markers. An increase 
in expression of SOX10 and a decrease in p75 expression were observed, suggesting a 
more differentiated state of the cells (Figure 11b). Moreover, an increase in differentiation-
markers MITF and TRP2 was observed in the SK Mel 103 KD cells compared to the 
scrambled control (Figure 11f). 
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Furthermore to investigate EMT-related marker expression, cadherins were investigated and 
upon SOX2 KD in SK Mel 103 melanoma cell line an upmodulation of E-cadherin (CDH1) 
was observed together with a slight downmodulation of N-cadherin (CDH2) (Figure 11c). 
Additionally, an upregulation of ZEB2 and SNAI2 was observed in the SK Mel 103 KD cells 
compared to the scrambled control, which suggests the cells were in a less invasive state 
(Figure 11f). Taken together, these data suggest the cells were more epithelial-like and the 
loss of SOX2 in the melanoma cell line SK Mel 103 leads to a more differentiated phenotype. 
Following, the alamarBlue® assay was performed to assess cellular metabolic activity of the 
SK Mel 103 SOX2 KD cells indicating effects of SOX2 depletion on proliferation. 4000 cells 
were seeded per well, and three days later alamarBlue® was applied. Three hours after 
alamarBlue® administration, measurements were taken (Figure 11d). No difference was 
observed in cellular metabolism when the scrambled control was compared to the SOX2 KD 
cells.  
Lastly, the invasive capacity of SOX2 KD cells was assessed using the Cultrex® 96 Well 
BME Cell Invasion Assay and wells were coated with 0.1 x basement membrane extract 
(BME). A significant decrease in invasive capacity was observed upon knocking down SOX2 
in the SK Mel 103 melanoma cell line (Figure 11e).  
5.4 Influence of SOX10 on SOX2 expression in human melanoma cells 
Independently, SOX2 and SOX10 have been closely studied in melanoma. SOX10 studies 
have shown that its expression is required for melanoma initiation and maintenance [280]. 
Meanwhile SOX2, previously described in studies and the data shown, has been associated 
to melanoma cell invasion and regulation of melanoma-initiating cell self-renewal and 
tumorigenicity [284, 286, 295].  
This reciprocal function of SOX2 and SOX10 was further investigated by analyzing the 
expression of SOX10 in SOX2-OE cell lines. When SOX2 was overexpressed in several 
human melanoma cell lines, SOX10 was drastically downregulated (Figure 12a). Moreover, 
when relative gene expression of SOX2 and SOX10 was analyzed in a panel of 12 
melanoma cell lines an inverse correlation between the two genes was discovered 
(r=-0.2120) (Figure 12b). This data illustrated that there is inverse expression between 
SOX2 and SOX10 in melanoma. 
To further understand the reciprocal function of SOX10 in melanoma compared to SOX2 
loss-of-function studies were performed using shRNA targeting SOX10. The BRAF-mutated 
C32 cell line was transduced with four different shRNA clones and the scrambled control. 
After transduction, these cells were selected with puromycin for three days (Table 3). Next, 
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KD of SOX10 in these cells was validated on RNA-level and protein-level and a 60 % KD of 
SOX10 was observed in clone 2 (Figure 12c).  
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In order to determine whether or not SOX2 and SOX10 play a reciprocal role in melanoma 
levels of SOX2 expression were checked after SOX10 KD. No increase in SOX2 expression 
after knocking down SOX10 was detected (Figure 12d, blue). In fact, a slight downregulation 
of SOX2 was observed on RNA-level upon SOX10 KD. Expression of the dedifferentiation 
marker p75 was analyzed and no increase could be detected (Figure 12d, purple). These 
results were confirmed on protein-level using immunoblotting where no difference in SOX2 
protein was identified upon SOX10 KD (Figure 12e). These results suggest that SOX2 may 
operate upstream of SOX10 and that alteration of SOX10 therefore has no direct impact on 
SOX2 expression levels. The reciprocal effect observed between SOX2 and SOX10 is 
therefore a causative effect and levels of expression may determine the differential 
phenotype observed. 
5.5 TGF-β induces SOX2 expression in melanoma in vitro 
The mechanisms responsible for the overexpression of SOX2 and melanoma 
dedifferentiation, which is linked to the invasive phenotype, remain unknown. I showed that 
SOX2 overexpression can be induced via SOX2 gene amplification (Figure 8e-f). In order to 
further elucidate the mechanism behind SOX2 induction in melanoma, possible mechanisms 
of SOX2 induction in other cancers were investigated. Interestingly, studies found that TGF-β 
induces SOX2 expression in glioma-initiating cells [276]. Since TGF-β signaling is of high 
importance in melanoma progression and its autocrine responses includes enhanced motility 
and invasion, this possible mechanism of action was further investigated [168]. Therefore, 
melanoma cells were stimulated with TGF-β and SOX2 expression was assessed 
(Figure 13).  
Upon TGF-β1 stimulation in two human melanoma cell lines, A375 and SK Mel 30, 
morphological differences were observed after one week compared to the ALK5 inhibitor 
SB431542 treated or the no treatment (0.1 % DMSO) control cells (Figure 13a). SB 431542 
is an inhibitor of activin receptor-like kinase (ALK)5 (TGF-beta type I receptor) and functions 
through competitive binding to the ATP binding site, which inhibits the in vitro 
phosphorylation of SMAD3 [305, 306]. Long dendrites were noted upon TGF-β1 stimulation 
in both cell lines, indicated by black arrowheads (Figure 13a). This morphology was similar 
to that observed when SOX2 was overexpressed (Figure 9c). Next, the induction of SOX2 
upon one week of TGF-β1 stimulation was investigated in SK Mel 30 and A375 melanoma 
cell lines. First, in SK Mel 30, a significant induction in SOX2 expression was observed 
compared to the no treatment (0.1 % DMSO) control or the SB431542 inhibitor treated cells 
(Figure 13b). Similarly, in the A375 cell line, a significant induction of SOX2 expression was 
found upon TGF-β1 treatment for one week compared to the no treatment (0.1 % DMSO) 
control or the SB431542 inhibitor treated cells (Figure 13e). These results suggest that 
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similar to glioma-initiating cells, SOX2 expression in melanoma cells is induced via TGF-β1 
signaling. To further confirm that SOX2 can be induced by TGF-β1, SOX2 was checked on 
protein-level after stimulation with TGF-β1 for one week in SK Mel 30 melanoma cell line 
(Figure 13c). In SK Mel 30 cells stimulated with TGF-β1, increased SOX2 protein-levels 
were observed compared to the no treatment (0.1 % DMSO) control or the cell treated with 
the SB431542 inhibitor. These data further verify that SOX2 is induced upon TGF-β 
treatment.  
Results 
76 
To validate successful TGF-β1 stimulation, TGFBR2 expression and downstream c-JUN 
expression was investigated on protein-levels upon TGF-β1 treatment for one week in the 
melanoma cell line SK Mel 30. As expected, a strong increase in TGFBR2 protein expression 
was observed upon stimulation in combination with a slight increase in c-JUN expression 
(Figure 13d). The enhanced TGFBR2 expression upon stimulation indicates that SOX2 is 
induced by TGF-β signaling. Similarly, the slight upregulation of c-JUN protein expression 
suggests the activation of the TGF-β signaling cascade, however investigating 
phosphorylated c-JUN may show more drastic differences. To further confirm that the TGF-β 
signaling pathway was activated upon treatment and in turn induced SOX2 expression, 
immunofluorescence staining was performed in TGF-β1, SB431542 inhibitor and no 
treatment (0.1 % DMSO) control cells against SMAD2 and SMAD3 proteins (Figure 13f, 
Figure S3). These proteins form a heterodimer and become phosphorylated upon TGF-β 
stimulation and translocate from the cytoplasm to the nucleus. Therefore, this re-localization 
upon stimulation would further confirm the activation of the TGF-β signaling cascade. A 
cytoplasmic staining of SMAD2 in both the no treatment (0.1 % DMSO) and SB431542 
inhibitor-treated cells was detected, while predominant nuclear staining was found in the 
TGF-β1-stimulated cells in A375 and SK Mel 30 melanoma cell lines (Figure 13f). Similarly, 
cytoplasmic distribution of SMAD3 was observed in the majority of control- and inhibitor-
treated cells while translocation into the nucleus was detected upon TGF-β1 stimulation in 
both cell lines (Figure S4). These results further confirm that upon TGF-β1 stimulation, 
TGF-β signaling is activated and in turn induces SOX2 expression in vitro.  
The phenotype observed upon TGF-β1 stimulation was further investigated in human 
melanoma cells. After one week of stimulation with TGF-β1, the RNA expression of the EMT-
related markers SNAI1 (SNAIL) and CDH2 (N-cadherin) were upregulated in melanoma cell 
line SK Mel 30 (Figure 13g) indicating that the cells are undergoing EMT-like processes 
upon TGF-β1 stimulation. Furthermore, upon TGF-β1 stimulation CDH1 (E-cadherin) is 
downregulated, which further suggests that TGF-β may be involved in melanoma 
progression since the loss of E-cadherin expression has been implicated in cancer 
progression and metastasis [307] (Figure 13g).  
In addition, the expression of several differentiation markers, including MITF, TRP2 and TYR 
after one week of TGF-β1 stimulation was analyzed (Figure 13g). All three markers were 
downregulated upon TGF-β1 stimulation; however TRP2 showed the most drastic difference 
with nearly 70 % downmodulation compared to no treatment (0.1 % DMSO) control cells. 
Moreover, SK Mel 30 cells overexpressing SOX2 showed an induction of TGFBR2, TGFBR3 
and JUN expression using qPCR analysis (Figure 13h). These data suggest a distinct 
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mechanism, by which SOX2 regulates its own expression and TGF-β signaling in a positive 
feedforward loop.  
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5.6 SOX2 and novel protein-protein interactions 
Protein-protein interactions play crucial roles in regulating important cellular pathways. 
Therefore, novel potential interacting partners of SOX2 were investigated using yeast-2-
hybrid (y2h) pairwise experiments and bimolecular fluorescence complementation (BiFC) 
experiments in collaboration with the DKFZ proteomics core facility (methods described in 
Supplemental section 8.1.2.2 and 8.1.2.3)  
Using BiFC, the potential interaction between SOX2 and PAX3, SOX10, and PAX6, 
respectively, was investigated. PAX6 is a known interacting partner of SOX2, particularly in 
the retina and was used as a positive control [245]. HEK 293T cells were transfected with 
bait and prey vectors containing fragments of complementary fluorescent reporter proteins. 
Upon interaction in vitro, the fusion reporter protein reforms and fluoresces. A positive 
interaction between PAX3 and SOX2 was observed in three independent BiFC experiments, 
similar to that of the positive control (Figure 14a, left panel). The differential role of SOX2 
and SOX10 was investigated in melanoma progression and therapy and it was found that 
SOX2 and SOX10 share a binding site on the proximal MITF promoter. Therefore, the 
mechanism, by which SOX2 and SOX10 may be regulated on protein-level, was of interest. 
Strong fluorescence was observed when SOX2-bait and SOX10-prey were transfected into 
HEK 293T cells, where the fluorescence was equal to positive control (Figure 14a, middle 
panel). The same fluorescence was observed when SOX10 was used as bait and SOX2 as 
prey (Figure 14a, middle panel).  
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Next, to confirm these interactions in a second independent experiment, the y2h pairwise 
experiment was performed. In brief, a construct containing the bait (SOX2) coupled to an 
enzyme capable of synthesizing tryptophan (TRP) and the prey of our choice coupled to an 
enzyme capable of synthesizing leucine (LEU) were transformed into yeast. The yeasts were 
then mated and diploid yeast were selected via nutritional selection on TRP/LEU deficient 
medium (Figure 14b). Growth of the diploid yeast was only possible upon interaction of the 
bait, containing the protein binding domain, and the prey, containing the activation domain 
(Figure 14c). This interaction allows for the reformation of a transcription factor which 
initiates transcription of the integrated HIS3 gene, enabling growth on histidine-deficient 
media. Therefore, only diploid yeast clones in which there is an interaction between the bait 
and prey proteins are able to transcribe their own HIS3 and survive on histidine-deficient 
medium. With this selection process, one is able to elucidate potential protein-protein 
interactions. Another level of stringency used in y2h experiments is 3-amino-1,2,4-triazole (3-
AT). This molecule is a competitive inhibitor of the product of the HIS3 gene, reducing 
possible autoactivation and false positives.  
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The same interactions, PAX3/SOX2 and SOX10/SOX2, identified by the BiFC assay were 
further examined in y2h experiments (Figure 14d). However, difficulties were observed when 
performing these experiments due to the strong autoactivation tendencies of SOX2. 
Therefore, the effect of autoactivation could not be completely ruled out in y2h pairwise 
experiments. Nonetheless, weak colony growth in the PAX3/SOX2 mating at the highest 
stringency of 2.0 mM 3-AT (bottom panels) was observed; however between replicates 
(column) there was great variability (Figure 14d, left panel). Next, the SOX2/SOX10 potential 
interaction was investigated in the y2h system; however the overexpression of both SOX2 
and SOX10 proved to be lethal in yeast even in the lowest stringency tested (Figure 14d, 
upper panels). Therefore, the possible interaction between SOX2 and SOX10 was not 
confirmed in yeast (Figure 14d, right panel).  
TWIST1 was further investigated as a potential interactor with SOX2. TWIST1 is known to be 
implicated in cell lineage determination and the EMT process. Since SOX2 plays important 
roles in both pathways possible protein-protein interactions between these two proteins were 
investigated. Unfortunately, TWIST1 analyses could not be performed using BiFC 
experiments due to cloning difficulties. Nonetheless, y2h pairwise experiments for TWIST1 
were performed. Although autoactivation-mediated effects could not be completely ruled out 
in all y2h pairwise experiments, weak colony growth in the TWIST1-SOX2 mating was 
observed at the highest stringency of 2.0 mM 3-AT (bottom panels); however between 
replicates (columns) there was great variability (Figure 14d, middle panels). In conclusion, 
SOX2 may form potential protein-protein interactions with PAX3, SOX10 and TWIST1; 
however since the y2h pairwise experiments were unreliable due to strong autoactivation of 
SOX2 and therefore these experiments need to be repeated with SOX2 construct lacking the 
HMG domain to eliminate autoactivation tendencies. Furthermore, these interactions should 
be confirmed in co-immunoprecipitation experiments in vitro. 
5.6.1 SOX2 forms protein-protein interactions with novel candidates related to 
SUMOylation 
In addition to y2h pairwise experiments, y2h high-throughput screen (HTS) was performed. 
We performed the screen on multiple libraries (human universal, full ORF N-terminal, full 
ORF C-terminal) to eliminate as many artifacts as possible. The concentration of 3-AT used 
depends on the strength of the interaction between the bait and prey used and is usually 
determined in preliminary experiments (Figure S5a). During this HTS, 3-AT was used at a 
concentration of 4 mM to eliminate as many promiscuous and artificial preys. The 
experimental setup of the screen is identical to the basics of y2h experiments, as described 
in Figure 14b-c. The main difference between the standard y2h pairwise experiments and 
the HTS is that in the screen, the prey proteins are not pre-selected but contained in a cDNA 
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library. Therefore, the mating occurred between a particular bait of interest (SOX2) and the 
prey offered by the cDNA library. Upon the reformation of the transcription factor, reporter 
genes were transcribed allowing fluorescence readout. After mating, the yeast were 
dispensed onto ten microtiter plates and allowed to grow (Figure S5b). Fluorescence was 
measured and the positive wells collected. Next, PCR was performed and the bands were 
sequenced and analyzed. 
Three independent HTSs were performed using three different cDNA libraries: universal 
human, full ORF library (N-terminal) and full ORF library (C-terminal). Several hits were 
isolated in at least two of the three screens. These hits included SUMO1, UBE2I, PIAS4, 
PCFG2, and CBX4 (Figure 14e). For example, small ubiquitin-related modifier 1 (SUMO1) 
was isolated 14 times from the universal human library and 37 times from the full ORF 
library. Ubiquitin-conjugating enzyme E2I (UBE2I) was isolated 11 times from the universal 
human library and 29 times from the full ORF library (C-terminal) (Figure 14e). 
The first hit, SUMO1, was particularly interesting since this protein is heavily involved in 
protein SUMOylation or post-translational modifications [252]. Literature research revealed 
that the conjugation of SOX2 to SUMO1 has already been investigated [252]. Moreover, it 
was discovered that upon conjugation of SUMO1 to SOX2, inhibition of the DNA binding 
activity by SOX2 was observed. This work not only suggests that SUMOylation has a 
functional effect on SOX2 but also validates that the y2h HTS likely identified true protein-
protein interactions. Likewise, the next hit, ubiquitin-conjugating enzyme (UBE) - 2I, is an 
enzyme responsible for performing SUMO conjugation is related to the SUMOylation 
process. Further hits, E3 SUMO-protein ligase (PIAS4) and Chromobox protein homolog 4 
(CBX4), function in the SUMOylation process by stabilizing the interaction between UBE2I 
and the substrate [247]. The identification of potential interactions occurring between SOX2 
and proteins related to the SUMOylation process suggest SOX2 can be SUMOylated. 
To determine whether SOX2 can be SUMOylated, the GPS-SUMO online database was 
used to predict SUMOlyation sites within the SOX2 protein (Figure 14f). The database 
identified two predicted SUMOylation sites for SOX2; one located at amino acid position 121 
and the other at 245. Interestingly, the publication which reported conjugation of SOX2 to 
SUMO1 describes a conjugation at lysine 247 [252]; but the exact positions where SOX2 is 
SUMOylated in vitro needs to be confirmed. Lastly, the SOX2 protein domains and its 
predicted SUMOylation sites were constructed using the open source software DOG 2.0 
(Figure 14g).  
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Taken together, y2h HTS experiments identified four key players in the SUMOylation 
process, SUMO1, UBE2I, PIAS4 and CBX4, which may form protein-protein interactions with 
SOX2.  
5.7 SOX2 in the clinic 
The final part of the current study involved investigating the role of SOX2 in the clinic. After 
showing that SOX2 is highly involved in regulating melanoma cell invasion and migration in 
vitro and SOX2 expression was found to be highly overexpressed in deep melanoma tumor 
regions and in stroma-infiltrating melanoma cells (Figure 10e-f). Detailed analyses were 
performed regarding SOX2 expression and corresponding clinical data. 
A tissue microarray (TMA) was used to further investigate SOX2 expression in primary 
melanoma patient tissues and melanocytic nevi samples. Representative TMA images are 
shown in Figure 15a, where primary melanoma samples are displayed in the bottom panel 
and melanocytic nevi in the upper panel. Upon scoring the TMA (method described in 
Figure S2), a significant increase in SOX2 expression was found in primary melanomas 
compared to melanocytic nevi (Figure 15b).  
 
To summarize these results, we have identified SOX2 to play a role in a melanocyte 
differentiation protocol, to be important in melanoma pathogenesis and possibly forming 
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novel protein-protein interactions with SUMO-related proteins. SOX2 was identified to be 
expressed at low levels during the established melanocyte differentiation protocol from 
human iPSCs. Using FISH analysis, we demonstrated SOX2 amplification in primary 
melanoma tissue compared to melanocytic nevi. The functional analysis of SOX2 in 
melanoma revealed the requirement for SOX2 in melanoma cell invasion in vitro and was 
linked to EMT-marker induction. Furthermore, dedifferentiation in melanoma cell may be 
influenced by SOX2 binding and repression of the MITF-M promoter. Additionally, we found 
that SOX2 was induced by TGF-β1 in vitro. Finally, in protein studies using y2h HTS, we 
identified potential new interacting partners of SOX2 related to the SUMOylation process. 
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6 Discussion 
The resistance of advanced melanoma to current targeted therapies, unavailable prognostic 
tools and lack of knowledge about the molecular mechanisms underlying the pathogenesis of 
this cancer together highlight the deficiencies in the melanoma field. To date, research has 
identified alterations in key regulators in both, tumor suppressor and oncogenic pathways, 
which are responsible for disturbed signaling in mitogen-activated protein kinase (MAPK) 
pathway [308], inhibition of the RB tumor suppressor pathway [309] and further activation of 
downstream tyrosine kinases [310]. In melanoma, these modifications cause cellular 
proliferation and uncontrolled growth which can progress quickly into metastatic cancer. 
Accordingly, widespread dissemination of melanoma cells to distant organs is a common 
occurrence in melanoma progression.  
There are several proposed mechanisms for malignant transformation in melanoma. One 
mechanism is through the acquisition of genetic aberrations that lead to malignant 
transformation, such as the acquisition of mutant BRAFV600E and p16INK4a/p19ARF loss or 
mutations in p53 and PTEN [142–144]. The acquisition of these aberrations can occur 
through various means including exposure to environmental risk factors, such as UV 
radiation. Aside from somatic mutations, it has been suggested that, in melanoma, there is 
an inheritance of melanoma susceptibility genes. To date there have been four different 
genes at three different loci identified to confer susceptibility in melanoma, the genes include: 
p16INK4a, p14ARF, CDK4 and TERT. Lastly, melanocytes are derived from embryonic, 
migratory neural crest cells (NCCs). Throughout development, the NCC population gives rise 
to various lineages including bone and cartilage, pigmented cells, neurons and glial cells of 
the peripheral nervous system. Upon the induction of the neural crest (NC) and formation of 
the neural tube, NCCs migrate dorsolaterally by acquiring migratory features through the 
epithelial-to-mesenchymal transition (EMT), before becoming fully differentiated melanocytes 
when reaching the epidermis [4]. Due to their developmental program, which gives the 
lineage invasive, metastatic qualities [207], melanocytes may be intrinsically predisposed to 
transformation and metastasis. Taken together, melanoma has several routes towards 
malignant transformation and it’s likely a combination of routes that ultimately confers 
malignancy. 
6.1 Embryonic stem cell marker expression during melanocytic differentiation 
from human induced pluripotent stem cells 
In this study, a protocol was established to terminally differentiate melanocytes from human 
induced pluripotent stem cells. For this approach differentiation medium (Table 4) 
supplemented with BMP4 and ascorbic acid was used; which directed differentiation into all 
ectodermal lineages (Figures 3). Further cultivation in melanocyte medium successfully 
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selected a pure population of melanocytes, which were characterized in depth for their 
differentiation- and pluripotency-marker expression (Figure 4a-b,e), melanosome 
development (Figure 5), and whole genome expression array analyses (Figure 6) compared 
to normal human melanocytes (NHMs). Minor differences were noted when comparing the 
hiPSC-derived melanocytes (Mel D1) compared to NHMs, such as the observed difference in 
the Ingenuity-derived pathway ‘transcriptional regulatory network in embryonic stem cells’ 
where there was stronger enrichment in differentially expressed genes in NHMs compared to 
Mel D1 cells. If this has any significant meaning remains under investigation, but it is not 
surprising that differentiating hiPSCs towards the melanocytic lineage would utilize slightly 
different pathways (Figure  6c). 
To date, there are several well-established models of the NC that allow for the critical 
investigation of different developmental stages such as: iPSCs, NC, melanoblast and 
terminally differentiated melanocytes. Of note, Studer and colleagues recently modeled the 
NC using a complete and comprehensive in vitro system [83]. Upon using timed exposure to 
WNT, BMP, and EDN3 and under dual-SMAD inhibiting culture conditions, the sequential 
induction of the NC and melanocyte precursor fates was triggered. Moreover, the global 
gene expression profile was analyzed throughout the differentiation process, giving new 
perspectives into the NC and melanocyte fate determination [83]. In comparison, our 
established melanocyte differentiation protocol did not include the usage of the particular 
factors driving a specific route of melanocyte differentiation. It cannot be excluded that also 
other factor combinations may induce the development of neural crest cells or melanocyte 
differentiation. The Studer protocol permits for the investigation of defined stages throughout 
melanocyte development which makes it an ideal model for studying processes such as the 
NC; while the protocol used in this study is a more general approach that directs cells into 
the ectodermal lineage. Although the Studer protocol allows in-depth analyses of each 
processes throughout melanocyte development, both protocols end with terminally 
differentiated melanocytes which indicates that either can be used for this purpose. 
The lack of characterization throughout the differentiation process allows limited 
interpretation of the particular differentiation stages; however, the protocol used in the current 
study generated terminally differentiated melanocytes at a reasonable efficiency. The 
protocol used was not necessarily established for neural crest modeling purposes by Nissan 
and colleagues [292] but rather to obtain fully functional melanocytes. The protocol used in 
this study was based on a study that differentiated human embryonic stem cells (hESCs) into 
another ectodermal derivative: keratinocytes [311]. Researchers found that high 
concentrations of BMP4 and ascorbic acid controlled and mediated pluripotent stem cell 
differentiation along the ectodermal lineage resulting in keratinocyte lineage differentiation in 
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approximately 50-60 % of cells, while the remaining cells formed clusters of pigmented cells. 
Consequently, Nissan and colleagues hypothesized that these pigmented cells may contain 
melanocytes or neuroectodermally-derived RPE cells [312] and adapted the protocol for the 
derivation of terminally differentiated melanocytes [292].  
In the current study, this protocol was utilized due to its high efficiency in generating 
terminally differentiated melanocytes. After the completion of the differentiation protocol, a 
pure population of hiPSC-derived Mel D1 cells was achieved without any keratinocyte or 
RPE cell contamination. A pure population was generated by culturing the pigmented 
colonies from the differentiation protocol in separate culture dishes with a melanocytes 
specific medium, which only permits growth of melanocytes. 
One would assume that after placing human iPSCs in differentiation medium containing high 
levels of BMP4 and ascorbic acid, expression of all pluripotency markers would diminish at a 
rapid pace. This holds true for both OCT4 (Figure 4a) and NANOG (Figure 7a) expression. 
Interestingly, SOX2 remained expressed after an initial decrease upon the initiation of 
differentiation (Figure 7a-b). Moreover, SOX2 was found to be highly expressed in NC-
derived cells (Figure 7c). The expression of SOX2 in cells that were enriched for NCCs by 
sorting for HNK-1 and p75 expression (method described in Supplemental section 8.1.1.2), 
suggested that SOX2 may play a role in the developing NC (Figure 7c). To date, there have 
been several important studies, which have investigated the role and function of SOX2 in NC 
development; one of which used an in vitro model for NC characterization to demonstrate a 
key role for SOX2 is neurogenesis [77]. Moreover, an in vivo system for modeling NC 
development examined tumor cell invasion by transplanting human metastatic melanoma 
cells into chick embryonic NC environment [210]. These transplantation experiments 
revealed that the invasion and migratory pathways employed by melanoma cells were 
heavily influenced by NC microenvironmental signals. In addition to in vivo modeling, laser 
capture microdissection (LCM)-assisted gene profiling was utilized to identify novel 
interactions and signaling networks. Cells were collected from distinct locations, including 
migrating NCCs, from the in vivo model and analyzed using qPCR [210]. Pluripotency 
markers were analyzed and SOX2 showed the highest expression in the migratory cells, 
supporting the model used in the current study that also suggests a role for SOX2 in the NC.  
Although the spatiotemporal expression of SOX genes in the NC has not been fully 
investigated, some of these genes have been analyzed in detail, e.g. SOX10 [313]. SOX10 is 
expressed in early migrating NCCs [314, 315]. In detailed investigations of NC-derived cells 
in vitro, SOX10 was required for survival and glial differentiation [316]. High expression of 
SOX10 was observed throughout the days of differentiation towards the ectodermal lineage 
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in our melanocyte differentiation protocol (Figure 7b), which suggests that this protocol not 
only follows a NC-like path but that SOX10 is also important for this lineage determination.  
During the differentiation process, SOX2 expression levels remain lower than SOX10 
expression levels but remain detectable even at late differentiation stages, suggesting that 
complete ablation of SOX2 is not required for successful ectodermal lineage differentiation. 
Moreover, these experiments were normalized to hiPSCs, therefore SOX2 expression levels 
remain equivalent or slightly to that of hiPSCs (Figure 7b).This is in agreement with the fact 
that the majority of terminally differentiated cells derived from the ectoderm requires the 
expression of SOX2, such as neurons (Figure 7b) (reviewed in [303]).Conversely, SOX2 has 
been reported to inhibit NC formation and subsequent EMT in avian studies [313]. Moreover, 
SOX2 is actually downregulated in both early premigratory and migratory NCCs [11, 313]. In 
neural plate explants and in the embryonic ectoderm, SOX2 expression was aberrant and 
mutant forms of SOX2 were used to reveal that SOX2 is an inhibitor of NC formation [313]. 
This may explain the lower levels of SOX2 expression seen throughout the melanocyte 
differentiation protocol compared to SOX10 expression (Figure 7b). Moreover, the observed 
downregulation of NC-related markers, such as SOX10, upon the overexpression of SOX2 in 
the human melanoma cell lines (Figure 12a) might be explained by the inhibitory effect 
SOX2 has on the neural crest during development. The patterning of SOX10 vs. SOX2 
observed during melanocyte differentiation from hiPSCs is in line with this hypothesis 
(Figure 7b). Since SOX2 was suggested to be an inhibitor of the induction of NCCs, the 
expression of SOX2 found in NC-derived cells remains under investigation (Figure 7c). 
However, the expression of SOX2 in this NCC- population may provide evidence that further 
characterization of these cells is needed to ensure the population contains cells in the pure 
NC-state.  
In summary, the temporal expression of SOX2 and SOX10 during the ectodermal-specific 
differentiation supports developmental studies showing the importance of SOX10 expression 
and lower relative levels of SOX2 for successful ectodermal lineage development and 
progression. Several studies, including the current one, reveal that NC development and the 
characterization of melanocyte progenitors can be successfully simulated using in vitro 
modeling systems. These model systems require full characterization to allow for 
comprehensive analyses of melanocyte development that was otherwise impossible to study 
due to constraints of animal models, ethics or limited resources.  
6.2 Functional analysis of SOX2 in melanoma 
The function of stem cell-associated markers in cancer has been investigated in several 
studies (reviewed in [317]). One study found significant overexpression of at least one out of 
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the four pluripotency factors OCT4, SOX2, c-MYC or KLF4 in 45 % of cancer types 
investigated using the Oncomine online database [283]. Another study identified three stem 
cell markers, CD166, CD133 and NESTIN, and observed increased expression of these 
markers in metastatic melanoma samples, where at least one of the markers was expressed 
in all metastatic samples [290]. Taken together, these studies illustrate the importance of 
stem cell-associated markers in cancer, including melanoma.  
To date, limited research has been done on SOX2 in the context of malignant melanoma. 
The 3-year median survival for patients with SOX2-positive metastatic melanomas 
decreased by 145 days compared to patients with SOX2-negative metastatic melanomas 
[283, 284], implicating role for SOX2 in melanoma progression. Further functional studies 
have been performed linking SOX2 to melanoma cell invasion, growth and to NESTIN 
expression [282, 284, 295, 318]. Recently, it has been demonstrated that SOX2 is crucial for 
regulating self-renewal capacity and tumorigenicity in melanoma initiating cells via Hedgehog 
(HH) signaling [286]. The complete understanding of SOX2 in melanoma pathogenesis 
including its induction, regulatory mechanisms involved in SOX2 expression in melanoma 
and potential protein binding partners of SOX2 remains not well understood. The current 
study set out to confirm defined key functions of SOX2 in melanoma pathogenesis. 
6.2.1 Genomic SOX2 amplification in melanoma 
Tumor formation and development occurs when a cell accumulates genetic aberrations that 
alter normal cell cycle control. There are several means of genetic aberrations including gene 
deletions or gene amplifications. Gene amplification is defined as a copy number increase of 
a particular chromosomal region and SOX2 amplification is caused by multiplication of the 
3q26.3 gene locus [264, 265]. SOX2 amplification has been widely studied in several cancer 
types including glioblastoma, SCLC and many forms of SCC [264, 266–269, 271, 273, 319]. 
(reviewed in [262]). To date SOX2 amplifications have not been investigated in melanoma, 
however the amplification of SOX2 in SCC is well established [269]. In order to understand if 
amplification is one possible mechanism, by which the SOX2 gene is upregulated in 
melanoma, fluorescence in situ hybridization (FISH) analyses were performed in primary 
melanoma tissue using previously described protocols (Figure 8e-f, method describe in 
Supplemental section 8.1.1.1) [320]. Notably, SOX2 was significantly amplified in both low-
risk (≤1mm) and high-risk (≥1mm) primary melanoma compared to nevi samples (Figure 8e). 
Additionally, all metastatic samples from lymph-nodes, in-transit (metastasis moving towards 
lymph-nodes), skin and visceral organs, were significantly amplified when compared to 
melanocytic nevi (Figure 8e). A common drawback to this technique is the high false-positive 
rate due to the evident co-localization of two signals, which occurs when viewing a three- 
dimensional nucleus in two dimensions [321]. However, the location of the investigated locus 
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and the clear pairs of reference signals per nuclei confirm the amplification observed 
(Figure 8f).  
Amplification typically correlates with expression levels and thus these data suggest 
accelerated SOX2 expression in both low- and high-risk primary melanoma and metastatic 
melanoma compared to melanocytic nevi samples (Figure 8e-f). Correspondingly, these 
results correlate with the significant increase of SOX2 expression in primary melanoma 
compared to melanocytic nevi in the TMA analyses (Figure 15) and, in IHC analyses, 
metastatic melanoma, displayed strong immunopositivity of SOX2 compared to slight 
staining of primary melanoma and no staining in the melanocytic nevi (Figure 8d). 
Furthermore, SOX2 was seen to be highly expressed in 67 % of human melanoma cell lines 
(n=9) (Figure 8a-b). Taken together, the amplification of SOX2 in melanoma likely enhances 
SOX2 expression in primary and metastatic melanoma compared to melanocytic nevi. 
6.2.2 SOX2 expression induces dedifferentiation of melanoma cells in vitro 
The differentiation status of tumor can have drastic impacts on the phenotype and 
aggression of the disease. In fact, tumor cell dedifferentiation is a crucial step towards the 
acquisition of invasive properties and even subtle changes in the differentiation status allows 
tumor progression [301]. In epithelial cancers, i.e. carcinomas, both primary tumors and 
corresponding metastasis display similar heterogeneous organization, where dedifferentiated 
tumor cells are observed along the invasive front [218]. These regions of dedifferentiated 
cells possess hallmarks of EMT and the acquisition of this process is now heavily associated 
with tumor cell dissemination. In melanoma, the high heterogeneity allows for subpopulations 
to switch into a more dedifferentiated phenotype, known in melanoma as the ‘phenotype-
switch’ (reviewed in [217]). The phenotype-switch is a phenomenon where melanoma cells 
switch from a proliferative to an invasive state, which is a process that resembles the EMT 
and permits the acquisition of therapy resistance [322]. The dedifferentiated subpopulations 
within melanomas retain stem cell-like properties and dedifferentiation is a key step in 
switching towards an invasive phenotype that also correlates to therapy resistance. In 
regards to therapy resistance, differentiation-related markers were downregulated and the 
dedifferentiation-related marker p75 (also known as NGFR and CD271) was upregulated 
upon TNF-α treatment, which mimics immunotherapy-induced tumor inflammation [323]. 
Moreover, in B16 murine melanoma cells, the inhibition of MITF led to the upregulation of 
stem cell-associated markers, OCT4 and NANOG, and promoted an invasive phenotype 
[219]. This agrees with work revealing that MITF expression regulates the phenotype switch 
and controls dedifferentiation in melanoma [214, 215, 304]. 
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Although SOX2 expression is low in terminally differentiated melanocytes the observed 
expression of SOX2 in melanoma may be caused by insufficient silencing of SOX2 in 
melanocyte precursors which facilitates tumorigenic potential; this supports the theory that 
cancers arise from early progenitor or cancer stem cells. Conversely, SOX2 may be 
expressed in melanoma but not in melanocytes due to early molecular events during the 
initiation of transformation process which leads to the re-expression of SOX2 in melanoma 
cells. However, to date, the reactivation of SOX2 in human melanoma and its influence on 
melanoma dedifferentiation remains unknown. 
Studies in murine melanoma cells revealed that SOX2 is capable of binding directly to the 
promoter of MITF-M [297], suggesting a connection between SOX2, MITF expression and 
dedifferentiation of melanoma cells. Here, binding of human SOX2 to the human promoter of 
MITF-M promoter was suggested using a computer-based DNA sequence analysis with 
JASPAR [298]. One putative binding site that matches results from the murine study was 
confirmed (Figure 9e). Furthermore, there is high conservation between mouse and human 
for this particular binding site (Figure 9h) [299], which further supports the identification of a 
putative binding site for SOX2 on the MITF-M promoter in silico. However, future chromatin 
immunoprecipitation experiments are required to confirm this in vitro. Consistent with results 
from the mouse study, I observed a functional repression of the MITF promoter upon SOX2 
expression using luciferase reporter assays (Figure 9g, method described in Supplemental 
section 8.1.2.4). However, in the murine work an approximate 80 % repression was 
observed [297], in contrast to 20 % repression that was observed using SOX2 
overexpression in human melanoma cells (Figure 9g). There are several explanations for 
this variance regarding the repressive effect of SOX2 expression on MITF-promoter activity 
between the human and murine system. First, the difference in species may represent one 
reason for the difference in functionality of SOX2-mediated repression of the MITF-M 
promoter activity. However, due to the high conservation of the SOX2 binding site of interest, 
it is unlikely that the difference in species influences functional assays to such an extent. 
Secondly, another explanation might be the experimental setup used in the current work 
compared to the murine studies. In the B16 murine melanoma study, a MITF reporter was 
used that contains a fragment of the full-length MITF promoter including the regions between 
-515 and +90 [60], which contained the SOX2 binding site. This setup omitted further 
upstream activation elements including additional SOX10 binding sites [297]. In contrast, the 
reporter system used in the current study includes the full-length MITF-M promoter and 
therefore possesses all activation sites for SOX10 upstream from the SOX2 binding site 
[300]. In other words, the slight repression of the human MITF-M promoter observed in 
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SOX2-overexpressing human melanoma cells is likely weakened due to potential SOX10-
activation sites located upstream, which were eliminated in the murine studies. 
The implications of SOX2 binding to the MITF-M promoter in human melanoma cells would 
explain the downregulation of MITF upon SOX2 overexpression and upregulation upon 
SOX2 knockdown (Figure 9d-f, Figure 11f). To confirm the loss of MITF protein expression 
was due to SOX2 overexpression and not doxycycline or G418 side effects SK Mel 30-OE 
cells were cultured in the absence of doxycycline, treated with G418 or in the presence of 
both and immunoblotting of MITF revealed no difference compared to the non-selected cells 
(not shown). Therefore, the downregulation of MITF was caused by the upregulation of 
SOX2. For further experiments, only non-induced cells were used for control. Furthermore, 
the location of the putative binding site for SOX2 in the human MITF-M promoter revealed 
that this site is identical to a SOX10 binding site. This suggests that SOX2 and SOX10 
compete for binding at this particular binding site to either repress or activate the MITF-M 
promoter, respectively. It is of interest whether or not competitive binding assays will confirm 
this hypothesis. Nevertheless, the current study suggests one mechanism, by which SOX2 
may be contributing to melanoma dedifferentiation through binding and repressing the MITF-
M promoter in vitro. 
6.2.3 SOX2 is required for melanoma cell invasion and induces EMT-marker 
expression 
Activating invasion and enabling metastasis is not only a hallmark of cancer in general but 
also causes most cancer-related deaths, especially in malignant melanoma [202]. Invasion 
and metastatic spreading are processes that alter tumor cell shape and their attachment to 
other cells and the extracellular matrix (ECM). Alterations in cadherin expression represent a 
well characterized feature of invasive cells [202]. Typically, invasive cells lose their 
expression of E-cadherin (CDH1), which is a key cell-to-cell adhesion molecule. In contrast, 
N-cadherin (CDH2) is upregulated in invasive tumor cells and gives the cells a more 
meschenchymal phenotype [202]. In 2003, a depiction of the connections between invasive 
properties of cancer cells and metastatic spreading was described by Fidler [324, 325]. 
There are different stages in tumor cell invasion and metastatic dissemination. First, local 
invasion is detectable, followed by intravasation of tumor cells into neighboring blood and 
lymphatic vessels. The tumor cells are transported through these circulation systems, then 
escape from lumina into distant tissues by extravasation and finally, they form small nodules 
of tumor cells, i.e. micrometastases [202, 324, 325].  
The EMT has been implicated in regulating both, tumor cell invasion and metastatic spread. 
This developmental regulatory process allows tumor cells to gain abilities to resist apoptosis, 
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invade and disseminate from the primary tumor [202, 218]. A set of transcription factors, 
mainly SNAI1 (SNAIL), SNAI2 (SLUG), TWIST and ZEB1/2 are responsible for orchestrating 
the EMT process and many of these factors have been implicated in melanoma invasion and 
metastasis [218]. These transcription factors are responsible for several hallmark features of 
invasive cancer cells including: loss of adherent junctions, changes in morphology and 
polarity [202]. 
To date, many associations have been made between SOX2 expression and tumor cell 
invasion (reviewed in [262]). For example, SOX2 has been implicated in cellular migration 
and invasion in vitro by regulating MMP-2 in colorectal cancer cells [326]. Likewise, the 
overexpression of SOX2 in a glioma cell line resulted in significant increase in migratory and 
invasive properties of cells [273]. This association has also been demonstrated in melanoma. 
A SOX2 knockdown study in the human melanoma cell line A375 showed a 4.5-fold 
decrease in invasive capacity [284]. Results from this current study confirm this by 
demonstrating that both, migratory and invasive capacities were significantly increased in the 
human melanoma cell line SK Mel 30 upon SOX2 overexpression (Figure 10a & c) In 
agreement, shRNA-mediated knock down of SOX2 expression in the human melanoma cell 
line SK Mel 103 confirms a significant decrease in invasion capacity (Figure 11e). Taken 
together, the current study confirms that SOX2 is required for melanoma cell invasion, which 
is in line with results from previous studies. 
SOX2 expression has also been investigated in melanoma patients. In preliminary analyses 
SOX2 immunopositivity correlated with dermal invasion and was found in close proximity to 
invasive-fronts of a melanoma [282, 284]. Here, using immunohistochemistry analysis, high 
expression of SOX2 in primary and metastatic melanoma patient samples compared to 
melanocytic nevi was confirmed (Figure 8d). Moreover, a drastically increased 
immunopositivity of SOX2 was found in deeper regions of primary melanoma samples 
(Figure 10e). In line with previous studies and the functional data, high SOX2-positive cells 
were observed invading into the extracellular matrix (Figure 10f), between fat cells 
(Figure S4b), into the epidermis (Figure S4a) and along nerve cells (Figure 10g). These 
results further indicate an important role for SOX2 in melanoma cell invasion, not only in 
vitro, but also in melanoma patients in vivo.  
Tumor cell invasion is mainly regulated and orchestrated by a set of transcription factors 
(TFs) governing the EMT process. SOX2 has been demonstrated in many cancer types to be 
associated with these EMT-TFs. For example, in colorectal cancer cells, SOX2 induced 
EMT-TFs which led to the downregulation of E-cadherin [327]. Melanoma represents a 
unique case in EMT-TF expression because normal melanocytes express SNAIL2 and ZEB2 
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and these markers activate the MITF differentiation program resulting in tumor-suppressive 
signaling. However, upon melanoma initiation, either by BRAF or NRAS hyperactivation, the 
EMT-TF network undergoes dramatic restructuring and the expression of TWIST1 and ZEB1 
are favored [203]. Moreover, after this reorganization, melanoma cells are more 
dedifferentiated and invasion is enhanced. Results from the current study are in agreement 
with this work since SOX2 leads to melanoma cell dedifferentiation and is required for 
melanoma cell invasion (Figure 9-10). Furthermore, upon the overexpression of SOX2 in the 
human melanoma cell line SK Mel 30, an upregulation of both ZEB1 and TWIST1 expression 
was observed (Figure 10b). Additionally, in the knockdown of SOX2 in SK Mel 103 
melanoma cell lines, a slight increase in SNAI2 and ZEB2 expression was demonstrated 
(Figure 11f). Taken together, this suggests that SOX2 may be involved in regulating several 
aspects of the melanoma invasive switch, by controlling dedifferentiation which may in part 
be caused via repressing the MITF-M promoter, being required for melanoma invasive 
capacity and enhancing EMT-TFs, TWIST1 and ZEB1, identified to be involved in melanoma 
progression.  
Linking SOX2 to these aspects further implicates SOX2 in the melanoma phenotype switch. 
This switch describes highly proliferative cells with low invasion capacity, which is converted 
into highly invasive and slow proliferating cells during melanoma progression. This switch 
provides melanoma cells with mechanisms in progression, maintenance and evasion of 
melanoma therapy [304]. After investigating SOX2 in melanoma cell invasion, the effect of 
SOX2 overexpression on melanoma cell metabolism was investigated. Thereby, a significant 
decrease in melanoma cell metabolism in the SOX2 overexpressing cells was revealed 
(Figure 10d) although knockdown experiments had little effect on the metabolism (Figure 
11d). It is important to mention that the alamarBlue® assay is a metabolism-based method 
and therefore one cannot rule out that metabolic changes may lead to altered reduction of 
the dye without true impact on the cell cycle. Further cell cycle analysis using fluorescence-
activated cell sorting (FACS) is needed to reveal whether SOX2 overexpression had a 
cytostatic effect or induced apoptosis resulting in cellular cytotoxicity. Furthermore, one 
explanation why there was not a significant increase in invasion and in turn significant 
decrease in cellular metabolism in the SK Mel 173-OE may be explained by the lower levels 
SOX2 overexpression observed in this cell line compared to the high levels of SOX2 in the 
SK Mel 30-OE (Figure 9b). Therefore, the effect seen is only a slight tendency but not 
significant. Nonetheless, these studies suggest that SOX2 overexpression induces a highly 
invasive, slowly proliferative phenotype and taken together with the knockdown studies, 
SOX2 is required for melanoma cell invasion in vitro, but not cellular metabolism. 
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In summary, SOX2 is a key regulator in melanoma cell plasticity. This stem cell-marker 
dedifferentiates human melanoma cells by repressing the MITF-M promoter, is required for 
melanoma cell invasion and upregulates EMT-TFs related to dedifferentiation and an 
invasive phenotype. 
6.3 SOX2 expression is induced by TGF-β signaling 
The mechanisms of melanoma cell invasion and metastatic spreading are governed by 
several signaling pathways, mainly TGF-β and WNT/β-catenin signaling. The initiation of 
invasive properties is predominantly induced by the EMT process. EMT-like processes are 
typically initiated in epithelial precursor cells in response to extrinsic TGF-β stimulation. 
TGF-β has been described as a potent inducer of the EMT [328, 329] via SMAD-related or 
SMAD-independent pathways [330], and the blockade of transforming growth factor receptor-
I (TGFBRI) led to the induction of a more epithelial phenotype [204]. Furthermore, in human 
carcinomas, characteristic features of the EMT were observed at the invasive front of the 
tumors, an area containing high levels of stromal TGF-β [166]. In melanoma, the common 
routes towards tumor cell invasion heavily involve TGF-β signaling. A reduction in colony 
formation, invasion and expression of MMP-2 and MMP-9 was observed after the 
overexpression of the inhibitory SMAD protein, SMAD7 [331]. Furthermore, studies in mice 
demonstrated that similar to breast cancer bone metastasis [332, 333], SMAD7 
overexpression blocked melanoma bone metastasis [171]. 
For these reasons, an understanding of the mechanisms controlling TGF-β signaling is 
needed to prevent invasion and metastatic spreading. In glioma-initiating cells, TGF-β was 
found to induce the expression of SOX2 in vitro. This mechanism was confirmed in 
melanoma in two independent human melanoma cell lines after one week of TGF-β 
stimulation (Figure 13b & e). Moreover, a more mesenchymal phenotype was observed 
upon stimulation, where cells stimulated with TGF-β had long protrusions and loss of the 
polygonal body shape (Figure 13a). In accordance with this, drastic upregulation of 
N-cadherin expression and corresponding downregulation of E-cadherin was found (Figure 
13g), demonstrating the key characteristics of the activation of tumor cell invasion [202].  
As described in Section 6.2.3, melanoma cells undergo dramatic reorganization of EMT-
related TFs upon tumor initiation [203]. Moreover, this reorganization operates upstream of 
MITF and controls dedifferentiation and melanomagenesis. The EMT-TFs ZEB1 and TWIST1 
were found to induce TGF-β and, in turn, melanoma cell invasion [203]. In line with these 
findings, data from the current study suggest that SOX2 is playing a critical role in this 
process. This study proposes that TGF-β1 induces SOX2 expression, which may lead to 
melanoma progression by: i) SOX2 binding and repressing the MITF-M promoter, which may 
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influence the dedifferentiation of human melanoma cells, and ii) SOX2 inducing high 
expression of ZEB1 and TWIST1, which promotes a mesenchymal phenotype. In line with 
the described phenotypic alterations, this work revealed that SOX2 enhances melanoma cell 
migration and invasion and depletion of this transcription factor results in loss of cellular 
motility. The overall phenotype observed upon the overexpression of SOX2 matches parts of 
EMT-TF restructuring and the dedifferentiation phenotype in melanoma. Therefore, I 
identified a key player in this complex network that is responsible for several mechanisms 
observed in aggressive melanoma. Future experiments will solidify these finding, such as 
chromatin immunoprecipitation (ChIP) experiments to elucidate the possible direct regulation 
of EMT-TFs by SOX2 promoter binding. This has been demonstrated in pancreatic cancer, 
where SOX2 was demonstrated to bind to the promoter of SNAI1 [327]. Furthermore, in 
affinity capture mass spectrometry experiments, SOX2 was found to potentially form a 
protein-protein interaction with ZEB2 [334], which may be another mechanism by which 
SOX2 controls the restructuring of the EMT-TF network in melanoma to promote the invasive 
phenotype switch. 
Interestingly, the results from the current study also suggest a unique role for SOX2 in 
regulating itself and possibly parts of the TGF-β signaling pathway. The induction of several 
TGF-β-related markers: TGFβR2, TGFβR3 and JUN in SK Mel 30 SOX2 overexpressing 
cells was demonstrated (Figure 13h). This suggests that SOX2 may be involved in a positive 
feedforward loop in regulating first, TGF-β signaling-related genes and second, itself since 
SOX2 expression is also induced by TGF-β. Furthermore, this has been demonstrated in 
pluripotency and SOX2 was found to contain SOX2 binding sites for its own autoactivation 
[335]. It is of great interest to understand this mechanism in more detail and further studies 
need to be done to confirm this, such as determining if SOX2 can bind the promoters of 
genes involved in TGF-β signaling using ChIP analysis. 
6.4 SOX2 may form potential interactions with several melanocyte- and 
SUMO-related proteins 
Understanding expression levels of particular gene sets gives an impression of the cellular 
state, activated signaling pathways and possible phenotypes. However, there are many 
levels of regulation that are involved in controlling cellular functions, such as protein-protein 
interactions. SOX2 is essential in embryogenesis and development, and there are many 
different partners that can associate with SOX2 (Figure 2c). The recent association between 
SOX2 expression and tumorigenesis has led to investigations attempting to identify novel 
SOX2-interacting partners in the context of cancer. Mass spectrometry studies identified 
several novel heterogeneous nuclear ribonucleoprotein family proteins, including 
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HNRNPA2B1, HNRNPA3, as well as other ribonucleoproteins, DNA repair proteins and 
helicases as potential interacting partners of SOX2 if glioblastoma [257]. 
Next to mass spectrometry, the bimolecular fluorescence complementation (BiFC) assay can 
be used to determine novel interactions between proteins. [336]. The principle of the BiFC 
assay is the reformation and fluorescence of two fragments of a single fluorescent protein 
upon interaction. Using BiFC experiments, interactions between three proteins, ERNI, BERT, 
and Geminin, were found to modulate the choice of repressors and regulate SOX2 
expression in early neuronal development [337]. The experiments performed in the current 
study investigated potential interactions between SOX2 and PAX3, and between SOX2 and 
SOX10, respectively, using BiFC experiments. PAX3 was chosen since it is known to be 
important for the melanocytic lineage and responsible for co-activating the MITF promoter 
[56, 92, 338, 339]. Moreover, studies discovered that PAX3 interacts with SOX10 using its 
paired domain that binds to the HMG domain of SOX10 [92]. Therefore, it is likely that SOX2 
may be using its HMG domain to form an interaction with the paired domain of PAX3.  
The interactions between SOX family members remain not well studied. However, the 
interaction between SOX2 and SOX10 would have immense impact on further understanding 
the regulation between the two. Results from the current study suggest that in melanoma, 
SOX2 operates upstream of SOX10, since knockdown of SOX10 had no effect on the 
expression of SOX2 (Figure 12). Therefore, further investigations are needed to understand 
the reciprocal role and possible interactions between these two proteins and what functional 
effect this has in vitro. 
Upon co-transfection of SOX2-bait and either PAX3- or SOX10-prey constructs into 
HEK293T cells, a positive fluorescent signals was observed when using both combinations 
(Figure 14a), with fluorescence at levels similar to the positive control. This experiment was 
performed three times independently with a reproducible outcome indicating true interaction 
between SOX2 and PAX3 or SOX10, respectively. However, these results must be 
confirmed using parallel BiFC analysis of proteins containing mutated interaction interfaces. 
It is important to note that although these studies are performed in vitro, the prospect of false 
positives is still possible since the overexpression of proteins may not represent proteins 
concentrations reached in vivo. 
Yeast-2-hybrid (y2h) pairwise experiments were performed to verify these observed 
interactions in a different system. PAX3-SOX2 interactions were analyzed in the y2h pairwise 
setup with PAX6 a positive control (known interactor of SOX2) [245]. However, difficulties 
were observed because SOX2 showed strong autoactivation tendencies. Therefore, it cannot 
completely be ruled out that the effect of autoactivation in the y2h pairwise experiments 
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influences the results. Nonetheless, weak colony growth was observed in the PAX3/SOX2 
mating at the highest stringency of 2.0 mM 3-AT, though there was great variability between 
replicates (column) (Figure 14d, bottom panels). Another level of stringency used in y2h 
experiments is 3-amino-1, 2, 4-triazole (3-AT). This molecule is a competitive inhibitor of the 
product of the HIS3 gene, reducing possible autoactivation and false positives.  
Furthermore, we aimed at confirming the interactions between SOX2-SOX10 in pairwise y2h 
experiments; however the overexpression of both SOX2 and SOX10 proved to be lethal in 
yeast even at the lowest 3-AT concentrations tested (Figure 14d, upper panels). Therefore, 
possible interactions between SOX2 and SOX10 could not be confirmed in yeast 
(Figure 14).  
Since the yeast-2-hybrid (y2h) pairwise experiments could not independently confirm these 
interactions, these experiments should be repeated using SOX2-bait construct lacking the 
HMG domain to remove autoactivation tendencies. The autoactivation function of the SOX2 
protein has been thoroughly studied, as previously mentioned, and SOX2 itself contains 
SOX2 binding sites to regulate its own transcription. In the field of pluripotency this has been 
well described and SOX2 has been shown to autoactivate itself in a complex and well-
described pluripotency circuit [335, 340].  
TWIST1 is known to be implicated in cell lineage determination and the EMT process. 
Therefore, the interaction between SOX2 and TWIST1 would further implicate SOX2 in the 
regulation of the EMT process. The interaction between SOX2 and TWIST1 was found in 
affinity capture-mass spectrometry [261], but was not the focus of the study. This work 
suggests that SOX2 and TWIST1 are likely to interact but further in vitro studies need to 
confirm this. Nonetheless, y2h pairwise experiments for TWIST1 were performed but due to 
the strong SOX2 autoactivation, false positive results cannot be completely ruled out. 
Nevertheless, weak colony growth in the TWIST1/SOX2 mating setup was observed at the 
highest stringency of 2.0 mM 3-AT; however between replicates (column) there was great 
variability, due to technical problems (Figure 14d, bottom panels). 
In conclusion, SOX2 may form potential protein-protein interactions with PAX3, SOX10 and 
TWIST1; however this needs to be confirmed by further protein studies, such as co-
immunoprecipitation.  
In addition to protein-protein interactions, cellular regulation can also occur through post-
translational modifications. These modifications include protein cleavage or additional protein 
folding, which can allow additional co-factors to bind or complexes to form. SUMOylation is a 
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type of post-translational modification by which a SUMO molecule is attached by reversible 
covalent linkage (reviewed in [247]).  
In the SOX family, SUMOylation has been shown to be important for functional diversity in 
the SOXE subgroup. Studies found that in Xenopus, both SOX9 and SOX10 can be SUMO-
modified in vivo [248]. Non-SUMOylatable SOX9 and SOX10 promoted the expression of NC 
markers and the SOX9/10-SUMO-1 fusion inhibited the expression of NC markers. 
Moreover, neither phenotype was able to completely reproduce the wildtype (WT) 
phenotype, which suggests that both unmodified and SUMOylated forms of SOXE proteins 
contribute to the activities of WT SOXE family members in vivo [248, 249]. Additionally, 
another study observed that SUMOylation of SOX10 represses the transcriptional activity of 
its target genes, including MITF [250]. In addition to the SOXE group, a study found that 
SOX2 reduced its binding to the FGF4 enhancer element when conjugated to SUMO-1 [252].  
In accordance to these studies, four SUMO-related proteins were identified that may form 
protein-protein interactions with SOX2 in y2h high throughput screens (HTS) (Figure 14e). In 
detail, Small ubiquitin-related modifier 1 (SUMO1), Ubiquitin-conjugating E2I (UBE2I), E3 
SUMO-protein ligase (PIAS4), and chromobox homolog 4 (CBX4), which is also an E3 
SUMO-protein ligase were found (Figure 14e). Interestingly, SOX2 was shown to bind to 
SUMO1 in another study using y2h HTS and bioinformatics analyses [341]. Furthermore, 
other hits were previously identified, including SOX2 interaction with CBX4, using affinity 
capture mass spectrometry [334]. These studies support results derived from the y2h HTS 
used in the current study and suggests that true interaction partners of SOX2 and not false-
positives were identified. Validation of these hits and the function of their interaction with 
SOX2 remain under investigation. 
In summary, this work suggests that SOX2 may be SUMOylated and this could have further 
functional implications. There may be important functional effects of SUMOylation on SOX2 
in melanoma that remain unknown, since one study found the conjugation of SOX2 with 
SUMO1 decreased the transcriptional activity of the protein [252]. Furthermore, I could 
predict two SUMOylation sites within the SOX2 protein using GPS-SUMO online database; 
one located close to the HMG domain and the other one located in the transactivation 
domain (Figure 14f-g). This further supports results from the y2h HTS. Taken together, the 
identification of four SUMO-related proteins and identification of putative SUMOylation sites 
in the SOX2 protein suggests that SOX2 can be SUMOylated. Therefore, the role of 
SUMOylation in the context of SOX2 may be crucial in further understanding its regulation in 
melanocyte development and melanoma.  
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6.5 SOX2 in the clinic 
Malignant melanoma remains a challenging disease to treat due to the acquisition of 
resistance and fast metastatic spread. Therefore, the identification of new markers for 
prognostic and therapeutic intervention would greatly benefit melanoma patients. SOX2 has 
proven to be clinically relevant in many different cancer types. Not only is SOX2 highly 
expressed in many different cancer types but it has also shown potential as a useful 
biomarker in the clinic for some cancer types, for the identification of cancer stem cell 
populations and in tumor staging (reviewed in [262]). For example, SOX2 was found to be 
overexpressed with SALL4, another stemness regulator, in esophageal cancer samples. 
Moreover, the co-expression of these markers correlated with depth of tumor invasion and 
occurrence of metastasis [342]. 
To date, only a few studies have investigated the impact of SOX2 in the clinic. Studies found 
that SOX2 and NESTIN expression are able to distinguish between melanocytic nevi and 
metastatic melanoma samples [282, 318]. Moreover, SOX2 was discovered to be present in 
up to 67 % of primary and 80 % of metastatic melanomas compared to only 14 % in 
melanocytic nevi samples [281, 284]. This work is in line with the tissue microarray (TMA) 
data form the current study where a significant increase in expression of SOX2 was 
observed in primary melanoma compared to melanocytic nevi samples (Figure 15b). 
Furthermore, bioinformatic studies investigating embryonic stem cell-associated markers in 
cancer analyzed mRNA expression using the Oncomine database. They revealed that the 3-
year median survival was decreased by 145 days in SOX2-expressing metastatic melanoma 
patients compared to those patients with SOX2-negative metastatic tumors [283]. Taken 
together, these data illustrate the potential ability of SOX2 to become a powerful diagnostic 
tool in melanoma. 
For the most part, therapeutic strategies targeting SOX2 remain unrealistic due to the 
functional nature of the protein and its importance in many normal processes. Nonetheless, 
recent studies have attempted to investigate SOX2 as a therapeutic target. For example, one 
study in oligodendroglioma, examined the use of SOX2 peptides for immunotherapy 
treatment in mice [343]. C57BL/6N mice were injected with WT oligodendroglioma cells from 
an established mouse model and, upon vaccination with SOX2 peptides, a significant delay 
in tumor growth was observed (reviewed in [262]). In another study, an experimental DNA 
vaccine against SOX2 was developed and, upon injection, found to significantly induce 
SOX2-specific lymphocyte activation. The vaccine was able to significantly reduce tumor 
growth but not prevent development in mice [344]. 
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Though a few studies have provided experimental evidence that direct inhibition of SOX2 
may have a therapeutic benefit in mice, targeting SOX2 directly remains impractical in 
humans, since the proper function of this protein is also important in many aspects of cellular 
function. Furthermore, SOX2 remains highly expressed and important in the brain and 
nervous system throughout adulthood and targeted therapy will likely cause many unwanted 
complications (reviewed in [262]). Nonetheless, targeting up- or-downstream of SOX2 may 
prove beneficial in anticancer therapy. In NSCLC CSCs, SOX2 is highly expressed and relies 
heavily on EGFR signaling in order to promote self-renewal [345]. Anticancer therapies 
targeting EGFR currently available on the market include gefitinib and erlotinib. These 
molecules may prove useful in inhibiting SOX2’s role in self-renewal capacity of NSCLC 
CSCs. However, resistance acquisition to anti-EGFR therapies is common in cancer cells 
and therefore it may be useful to further target SOX2-signaling in EGFR-mutant cancer cells 
with PI3K/AKT inhibitors to yield better results (reviewed in [262], [345]). 
My work suggests that SOX2 plays a pivotal role in the melanoma phenotype switch by 
dedifferentiating melanoma cells, enhancing invasion and inducing expression of EMT-TFs. 
Since highly invasive, slowly proliferating cells are more prone to melanoma therapy 
resistance, work has been done to investigate if switching these cells back to a highly 
proliferative, poorly invasive phenotype might be a successful anti-melanoma therapy option 
[322]. A directed phenotype switching method demonstrated the sensitization of melanoma 
cells to lineage-specific therapies [346]. Upon methotrexate (MTX) treatment, cells 
expressed MITF, showed differentiation-associated marker expression and inhibited 
invasiveness. Furthermore, after treatment with MTX, cells were sensitized to treatment with 
the tyrosinase-processed antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin 
(TMECG) [346]. This strategy shows the potential of inducing a phenotype switch as an 
effective, tissue-specific treatment for aggressive melanoma both in vitro and in vivo. 
However, successful pre-clinical and clinical trials need to be performed before this therapy 
can be applied to patients in the clinic. 
In light of these new results suggesting that SOX2 can be induced by TGF-β (Figure 13), 
several new therapeutic options are now being investigated to be utilized for the treatment of 
melanoma. The complexity of TGF-β signaling, as discussed above, also presents intricacies 
in therapy targeting TGF-β. The inhibition of TGF-β signaling through antagonists is currently 
under development in both pre-clinical and clinical studies (reviewed in [347]). To date, there 
are several options to target this pathway, including ligand traps [348], antisense 
olignonucleotides (ASOs) [349], peptide aptamers [350] and small molecule receptor kinase 
inhibitors [351]. Ligand traps, including anti-ligand neutralizing antibodies and soluble decoy 
receptor proteins, are able to capture excess TGF-β ligand produced by tumor cells and 
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fibroblasts, blocking the progression of tumor development [166, 352–354]. Similarly, ASOs 
can reduce the bioavailability of TGF-β ligands in the local microenvironment by directly 
blocking TGF-β synthesis and leading to enhanced mRNA degradation [355]. Another 
strategy is blocking the activity of TGF-β receptor signaling by using small kinase inhibitors 
that competitively block ATP catalytic activity. Moreover, additional targets include the 
intracellular SMAD proteins, which can be inhibited by using peptide aptamers that target, 
bind and interfere with SMAD downstream function (reviewed in [347]). 
All TGF-β therapeutic strategies face complex and problematic overlapping mechanisms that 
are essential for normal physiological function (reviewed in [347]). For instance, outgrowths 
of drug-resistant carcinomas was observed in a mouse study after long-term suppression of 
the TGF-β signaling pathway using the TβRI/II kinase inhibitor, LY2109761, [356]. However, 
with correct dose and duration of treatment with TGF-β therapies, beneficial outcomes may 
follow especially in malignant melanoma.  
Current pre-clinical and clinical trials using the therapeutic strategies targeting TGF-β 
signaling mentioned above are ongoing. Of these, the ligand traps are fully developed, with 
humanized pan-TGF-β monoclonal neutralizing antibodies, including Lerdelimumab [357, 
358], Metelimumab [359] and GC1008 or Fresolimumab [360]. In 2014, Genzyme sponsored 
a clinical trial for investigating GC1008 in patients with advanced renal cell carcinoma (RCC) 
and malignant melanoma. 25 % of malignant melanoma patients exhibited stable disease or 
improvement upon receiving therapy. Of those responders, 21 % had stable disease with a 
median progression-free survival of 24 weeks and one patient achieved partial repsonse 
[360]. Another pre-clinical study investigated the kinase inhibitor of TGF-β receptor I kinase 
(TβRI), SD-208, and revealed a reduction in both, progression and frequency of bone 
metastases in mice [361]. Further clinical trials will help to gain final approval of anti-
melanoma treatment using TGFβ-targeted therapy. 
The benefit of targeting TGF-β may improve the therapeutic prospects of success of 
melanoma patients in the future. Whether or not this tumor suppressive effect, which is seen 
when TGF-β signaling is impeded, is partially due to the downregulation of SOX2 remains 
unknown and future investigations are required to solidify the role of SOX2 in TGF-β 
signaling and anti-melanoma therapy. 
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7 Conclusions 
In the present study, I investigated the function of SOX2 in both, melanocyte differentiation 
from human induced pluripotent stem cells (hiPSCs) and melanoma progression. This work 
highlights the importance of this transcription factor during the differentiation from hiPSCs via 
the ectodermal lineage into fully differentiated melanocytes. It also outlines that SOX2 may 
regulate key processes in melanoma pathogenesis.  
The ectodermal germ layer specifies different lineages such as neuronal cells, retinoid 
pigmented epithelial cells and melanocytes. Interestingly, upon directed ectodermal lineage 
differentiation from hiPSCs, expression of all pluripotency markers decreased while SOX2 
remained moderately expressed, which suggests its role in this specific germ layer. Since 
SOX2 plays a role in the development of neurons its expression in cells derived via 
ectodermal-directed lineage differentiation is expected. However, this work proposes the 
investigation of early ectodermal markers in ectodermal-derived tumors, since these genes 
may also be reactivated during carcinogenesis. To date, melanoma research has focused on 
the predisposition of the lineage to malignant transformation due to its neural crest 
developmental program; however this work suggests that it may also be the reactivation of 
early ectodermal markers that are responsible for malignant behavior  
In-depth functional analyses of SOX2 in melanoma pathogenesis revealed multiple facets of 
SOX2 function emphasizing the importance of investigating ectodermal lineage markers in 
melanomagenesis. Upon the overexpression of SOX2 in melanoma cells, a change of the 
differentiation state in human melanoma cells was observed in vitro, which I demonstrated, 
may be achieved through its binding and repressing of the MITF-M promoter. 
Dedifferentiation in melanoma correlates to the aggressive behavior of melanoma cells and 
in agreement with that, SOX2 also demonstrated to enhance melanoma cell invasion and 
migration functionally, in combination with upregulated epithelial-to-mesenchymal transition 
(EMT) marker expression. In line, its depletion led to a loss of motility and EMT-marker 
expression. The invasive melanoma phenotype seems to rely heavily on the upregulation of 
SOX2 in order to orchestrate invasion-related processes including the induction of the EMT 
and repression of differentiation-related markers  
The regulation of SOX2 in melanoma remains unknown even though it plays a crucial role in 
melanoma pathogenesis. This study found additional genomic SOX2 copy numbers in 
primary and metastatic melanoma samples compared to melanocytic nevi, which correlated 
to SOX2 overexpression in tissue samples. On a molecular level, TGF-β1 was found to 
induce SOX2 expression in human melanoma cell lines. This suggests TGF-β to be an 
upstream regulator of SOX2 in melanoma, and furthermore SOX2 may play a role in a 
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positive feedforward loop, which regulates members of the TGF-β signaling cascade and 
itself. This has recently been shown in TGF-β signaling in kidney cells, where a study 
observed the promotion of TGF-β signaling through a positive feedback loop mediated by a 
microRNA [362]. It is of further interest, whether or not SOX2 is required for TGF-β-mediated 
invasion capacity in melanoma cells.  
In addition, I identified novel specific protein-protein interactions between SOX2-PAX3 and 
SOX2-SOX10 and analyses of mutated protein interfaces will help to determine specific 
interactions sites. Additionally, in vitro experiments, such as co-immunoprecipitation studies 
will help to confirm this interaction in the context of melanoma or the melanocytic lineage.  
Moreover, I revealed SUMOylation-related proteins potentially interacting with SOX2, 
proposing a further mechanism of SOX2 protein regulation. In depth analyses such as co-
immunoprecipitation experiments are needed to investigate whether these interactions are 
also formed in melanoma cells and what functional effect SUMOylation has on SOX2 protein 
in the context of melanocyte development and melanoma pathogenesis.  
This study highlights the complex networks SOX2 may be involved in during melanoma 
pathogenesis. Here, SOX2 is suggested to play a role in melanoma cell dedifferentiation, 
motility and invasion. Moreover, gene amplification may cause SOX2 overexpression in 
melanoma and TGF-β induces its expression in melanoma cell lines. Therefore, I identified a 
key player in melanoma pathogenesis that is responsible for several invasion-related 
processes observed in aggressive melanoma. For these reasons, targeting TGF-β or 
inhibiting the induction of phenotypic alterations, i.e. dedifferentiation, may be beneficial for 
indirectly impeding enhanced SOX2 expression and therefore inhibiting the progression of 
aggressive, metastatic melanoma. However, as the TGF-β inhibitor used in this study only 
showed little effect on inhibiting SOX2 expression, a combination of TGF-β inhibition, which 
leads to melanoma differentiation, together with conventional anti-melanoma therapy may 
prove beneficial for melanoma patients.  
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8 Supplemental material 
The following data and extended experimental procedures are listed below. 
8.1 Extended experimental procedures 
The following experimental procedures were performed in collaborations or by others from 
the Utikal laboratory and are mentioned accordingly. Note these methods are only mentioned 
in brief. 
8.1.1 Experimental procedures performed by others in the Utikal laboratory 
The below procedures were performed with the help of other members in the Utikal 
laboratory. 
8.1.1.1 Fluorescence in situ hybridization 
FISH experiments were performed by a colleague in the Utikal laboratory, Elias Orouji, with 
support from our technician, Sayran Arif-Said. In brief, the CTD-2348H10 BAC clone, 
hybridizing to the locus 3q26.33, was used to detect human SOX2. The RP11-286G5 BAC 
clone, hybridizing to 3p22.3-3p22.2, was used as a reference probe purchased from 
Invitrogen). DNA was isolated using a MAXIprep (Qiagen) from E. coli containing the BAC 
clones. Nick translation was performed using different fluorochromes for dUTPs to prepare 
the reference and gene probes (Nick Translation System, Life Technologies, Catalog 
Number 18160-010). Probe size was determined by agarose gel electrophoresis. FISH was 
performed on samples using previously described protocols [320]. Control hybridizations 
were performed on metaphase spreads of euploid cells. To analyze the slides, only FISH 
signals of intact, non-overlapping nuclei (n=100) were counted. The total number of SOX2 
gene copies in relation to the reference probe copy number is indicated as the SOX2-FISH 
ratio. Amplification of SOX2 was defined as a ratio > 1.3. This cutoff value was determined 
using Hothorn and Lausen method and using a package developed in the R program [296]. 
8.1.1.2 NC differentiation protocol from human induced pluripotent stem cells 
The neural crest cell population was differentiated in a different manner than melanocytes. 
This protocol was established and performed by Dr. Lionel Larribere from the Utikal lab. In 
brief, hiPSCs were trypsinized and seeded into cell culture dishes coated with Matrigel® and 
cultured in mTeSR™ stem cell medium with Rock inhibitor. The day after the seeding, the 
medium was changed to differentiation medium supplemented with cytokines (BMP4, 
ascorbic acid, hSCF, EDN3 and WNT3A). Cells were cultured in the above medium for 11 
days and sorted by fluorescence-activated cell sorting (FACS) using HNK1 and p75 
expression. 
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8.1.2 Extended experimental procedures performed in collaborations 
The following procedures were performed in collaboration with other groups or core facilities 
at the DKFZ. 
8.1.2.1 Electron microscopy 
Electron microscopy was performed in collaboration with the DKFZ Microscopy Core Facility. 
Cells were seeded on ACLAR® cover slips and cultured for one week before submission to 
the Microscopy Core Facility, where they were fixed, sliced and imaged. 
8.1.2.2 Yeast-2-Hybrid experiments 
Yeast two-hybrid (y2h) experiments were performed in collaboration with the DKFZ 
Proteomics Core Facility. Constructs were provided by the core facility or cloned in our 
laboratory with the help of Dr. Daniel Novak. In brief, yeast were transformed with bait and 
prey vectors of our choice. Bait- and prey-transformed yeast were mated and successful 
diploids were nutritionally selected on medium lacking tryptophan and leucine. The y2h high-
throughput screen was performed similarly to aforementioned experiments, expect that only 
the bait construct was needed and the prey constructs were provided in selected cDNA 
libraries. Positive matings were detected via fluorescence. These signals were further 
analyzed by PCR and sequencing to determine potential new interacting partners. 
8.1.2.3 Bimolecular fluorescence complementation assay 
The bimolecular fluorescence complementation (BiFC) assay was performed in collaboration 
with the DKFZ Proteomics Core Facility. In brief, HEK293T cells were seeded in 96-well plate 
format and transfected with both bait and prey constructs containing the gene of interest plus 
a partially fluorescent fluorophore. Upon transfection, cells were visualized and imaged under 
fluorescence microscope. 
8.1.2.4 Luciferase reporter assay 
Luciferase reporter assay was performed in the lab of Dr. Corine Bertolotto at the INSERM 
institute in Nice, France. Briefly, The luciferase reporter plasmids pMITF and the expression 
vector encoding the wild-type or the dominant negative form of MITF were previously 
described [363]. The SK Mel 30 SOX2-overexpressing cells and non-induced control were 
seeded in 24-well dishes and transient transfections were performed the following day using 
2 µL of lipofectamine and 0.5 g of total DNA plasmid. pCMV Gal was transfected with the test 
plasmids to control the variability in transfection efficiency. After 48 h, cells were harvested in 
50 µL of lysis buffer and assayed for luciferase and galactosidase activities. All transfections 
were repeated at least three times and performed in triplicate [300]. 
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8.2 Supplemental figures 
The following figures are supplemental to this doctoral work. 
 
Supplemental material 
108 
 
 
 
 
 
 
Supplemental material 
109 
 
 
 
  
References 
110 
9 References 
1. His N: Untersuchungen über die erste Anlage des Wirbeltierleibes. Die erste Entwicklung des Hühnchen 
im Ei. FCW Vogel Leipzig 1868. 
2. Gershon M: Development of the Neural Crest. J Neurobiol 1993, 24:141–145. 
3. Knecht AK, Bronner-Fraser M: Induction of the neural crest: a multigene process. Nat Rev Genet 2002, 
3:453–61. 
4. Silver DL, Pavan WJ: The origin and development of neural crest-derived melanocytes. In From 
melanocytes to melanoma: The progression to malignancy. Edited by Hearing VJ, Leong SP. Totowa, NJ: 
Humana Press; 2006:3–26. 
5. Kalcheim C: Mechanisms of early neural crest development: from cell specification to migration. Int Rev 
Cytol 2000, 200:143–96. 
6. Kanzler B, Foreman R, Labosky P, Mallo M: BMP signaling is essential for development of skeletogenic 
and neurogenic cranial neural crest. Development 2000, 1104:1095–1104. 
7. Sauka-Spengler T, Bronner-Fraser M: A gene regulatory network orchestrates neural crest formation. Nat 
Rev Mol Cell Biol 2008, 9:557–68. 
8. Gammill LS: Genomic analysis of neural crest induction. Development 2002, 129:5731–5741. 
9. Marchant L, Linker C, Ruiz P, Mayor R: The inductive properties of mesoderm suggest that the neural 
crest cells are specified by a BMP gradient. Dev Biol 1998, 198:319–329. 
10. Bonstein L, Elias S, Frank D: Paraxial-Fated Mesoderm Is Required for Neural Crest Induction in 
Xenopus Embryos. Dev Biol 1998, 193:156–168. 
11. Endo Y, Osumi N, Wakamatsu Y: Bimodal functions of Notch-mediated signaling are involved in neural 
crest formation during avian ectoderm development. Development 2002, 129:863–873. 
12. Kléber M, Lee H-Y, Wurdak H, Buchstaller J, Riccomagno MM, Ittner LM, Suter U, Epstein DJ, Sommer L: 
Neural crest stem cell maintenance by combinatorial Wnt and BMP signaling. J Cell Biol 2005, 169:309–20. 
13. Theveneau E, Mayor R: Neural crest delamination and migration: from epithelium-to-mesenchyme 
transition to collective cell migration. Dev Biol 2012, 366:34–54. 
14. Dottori M, Gross M, Labosky P, Goulding M: The winged-helix transcription factor Foxd3 suppresses 
interneuron differentiation and promotes neural crest cell fate. Development 2001, 128:4127–4138. 
15. Goulding M, Chalepakis G, Deutsch U, Erselius J, Gruss P: Pax-3, a novel murine DNA binding protein 
expressed during early neurogenesis. EMBO J 1991, 10:1135–1147. 
16. Lobjois V, Benazeraf B, Bertrand N, Medevielle F, Pituello F: Specific regulation of cyclins D1 and D2 by 
FGF and Shh signaling coordinates cell cycle progression, patterning, and differentiation during early 
steps of spinal cord development. Dev Biol 2004, 273:195–209. 
17. Hong C-S, Saint-Jeannet J-P: Sox proteins and neural crest development. Semin Cell Dev Biol 2005, 
16:694–703. 
18. Cheung M, Briscoe J: Neural crest development is regulated by the transcription factor Sox9. 
Development 2003, 130:5681–93. 
19. Mollaaghababa R, Pavan WJ: The importance of having your SOX on: role of SOX10 in the development 
of neural crest-derived melanocytes and glia. Oncogene 2003, 22:3024–34. 
References 
111 
20. Kuriyama S, Mayor R: Molecular analysis of neural crest migration. Philos Trans R Soc Lond B Biol Sci 
2008, 363:1349–62. 
21. Cheung M, Chaboissier M-C, Mynett A, Hirst E, Schedl A, Briscoe J: The transcriptional control of trunk 
neural crest induction, survival, and delamination. Dev Cell 2005, 8:179–92. 
22. DeLuca S, Gerhart J, Cochran E, Simak E, Blitz J, Mattiacci-Paessler M, Knudsen K, George-Weinstein M: 
Hepatocyte growth factor/scatter factor promotes a switch from E-to N-cadherin in chick embryo epiblast 
cells. Exp Cell Res 1999, 251:3–15. 
23. Cano A, Pérez-Moreno M, Rodrigo I, Locascio A, Blanco M, del Barrio M, Portillo F, Nieto M: The 
transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin 
expression. Nat Cell Biol 2000, 2:76–83. 
24. Carl T, Dufton C, Hanken J, Klymkowsky M: Inhibition of Neural Crest Migration in Xenopus Using 
Antisense Slug RNA. Dev Biol 1999, 213:101–115. 
25. LaBonne C, Bronner-Fraser M: Snail-related transcriptional repressors are required in Xenopus for both 
the induction of the neural crest and its subsequent migration. Dev Biol 2000, 221:195–205. 
26. Nieto M, Sargent M, Wilkinson D, Cooke J: Control of cell behavior during vertebrate development by 
Slug, a zinc finger gene. Science (80- ) 1994, 264:835–839. 
27. Barrio M del, Nieto M: Overexpression of Snail family members highlights their ability to promote chick 
neural crest formation. Development 2002, 129:1583–1593. 
28. Rickmann M: The migration of neural crest cells and the growth of motor axons through the rostral half 
of the chick somite. J Embryol Exp Morphol 1985, 455:437–455. 
29. Lumsden A, Keynes R: Segmental patterns of neuronal development in the chick hindbrain. Nature 
1989. 
30. Schilling TF, Kimmel CB: Segment and cell type lineage restrictions during pharyngeal arch 
development in the zebrafish embryo. Development 1994, 494:483–494. 
31. Kulesa PM, Fraser SE: Segmentation of the vertebrate hindbrain : a time-lapse analysis. Int J Dev Biol 
1998, 392:385–392. 
32. Farlie P, Kerr R, Thomas P: A paraxial exclusion zone creates patterned cranial neural crest cell 
outgrowth adjacent to rhombomeres 3 and 5. Dev Biol 1999, 84:70–84. 
33. Sechrist J, Serbedzija G, Scherson T: Segmental migration of the hindbrain neural crest does not arise 
from its segmental generation. Development 1993, 703:691–703. 
34. Birgbauer E, Sechrist J: Rhombomeric origin and rostrocaudal reassortment of neural crest cells 
revealed by intravital microscopy. Development 1995, 945:935–945. 
35. Krull C, Collazo A, Fraser S, Bronner-Fraser M: Segmental migration of trunk neural crest: time-lapse 
analysis reveals a role for PNA-binding molecules. Development 1995, 3743:3733–3743. 
36. Sommer L: Generation of melanocytes from neural crest cells. Pigment Cell Melanoma Res 2011, 
24:411–21. 
37. Ernfors P: Cellular origin and developmental mechanisms during the formation of skin melanocytes. 
Exp Cell Res 2010, 316:1397–407. 
38. Adameyko I, Lallemend F, Aquino JB, Pereira J a, Topilko P, Müller T, Fritz N, Beljajeva A, Mochii M, Liste I, 
Usoskin D, Suter U, Birchmeier C, Ernfors P: Schwann cell precursors from nerve innervation are a cellular 
origin of melanocytes in skin. Cell 2009, 139:366–79. 
References 
112 
39. Camp E, Lardelli M: Tyrosinase gene expression in zebrafish embryos. Dev Genes Evol 2001, 211:150–
153. 
40. Dupin E, Real C, Glavieux-Pardanaud C, Vaigot P, Le Douarin N: Reversal of developmental restrictions 
in neural crest lineages: transition from Schwann cells to glial-melanocytic precursors in vitro. PNAS 
2003, 100:5229–5233. 
41. Dupin E, Sommer L: Neural crest progenitors and stem cells: from early development to adulthood. Dev 
Biol 2012, 366:83–95. 
42. Trainor P, Krumlauf R: Plasticity in mouse neural crest cells reveals a new patterning role for cranial 
mesoderm. Nat Cell Biol 2000, 2(February). 
43. Kulesa P, Ellies DL, Trainor P a: Comparative analysis of neural crest cell death, migration, and function 
during vertebrate embryogenesis. Dev Dyn 2004, 229:14–29. 
44. Krull CE: Segmental organization of neural crest migration. Mech Dev 2001, 105:37–45. 
45. Graham A, Begbie J, McGonnell I: Significance of the cranial neural crest. Dev Dyn 2004, 229:5–13. 
46. Lin JY, Fisher DE: Melanocyte biology and skin pigmentation. Nature 2007, 445:843–50. 
47. Wehrle-Haller B, Weston J: Soluble and cell-bound forms of steel factor activity play distinct roles in 
melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development 
1995, 742:731–742. 
48. Nishimura E, Yoshida H: Regulation of E-and P-cadherin expression correlated with melanocyte 
migration and diversification. Dev Biol 1999, 215:155–166. 
49. Jouneau A, Yu Y-Q, Pasdar M, Larue L: Plasticity of cadherin–catenin expression in the melanocyte 
lineage. Pigment Cell Res 2000:260–272. 
50. Nakagawa S, Takeichi M: Neural crest emigration from the neural tube depends on regulated cadherin 
expression. Development 1998, 2971:2963–2971. 
51. Nakagawa S, Takeichi M: Neural crest cell-cell adhesion controlled by sequential and subpopulation-
specific expression of novel cadherins. Development 1995, 1332:1321–1332. 
52. Hornyak T, Hayes D, Chiu L, Ziff E: Transcription factors in melanocyte development: distinct roles for 
Pax-3 and Mitf. Mech Dev 2001, 101:47–59. 
53. Thomas AJ, Erickson C a: The making of a melanocyte: the specification of melanoblasts from the 
neural crest. Pigment Cell Melanoma Res 2008, 21:598–610. 
54. Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, Le Caignec C, Wegner M, Goossens M: 
Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet 
2000, 9:1907–17. 
55. Potterf S, Furumura M, Dunn K, Arnheiter H, Pavan WJ: Transcription factor hierarchy in Waardenburg 
syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet 2000, 107:1–6. 
56. Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D: Pigmentation PAX-ways: the role of Pax3 in 
melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res 2008, 
21:627–45. 
57. Fenby BT, Fotaki V, Mason JO: Pax3 regulates Wnt1 expression via a conserved binding site in the 5’ 
proximal promoter. Biochim Biophys Acta 2008, 1779:115–21. 
58. Stolt CC, Lommes P, Hillgärtner S, Wegner M: The transcription factor Sox5 modulates Sox10 function 
during melanocyte development. Nucleic Acids Res 2008, 36:5427–40. 
References 
113 
59. Kos R, Reedy M, Johnson R, Erickson C: The winged-helix transcription factor FoxD3 is important for 
establishing the neural crest lineage and repressing melanogenesis in avian embryos. Development 2001, 
128:1467–1479. 
60. Thomas AJ, Erickson C a: FOXD3 regulates the lineage switch between neural crest-derived glial cells 
and pigment cells by repressing MITF through a non-canonical mechanism. Development 2009, 136:1849–
58. 
61. Lahav R, Dupin E, Lecoin L, Glavieux C, Champeval D, Ziller C, Le Douarin N: Endothelin 3 selectively 
promotes survival and proliferation of neural crest-derived glial and melanocytic precursors in vitro. 
PNAS 1998, 95:14214–14219. 
62. Dupin E, Glavieux C, Vaigot P, Le Douarin N: Endothelin 3 induces the reversion of melanocytes to glia 
through a neural crest-derived glial-melanocytic progenitor. PNAS 2000, 97:7882–7887. 
63. Opdecamp K, Kos L, Arnheiter H, Pavan W: Endothelin signaling in the development of neural crest-
derived melanocytes. Biochem cell Biol 1998, 76:1093–1099. 
64. Pla P, Alberti C, Solov’eva O, Pasdar M, Kunisada T, Larue L: Ednrb2 orients cell migration towards the 
dorsolateral neural crest pathway and promotes melanocyte differentiation. Pigment Cell Res 2005, 
18:181–7. 
65. Shin M, Levorse J, Ingram R, Tilghman S: The temporal requirement for endothelin receptor-B signalling 
during neural crest development. Nature 1999, 402:496–501. 
66. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, Era T, Sakakura T, Nishikawa S-
I: In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of 
c-kit-dependency during melanocyte development. EMBO J 1991, 10:2111–2118. 
67. Yoshida H, Kunisada T, Kusakabe M, Nishikawa S, Nishikawa S-I: Distinct stages of melanocyte 
differentiation revealed by anlaysis of nonuniform pigmentation patterns. Development 1996, 122:1207–
1214. 
68. Larue L, Kumasaka M, Goding CR: Beta-Catenin in the Melanocyte Lineage. Pigment cell Res 2003, 
16:312–317. 
69. Dunn K, Williams B, Li Y, Pavan WJ: Neural crest-directed gene transfer demonstrates Wnt1 role in 
melanocyte expansion and differentiation during mouse development. PNAS 2000, 97:10050–10055. 
70. Jin EJ, Erickson C a, Takada S, Burrus LW: Wnt and BMP signaling govern lineage segregation of 
melanocytes in the avian embryo. Dev Biol 2001, 233:22–37. 
71. Dorsky R, Moon R, Raible D: Control of neural crest cell fate by the Wnt signalling pathway. Nature 
1998, 396:370–373. 
72. Takeda K: Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-
3a. J Biol Chem  2000, 275:14013–14016. 
73. Hari L, Brault V, Kléber M, Lee H-Y, Ille F, Leimeroth R, Paratore C, Suter U, Kemler R, Sommer L: Lineage-
specific requirements of beta-catenin in neural crest development. J Cell Biol 2002, 159:867–80. 
74. Hari L, Miescher I, Shakhova O, Suter U, Chin L, Taketo M, Richardson WD, Kessaris N, Sommer L: 
Temporal control of neural crest lineage generation by Wnt/β-catenin signaling. Development 2012, 
139:2107–17. 
75. Mackenzie M, Jordan S, Budd P, Jackson I: Activation of the receptor tyrosine kinase Kit is required for 
the proliferation of melanoblasts in the mouse embryo. Dev Biol 1997, 107:99–107. 
76. Opdecamp K, Nakayama a, Nguyen MT, Hodgkinson C a, Pavan WJ, Arnheiter H: Melanocyte development 
in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper 
transcription factor. Development 1997, 124:2377–86. 
References 
114 
77. Cimadamore F, Fishwick K, Giusto E, Gnedeva K, Cattarossi G, Miller A, Pluchino S, Brill LM, Bronner-Fraser 
M, Terskikh A V: Human ESC-derived neural crest model reveals a key role for SOX2 in sensory 
neurogenesis. Cell Stem Cell 2011, 8:538–51. 
78. Lee G, Chambers SM, Tomishima MJ, Studer L: Derivation of neural crest cells from human pluripotent 
stem cells. Nat Protoc 2010, 5:688–701. 
79. Bosserhoff AK, Ellmann L, Kuphal S: Melanoblasts in culture as an in vitro system to determine 
molecular changes in melanoma. Exp Dermatol 2011, 20:435–40. 
80. Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard JH, Sturm R a: 
Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth 
factor-2, stem cell factor, and endothelin-3. J Invest Dermatol 2003, 121:1150–9. 
81. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell 2006, 126:663–76. 
82. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, 
Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. PLoS One 
2011, 6:e16182. 
83. Mica Y, Lee G, Chambers SM, Tomishima MJ, Studer L: Modeling neural crest induction, melanocyte 
specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs. Cell Rep 
2013, 3:1140–52. 
84. Koster MI, Roop DR: Mechanisms regulating epithelial stratification. Annu Rev Cell Dev Biol 2007, 23:93–
113. 
85. Arnheiter H, Hou L, Nguyen M-TT, Bismuth K, Csermely T, Murakami H, Skuntz S, Liu W, Bharti K: MITF: A 
matter of life and death for developing melanocytes. In From melanocytes to melanoma: The progression to 
malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 2006:27–49. 
86. Feige E, Poling LL, Fisher DE: MITF: Critical regulator of the melanocyte lineage. In From melanocytes to 
melanoma: The progression to malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 
2006:51–79. 
87. Lister J, Robertson C, Lepage T, Johnson S, Raible D: Nacre encodes a zebrafish microphthalmia-related 
protein that regulates neural-crest-derived pigment cell fate. Development 1999, 126:3757–3767. 
88. Rees JL: Genetics of hair and skin color. Annu Rev Genet 2003, 37:67–90. 
89. Mountjoy K, Robbins L, Mortrud M, Cone R: The cloning of a family of genes that encode the 
melanocortin receptors. Science (80- ) 1992, 257:16–19. 
90. Wahlbuhl M, Reiprich S, Vogl MR, Bösl MR, Wegner M: Transcription factor Sox10 orchestrates activity 
of a neural crest-specific enhancer in the vicinity of its gene. Nucleic Acids Res 2012, 40:88–101. 
91. Lee M, Goodall J, Verastegui C, Ballotti R, Goding CR: Direct regulation of the Microphthalmia promoter 
by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. 
J Biol Chem  2000, 275:37978–83. 
92. Lang D, Epstein JA: Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET 
enhancer. Hum Mol Genet 2003, 12:937–945. 
93. Kim K, Hay E: Direct evidence for a role of the beta-catcnin/LEF-1 signaling pathway in induction of 
EMT. Cell Biol Int 2000, 26:463–476. 
94. Eastman Q, Grosschedl R: Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr 
Opin Cell Biol 1999:233–240. 
References 
115 
95. Hemesath T, Price E, Takemoto C, Badalian T, Fisher D: MAP kinase links the transcription factor 
Microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391:298–301. 
96. Wu M, Hemesath T, Takemoto C, Horstmann M, Wells A, Price E, Fisher D, Fisher D: c-Kit triggers dual 
phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes 
Dev 2000, 14:301–312. 
97. Takeda K, Takemoto C, Kobayashi I, Watanabe a, Nobukuni Y, Fisher DE, Tachibana M: Ser298 of MITF, a 
mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. 
Hum Mol Genet 2000, 9:125–32. 
98. Fang D, Tsuji Y, Setaluri V: Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of 
the activity of melanocyte transcription factor, MITF. Nucleic Acids Res 2002, 30:3096–3106. 
99. Gaggioli C, Busca R, Abbe P, Ortonne J, Ballotti R: Microphthalmia-Associated Transcription Factor 
(MITF) is Required but is Not Sufficient to Induce the Expression of Melanogenic Genes. Pigment cell Res 
2003, 16:374–382. 
100. Yamaguchi Y, Hearing VJ: Melanocyte distribution and function in human skin: Effects of ultraviolet 
radiation. In From melanocytes to melanoma: The progression to malignancy. Edited by Hearing VJ, Leong SP. 
Totowa, NJ: Humana Press; 2006:101–115. 
101. Wegner M: Melanocytes and the Transcription Factor Sox10. In From melanocytes to melanoma: The 
progression to malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 2006:71–80. 
102. Jiao Z, Mollaaghababa R, Pavan WJ, Antonellis A, Green ED, Hornyak TJ: Direct interaction of Sox10 
with the promoter of murine Dopachrome Tautomerase (Dct) and synergistic activation of Dct expression 
with Mitf. Pigment Cell Res 2004, 17:352–62. 
103. Ludwig A, Rehberg S, Wegner M: Melanocyte-specific expression of dopachrome tautomerase is 
dependent on synergistic gene activation by the Sox10 and Mitf transcription factors. FEBS Lett 2004, 
556:236–244. 
104. Uong A, Zon LI: Melanocytes in development and cancer. J Cell Physiol 2010, 222:38–41. 
105. Abdel-malek ZA, Kadekaro A: Human Cutaneous Pigmentation. In From melanocytes to melanoma: The 
progression to malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 2006:81–100. 
106. Miller AJ, Mihm MC: Melanoma. NEJM 2006, 355:51–65. 
107. Mason H: The structure of melanins. In Pigment Cell Biology. Edited by Gordon M. New York,NY: 
Academic; 1959:563–582. 
108. Mason H: The structure of melanin. In Advances in Biology of Skin VIII The Pigmentary System . Edited by 
Montagna W, Hu F. Oxford UK: Pergamon; 1967:293–312. 
109. Raper H, Wormall A: The tyrosinase-tyrosine reaction. Biochem J 1923. 
110. Riley P: The evolution of melanogenesis. In Melanin: Its Role in Human Photoprotection. Edited by Zeise 
L, Chedekel M, TB F. Overland Park, Kansas: Valdenmar; 1995:1–10. 
111. Sekulic A: Malignant Melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 
2008, 83:825–846. 
112. Land E, Riley P: Spontaneous redox reactions of dopaquinone and the balance between the 
eumelanic and phaeomelanic pathways. Pigment Cell Res 2000(V):273–277. 
113. Slominski A, Tobin D, Shibahara S, Wortsman J: Melanin pigmentation in mammalian skin and its 
hormonal regulation. Physiol Rev 2004:1155–1228. 
References 
116 
114. Wu X, Hammer III JA: Making sense of melanosome dynamics in mouse melanocytes. Pigment Cell 
Res 2000:241–247. 
115. Wu X, Wang F, Rao K, Sellers J, Hammer III JA: Rab27a is an essential component of melanosome 
receptor for myosin Va. Mol Biol Cell 2002, 13:1735–1749. 
116. Rogers S, Gelfand V: Membrane trafficking, organelle transport, and the cytoskeleton. Curr Opin Cell 
Biol 2000:57–62. 
117. Sakuraba K, Hayashi N, Kawashima M, Imokawa G: Down-Regulated PAR-2 is Associated in Part with 
Interrupted Melanosome Transfer in Pigmented Basal Cell Epithelioma. Pigment Cell Res 2004, 17:371–378. 
118. Babiarz-Magee L, Chen N, Seiberg M, Lin C: The Expression and Activation of Protease-Activated 
Receptor-2 Correlate with Skin Color. Pigment Cell Res 2004:241–251. 
119. Kippenberger S, Bernd A, Bereiter-Hahn J, Ramirez-Bosca A, Kaufmann R: The mechanism of 
melanocyte dendrite formation: the impact of differentiating keratinocytes. Pigment Cell Res 1998:34–37. 
120. Lei TC, Virador VM, Vieira WD, Hearing VJ: A melanocyte-keratinocyte coculture model to assess 
regulators of pigmentation in vitro. Anal Biochem  2002, 305:260–8. 
121. Scott G, Cassidy L: Rac1 mediates dendrite formation in response to melanocyte stimulating hormone 
and ultraviolet light in a murine melanoma model. J Invest Dermatol 1998, 111:243–50. 
122. Scott G: Rac and rho: the story behind melanocyte dendrite formation. Pigment cell Res 2002:322–330. 
123. Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature 2007, 
445:851–7. 
124. Melanoma Skin Cancer [http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-
cancer-key-statistics] 
125. Cummins DL, Cummins JM, Pantle H, Silverman M a, Leonard AL, Chanmugam A: Cutaneous malignant 
melanoma. Mayo Clin Proc 2006, 81:500–7. 
126. Clark Jr W, Goldman L, Mastrangelo M: Human Malignant Melanoma. New York (USA): Grune & Stratton; 
1979. 
127. Takata M, Murata H, Saida T: Molecular pathogenesis of malignant melanoma: a different perspective 
from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 2010, 23:64–71. 
128. Bennett DC: Familial melanoma genes, melanocyte immortalization, and melanoma initiation. In From 
melanocytes to melanoma: The progression to malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana 
Press; 2006:183–196. 
129. Hocker TL, Singh MK, Tsao H: Melanoma genetics and therapeutic approaches in the 21st century: 
moving from the benchside to the bedside. J Invest Dermatol 2008, 128:2575–95. 
130. Tsao H, Chin L, Garraway L a, Fisher DE: Melanoma: from mutations to medicine. Genes Dev 2012, 
26:1131–55. 
131. Quelle D, Zindy F, Ashmun R, Sherr C: Alternative reading frames of the INK4a tumor suppressor gene 
encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993–1000. 
132. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, 
Ascierto P a: Main roads to melanoma. J Transl Med 2009, 7:86. 
133. Eliason M, Hansen C, Hart M, Porter-Gill P, Chen W, Sturm R, Bowen G, Florell S, Harris R, Cannon-
Albright L, Swinyer L, Leachman S: Multiple primary melanomas in a CDKN2A mutation carrier exposed to 
ionizing radiation. Arch Dermatol Res 1979, 143:1409–1412. 
References 
117 
134. Fang S, Jensen J, Ludwig R, Vausden K, Weissmann A: Mdm2 Is a RING Finger-dependent Ubiquitin 
Protein Ligase for Itself and p53. J Biol Chem  2000, 275:8945–8951. 
135. Bergami P, Bhoumik A, Ronai Z: Altered signal transduction in melanoma. In From melanocytes to 
melanoma: The progression to malignancy. Edited by Hearing V, Leong S. Totowa, NJ: Humana Press; 
2006:119–147. 
136. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, 
Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science 2013, 
339:959–61. 
137. Huang FW, Hodis E, Xu MJ, Kryukov G V, Chin L, Garraway L a: Highly recurrent TERT promoter 
mutations in human melanoma. Science 2013, 339:957–9. 
138. Stadler S, Weina K, Gebhardt C, Utikal J: New therapeutic options for advanced non-resectable 
malignant melanoma. Adv Med Sci 2014. 
139. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, 
Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, 
Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson B a, Cooper C, Shipley J, et 
al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949–54. 
140. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-duvaz D, Springer CJ, Marais R: 
V599E B-RAF is an Oncogene in Melanocytes. Cancer Res 2004, 64:2338–2342. 
141. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, 
Traver D, Fletcher CDM, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI: BRAF mutations are 
sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005, 
15:249–54. 
142. Wellbrock C: Melanoma development and pigment cell transformation. In From melanocytes to 
melanoma: The progression to malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 
2006:247–263. 
143. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre G Della, Perrone F, Luoni C, 
Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti M a, Rodolfo M: BRAF alterations are 
associated with complex mutational profiles in malignant melanoma. Oncogene 2004, 23:5968–77. 
144. Tsao H, Zhang X, Fowlkes K, Haluska F: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in 
cutaneous melanoma cell lines. Cancer Res 2000, 60:1800–1804. 
145. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner II JW, DePinho R: 
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997, 11:2822–2834. 
146. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F: Metastasizing melanoma 
formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 
2005, 65:4005–4012. 
147. Garraway L a, Widlund HR, Rubin M a, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner D a, 
Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR: 
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant 
melanoma. Nature 2005, 436:117–22. 
148. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R: Oncogenic BRAF regulates 
melanoma proliferation through the lineage specific factor MITF. PLoS One 2008, 3:e2734. 
149. Widlund HR, Fisher DE: Microphthalamia-associated transcription factor: a critical regulator of 
pigment cell development and survival. Oncogene 2003, 22:3035–41. 
150. Hodis E, Watson IR, Kryukov G V, Arold ST, Imielinski M, Theurillat J-P, Nickerson E, Auclair D, Li L, Place 
C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, 
References 
118 
Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, 
Ladbury JE, et al.: A landscape of driver mutations in melanoma. Cell 2012, 150:251–63. 
151. Parker SCJ, Gartner J, Cardenas-Navia I, Wei X, Ozel Abaan H, Ajay SS, Hansen NF, Song L, Bhanot UK, 
Killian JK, Gindin Y, Walker RL, Meltzer PS, Mullikin JC, Furey TS, Crawford GE, Rosenberg S a, Samuels Y, 
Margulies EH: Mutational signatures of de-differentiation in functional non-coding regions of melanoma 
genomes. PLoS Genet 2012, 8:e1002871. 
152. Dahl C, Guldberg P: The genome and epigenome of malignant melanoma. APMIS 2007, 115:1161–76. 
153. Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte 
G: Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009, 34:1481–
1489. 
154. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher J a, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, 
Weber JS, Gajewski TF, O’Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio F a, Ernstoff MS, 
Heinrich MC, Beadling C, Zukotynski K a, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE: Imatinib for 
melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically 
sun-damaged skin. J Clin Oncol 2013, 31:3182–90. 
155. Tsao H, Zhang X, Benoit E, Haluska F: Identification of PTEN/MMAC1 alterations in uncultured 
melanomas and melanoma cell lines. Oncogene 1998, 16:3397–3402. 
156. Bastian BC: Understanding the progression of melanocytic neoplasia using genomic analysis: from 
fields to cancer. Oncogene 2003, 22:3081–6. 
157. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates 
C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, 
Garraway L a: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 
2008, 68:664–73. 
158. Dhillon a S, Hagan S, Rath O, Kolch W: MAP kinase signalling pathways in cancer. Oncogene 2007, 
26:3279–90. 
159. Cargnello M, Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated 
protein kinases. Microbiol Mol Biol Rev 2011, 75:50–83. 
160. Kortylewski M, Heinrich P, Kauffmann M, Bohm M, Mackiewicz A, Behrmann I: Mitogen-activated protein 
kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 2001, 357:297–303. 
161. Huntington JT, Shields JM, Der CJ, Wyatt C a, Benbow U, Slingluff CL, Brinckerhoff CE: Overexpression of 
collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF 
mutation and fibroblast growth factor signaling. J Biol Chem  2004, 279:33168–76. 
162. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M: Activation of p59(Fyn) leads to 
melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. 
J Biol Chem  2002, 277:6443–54. 
163. Maehama T, Dixon JE: The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second 
Messenger, Phosphatidylinositol 3,4,5-Trisphosphate. J Biol Chem  1998, 273:13375–13378. 
164. Vazquez F, Sellers WR: The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-
kinase signaling. Biochim Biophys Acta Rev Cancer 2000, 1470:21–35. 
165. Kim D, Kim S, Koh H, Yoon S, Chung A, Cho K, Chung J: Akt/PKB promotes cancer cell invasion via 
increased motility and metalloproteinase production. FASEB J 2001, 15:1953–1962. 
166. Massagué J: TGFbeta in Cancer. Cell 2008, 134:215–30. 
167. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. 
Nature 2003, 425:577–584. 
References 
119 
168. Javelaud D, Alexaki V-I, Mauviel A: Transforming growth factor-beta in cutaneous melanoma. Pigment 
Cell Melanoma Res 2008, 21:123–32. 
169. Poser I, Rothhammer T, Dooley S, Wiskirchen R, Bosserhoff AK: Characterization of Sno expression in 
malignant melanoma. Int J Oncol 2005, 26:1411–1417. 
170. Reed J, Bales E, Xu W, Okan N, Bandyopadhyay D, Medrano E: Cytoplasmic Localization of the 
Oncogenic Protein Ski in Human Cutaneous Melanomas in Vivo Functional Implications for Transforming 
Growth Factor β Signaling. Cancer Res 2001, 250:8074–8078. 
171. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, 
Guise T a, Mauviel A: Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. 
Cancer Res 2007, 67:2317–24. 
172. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M: Transforming 
Growth Factor-B1 Increases Survival of Human Melanoma through Stroma Remodeling. Cancer Res 2001, 
61:8306–8316. 
173. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim P, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton E, 
Wong B, Tsang G, West B, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis D, Schlessinger J, Su 
F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin P, Lee R, Grippo J, et al.: Clinical efficacy of a RAF 
inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596–599. 
174. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, 
Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’day S, Sosman J, Kirkwood J, Eggermont 
AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee R, Flaherty K, McArthur G: Improved survival with 
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507–2516. 
175. Ascierto P a, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob 
J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long G V, Martin A-M, Mazumdar J, Goodman VL, 
Trefzer U: Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with 
metastatic melanoma. J Clin Oncol 2013, 31:3205–11. 
176. Hallmeyer S, Hamid O, Sorof T, Mun Y, Liu S, Abhyankar S: Phase II study of vemurafenib in patients 
with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF 
mutations othen than V600E. J Clin Oncol 2014, 32:suppl; abstract 9075. 
177. Orouji E, Ziegler B, Umansky V, Gebhardt C, Utikal J: Leukocyte count restoration under dabrafenib 
treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. Med 2014, 93:e161. 
178. Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker a, Zelba H, Weide B, Trefzer U, 
Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, 
Paschen a, Hillen U, Schadendorf D: Differential influence of vemurafenib and dabrafenib on patients’ 
lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 2014, 25:747–53. 
179. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, 
Ibrahim N, Kudchadkar R, Burris H a, Falchook G, Algazi A, Lewis K, Long G V, Puzanov I, Lebowitz P, Singh A, 
Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined BRAF and MEK inhibition in 
melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694–703. 
180. Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, Wise A, Suter S, Ciria C, Love S, Collins L, 
Middleton MR: PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with 
paclitaxel. Eur J Cancer 2014. 
181. Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, 
Cantarini M, Spencer S, Middleton MR: Selumetinib plus dacarbazine versus placebo plus dacarbazine as 
first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. 
Lancet Oncol 2013, 14:733–40. 
182. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, 
Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R: MEK162 for patients with advanced 
References 
120 
melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 
Lancet Oncol 2013, 14:249–56. 
183. Kwong L, Costello J, Liu H, Genovese G, Jiang S, Jeong J, Bender R, Collines J, Chin L: Oncogenic NRAS 
signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18:1503–1510. 
184. Sosman J, Kittaneh M, Lolkema M, Postow M, Schwartz G, Franklin C: A phase IB/2 study of LEE011 in 
combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging 
clinical activity. J Clin Oncol 2014, 32:suppl; abstract 9009. 
185. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, 
Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S: Phase II, open-label, single-arm trial of imatinib mesylate 
in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011, 
29:2904–9. 
186. Zimmer L, Callahan M, Postow M, Romano E, Ramaiya N, Bluth M: Open-label, multicenter, single-arm 
phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with 
cutaneous melanoma and rare subgroups. J Clin Oncol 2014, 32:suppl; abstract 9031. 
187. Eggermont AM, Chiarion-Sileni V, Grobb J, Dummer R, Wolchok J, Schmidt H: Ipilimumab versus placebo 
after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 
phase III trial. J Clin Oncol 2014, 32:suppl; abstract LBA9008. 
188. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, 
Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, 
Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor 
responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134–44. 
189. Hodi F, Sznol M, Kluger HM, McDermott D, Carvajal RD, Lawrence DP: Long-term survival of ipilimumab-
naive patients (pts) with advanced melanoma (MEL) treated with nivolumabb (anti-PD-1, BMS-936558, 
ONO-4538) in a phase I trial. J Clin Oncol 2014, 32:suppl; abstract 9002. 
190. Chen K, Gottesman M: How Melanoma Cells Evade Chemotherapy: Role of Transporter-Dependent 
and -Independent Resistance Mechanisms. In From melanocytes to melanoma: The progression to 
malignancy. Edited by Hearing VJ, Leong S. Totowa, NJ: Humana Press; 2006. 
191. Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H, Chen Z, Lee M, Attar N, Sazegar H, Chodon T, Nelson 
S, McArthur G, Sosman J, Ribas A, Lo R: Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK 
or N-RAS upregulation. Nature 2010, 468:973–977. 
192. Kaplan FM, Mastrangelo MJ, Aplin AE: The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J 
Invest Dermatol 2010, 130:2669–71. 
193. Aplin AE, Kaplan FM, Shao Y: Mechanisms of resistance to RAF inhibitors in melanoma. J Invest 
Dermatol 2011, 131:1817–20. 
194. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Cogdill P, Barretina J, Caponigro G, Hieronymus H, 
Ryan R, Yang X, Alkan O, Kim S, Harris JL, Christopher J, Flaherty KT, Dummer R, Weber B, Sellers WR, 
Schlegel R, Wargo J, Hahn W, Garraway LA: COT/MAP3K8 drives resistance to RAF inhibition through MAP 
kinase pathway reactivation. Nature 2011, 468:968–972. 
195. Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems 
SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels 
LF a, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AMM, Bernards R: Reversible and adaptive 
resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118–22. 
196. Long G V, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, 
Grob J-J, Sileni V, Lebbe C, Mandala M, Milward M, Arance A, Bondarenko I, Haanen J, Jansson J, Utikal J, 
Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini D, Irani 
J, Casey M, et al.: Combined BRAF and MEK inhibition versus BRAF Inhibition Alone in Melanoma. N Engl 
J Med 2014, 371:1877–1888. 
References 
121 
197. Larkin J, Ascierto P, Dreno B, Atkinson V, Linszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, 
Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak M, Chang I, Choong N, Hack S, McArthur G, Ribas 
A: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371:1867–
1876. 
198. Robert C, Karaszewska B, Schanchter J, Rutkowski P, Mackiewicz A, Strojakovski D, Lichinistser M, 
Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long 
G, Flaherty K, Nathan P, Ribas A, Martin A, Sun P, Crist W, Legos J, Rubin S, Little S, Schadendorf D: Improved 
overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015, 372:30–39. 
199. Ribas A, Hodi F, Callahan M, Konto C, Wolchok JD: Hepatotoxicity with combination of vemurafenib and 
ipilimumab. N Engl J Med 2013, 368:1365–1360. 
200. Ward A, Touw I, Yoshimura A: The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 
2000, 95:19–30. 
201. Kudchadkar RR, Gibney G, Dorman D, Merek S, Ramadan H, Chen A: A phase IB study of ipilimumab 
with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol 2014, 
32:suppl; abstract 9098. 
202. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646–74. 
203. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, 
Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E: A Switch in the Expression 
of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma. Cancer Cell 2013, 24:466–80. 
204. Mani S a, Guo W, Liao M, Eaton EN, Zhou AY, Brooks M, Reinhard F, Zhang CC, Campbell LL, Polyak K, 
Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of 
stem cells. Cell 2009, 133:704–715. 
205. Ocaña OH, Córcoles R, Fabra Á, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto 
MA: Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer 
Prrx1. Cancer Cell 2012, 22:709–724. 
206. Tsai J, Donaher J, Murphy D, Chau S, Yang J: Spatiotemporal Regulation of Epithelial-Mesenchymal 
Transition is Essential for Squamous Cell Carcinoma Metastasis. Cancer Cell 2012, 22:726–736. 
207. Gupta PB, Kuperwasser C, Brunet J-P, Ramaswamy S, Kuo W-L, Gray JW, Naber SP, Weinberg R a: The 
melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 
2005, 37:1047–54. 
208. Maguire L, Thomas A, Goldstein A: Tumors of the neural crest: Common themes in development and 
cancer. Dev Dyn 2014:1–12. 
209. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan N V, Seftor E a, Seftor REB, Hendrix MJC: 
Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic 
microenvironment. PNAS 2006, 103:3752–7. 
210. Kulesa PM, Morrison J a, Bailey CM: The neural crest and cancer: a developmental spin on melanoma. 
Cells Tissues Organs 2013, 198:12–21. 
211. Oppitz M, Busch C, Schriek G, Metzger M, Just L, Drews U: Non-malignant migration of B16 mouse 
melanoma cells in the neural crest and invasive growth in the eye cup of the chick embyro. Melanoma Res 
2007, 17:17–30. 
212. Bailey C, Kulesa P: Dynamic Interactions between Cancer Cells and the Embryonic Microenvironment 
Regulate Cell Invasion and Reveal EphB6 as a Metastasis Suppressor. Mol Cancer Res 2014, 12:1303–
1313. 
213. Bailey C: Melanoma revives an embryonic migration program to promote plasticity and invasion. 
Pigment Cell Melanoma Res 2012, 25:573–583. 
References 
122 
214. Hoek K, Schlegel N, Brafford P, Sucker A, Ugurel S, Kumar R, Weber B, Nathanson K, Phillips D, M H, 
Schadendorf D, Dummer R: Metastatic potential of melanomas defined by specific gene expression profiles 
with no BRAF signature. Pigment Cell Res 2006, 19:290–302. 
215. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, Hemmi S, Dummer R: In vivo 
switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008, 68:650–6. 
216. O’Connell MMP, Marchbank K, Webster MMR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu 
Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TCT, Indig FEF, Flaherty KKT, Wargo J a J, Frederick DDT, Cooper 
Z a, Nair S, Amaravadi RRK, Schuchter LML, Karakousis GGC, Xu W, Xu X, Weeraratna ATA, Ling L, Herlyn M, 
Villanueva J, et al.: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the 
tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013, 3:1378–1393. 
217. Larribere L, Utikal J: De- and re-differentiation of the melanocytic lineage. Eur J Cell Biol 2014, 93:30–5. 
218. Brabletz T: To differentiate or not--routes towards metastasis. Nat Rev Cancer 2012, 12:425–36. 
219. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R: Mitf is 
the key molecular switch between mouse or human melanoma initiating cells and their differentiated 
progeny. Oncogene 2011, 30:2307–2318. 
220. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-
Badge R, Goodfellow PN: A gene from the human sex-determining region encodes a protein with homology 
to a conserved DNA-binding motif. Nature 1990, 346:240–244. 
221. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Muensterberg A, Vivian N, Goodfellow P, Lovell-
Badge R: A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a 
novel family of embryonically expressed genes. Nature 1990, 346:245–250. 
222. Waugh RJ, T PP: Evolution of the Sry Genes. Mol Biol Evol 1997, 14:49–55. 
223. Guth SIE, Wegner M: Having it both ways: Sox protein function between conservation and innovation. 
Cell Mol Life Sci 2008, 65:3000–18. 
224. Wegner M: From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999, 27:1409–20. 
225. Sarkar A, Hochedlinger K: The sox family of transcription factors: versatile regulators of stem and 
progenitor cell fate. Cell Stem Cell 2013, 12:15–30. 
226. Coriat a M, Muller U, Harry JL, Uwanogho D, Sharpe PT: PCR amplification of SRY-related gene 
sequences reveals evolutionary conservation of the SRY-box motif. Genome Res 1993, 2:218–222. 
227. Laudet V, Stehelin D, Clevers H: Ancestry and diversity of the HMG box superfamily. Nucleic Acids Res 
1993, 21:2493–501. 
228. Uwanogho D, Rex M, Cartwright EJ, Pearl G, Healy C, Scotting PJ, Sharpe PT: Embryonic expression of 
the chicken Sox2, Sox3 and Sox11 genes suggests an interactive role in neuronal development. Mech Dev 
1995, 49:23–36. 
229. Nagai K: Molecular evolution of Sry and Sox gene. Gene 2001, 270:161–9. 
230. Pevny LH, Lovell-Badge R: Sox genes find their feet. Curr Opin Genet Dev 1997, 7:338–44. 
231. Kamachi Y, Uchikawa M, Kondoh H: Pairing SOX off: with partners in the regulation of embryonic 
development. Trends Genet 2000, 9525:2–7. 
232. Harley VR, Lovell-Badge R, Goodfellow PN: Definition of a consensus DNA binding site for SRY. Nucleic 
Acids Res 1994, 22:1500–1. 
References 
123 
233. Wetering M Van De, Clevers H: Sequence-specific interaction of the HMG box proteins Watson -Crick 
double helix. EMBO J 1992, 1:3039–3044. 
234. Schepers GE, Teasdale RD, Koopman P: Twenty Pairs of Sox : Extent, Homology, and Nomenclature of 
Mouse and Human Sox Transcription Factor Gene Families. Dev Cell 2002, 3:167–170. 
235. Bowles J, Schepers G, Koopman P: Phylogeny of the SOX family of developmental transcription 
factors based on sequence and structural indicators. Dev Biol 2000, 227:239–55. 
236. Stevanovic M, Zuffardi O, Collignon J, Lovell-Badge R, Goodfellow P: The cDNA sequence and 
chromosomal location of the human SOX2 gene. Mamm Genome 1994, 5:640–2. 
237. Van Houte LP a., Chuprina VP, van der Wetering M, Boelens R, Kaptein R, Clevers H: Solution Structure 
of the Sequence-specific HMG Box of the Lymphocyte Transcriptional Activator Sox-4. J Biol Chem  1995, 
270:30516–30524. 
238. Werner MH, Huth JR, Gronenborn a M, Clore GM: Molecular basis of human 46X,Y sex reversal 
revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 1995, 
81:705–14. 
239. Ferrari S, Harley V: SRY, like HMG1, recognizes sharp angles in DNA. EMBO J 1992, 1:4497–4506. 
240. Connor F, Cary PD, Read CM, Preston NS, Driscoll PC, Denny P, Crane-Robinson C, Ashworth a: DNA 
binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5. Nucleic Acids 
Res 1994, 22:3339–46. 
241. Pontiggia a, Rimini R, Harley VR, Goodfellow PN, Lovell-Badge R, Bianchi ME: Sex-reversing mutations 
affect the architecture of SRY-DNA complexes. EMBO J 1994, 13:6115–24. 
242. Scaffidi P, Bianchi ME: Spatially precise DNA bending is an essential activity of the Sox2 transcription 
factor. J Biol Chem  2001, 276:47296–302. 
243. Grosschedl R, Giese K, Pagel J: HMG domain proteins: architectural elements in the assembly of 
nucleoprotein structures. Trends Genet 1994, 10:94–100. 
244. Kondoh H, Kamachi Y: SOX-partner code for cell specification: Regulatory target selection and 
underlying molecular mechanisms. Int J Biochem Cell Biol 2010, 42:391–9. 
245. Kamachi Y, Uchikawa M: Pax6 and SOX2 form a co-DNA-binding partner complex that regulates 
initiation of lens development. Genes Dev 2001:1272–1286. 
246. Wissmüller S, Kosian T, Wolf M, Finzsch M, Wegner M, Wißmüller S, Kosian T, Wolf M, Finzsch M, Wegner 
M: The high-mobility-group domain of Sox proteins interacts with DNA-binding domains of many 
transcription factors. Nucleic Acids Res 2006, 34:1735–44. 
247. Geiss-Friedlander R, Melchior F: Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007, 
8:947–56. 
248. Taylor KM, Labonne C: SoxE factors function equivalently during neural crest and inner ear 
development and their activity is regulated by SUMOylation. Dev Cell 2005, 9:593–603. 
249. Gill G: SUMO changes Sox for developmental diversity. Mol Cell 2005, 20:495–6. 
250. Girard M, Goossens M: Sumoylation of the SOX10 transcription factor regulates its transcriptional 
activity. FEBS Lett 2006, 580:1635–41. 
251. Lee P-C, Taylor-Jaffe KM, Nordin KM, Prasad MS, Lander RM, LaBonne C: SUMOylated SoxE factors 
recruit Grg4 and function as transcriptional repressors in the neural crest. J Cell Biol 2012, 198:799–813. 
References 
124 
252. Tsuruzoe S, Ishihara K, Uchimura Y, Watanabe S, Sekita Y, Aoto T, Saitoh H, Yuasa Y, Niwa H, Kawasuji 
M, Baba H, Nakao M: Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem Biophys Res 
Commun 2006, 351:920–6. 
253. Avilion A a, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R: Multipotent cell lineages in early 
mouse development depend on SOX2 function. Genes Dev 2003, 17:126–40. 
254. Orkin SH, Hochedlinger K: Chromatin connections to pluripotency and cellular reprogramming. Cell 
2011, 145:835–50. 
255. Thomson M, Liu SJ, Zou L-N, Smith Z, Meissner A, Ramanathan S: Pluripotency factors in embryonic 
stem cells regulate differentiation into germ layers. Cell 2011, 145:875–89. 
256. Cox JL, Mallanna SK, Luo X, Rizzino A: Sox2 uses multiple domains to associate with proteins present 
in Sox2-protein complexes. PLoS One 2010, 5:e15486. 
257. Fang X, Yoon J-G, Li L, Tsai YS, Zheng S, Hood L, Goodlett DR, Foltz G, Lin B: Landscape of the SOX2 
protein-protein interactome. Proteomics 2011, 11:921–34. 
258. Williamson K a, Hever AM, Rainger J, Rogers RC, Magee A, Fiedler Z, Keng WT, Sharkey FH, McGill N, Hill 
CJ, Schneider A, Messina M, Turnpenny PD, Fantes J a, van Heyningen V, FitzPatrick DR: Mutations in SOX2 
cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006, 15:1413–22. 
259. Kelberman D, Rizzoti K, Avilion A, Bitner-glindzicz M, Cianfarani S, Collins J, Chong WK, Kirk JMW, 
Achermann JC, Ross R, Carmignac D, Lovell-badge R, Robinson ICAF, Dattani MT: Mutations within 
SOX2/SOX2 are associated with abnormalities in the hypothalamo- pituitary-gonadal axis in mice and 
humans. J Clin Invest 2006, 116:2442–2455. 
260. Hagstrom S a, Pauer GJT, Reid J, Simpson E, Crowe S, Maumenee IH, Traboulsi EI: SOX2 mutation 
causes anophthalmia, hearing loss, and brain anomalies. Am J Med Genet A 2005, 138A:95–8. 
261. Engelen E, Akinci U, Bryne JC, Hou J, Gontan C, Moen M, Szumska D, Kockx C, van Ijcken W, Dekkers 
DHW, Demmers J, Rijkers E-J, Bhattacharya S, Philipsen S, Pevny LH, Grosveld FG, Rottier RJ, Lenhard B, Poot 
R a: Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet 2011, 
43:607–11. 
262. Weina K, Utikal J: SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med 
2014, 3:19. 
263. Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, Liu F, Que J, Lan X: The multiple roles for Sox2 in stem 
cell maintenance and tumorigenesis. Cell Signal 2013, 25:1264–71. 
264. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla 
E, du Manoir S: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung 
squamous cell carcinomas. PLoS One 2010, 5:e8960. 
265. Albertson DG: Gene amplification in cancer. Trends Genet 2006, 22:447–455. 
266. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks 
I, Ramos AH, Woo MS, Weir B a, Getz G, Beroukhim R, O’Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, 
Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, 
Giordano TJ, et al.: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell 
carcinomas. Nat Genet 2009, 41:1238–42. 
267. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D: SOX2 expression and amplification in gliomas 
and glioma cell lines. Cancer Genomics Proteomics 2011, 8:139–47. 
268. Freier K, Knoepfle K, Flechtenmacher C, Pungs S, Devens F, Toedt G, Hofele C, Joos S, Lichter P, 
Radlwimmer B: Recurrent copy number gain of transcription factor SOX2 and corresponding high protein 
expression in oral squamous cell carcinoma. Genes Chromosomes Cancer 2010, 49:9–16. 
References 
125 
269. Hussenet T, Manoir S du: SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along 
carcinogenesis. Cell Cycle 2010, 9:1480–1486. 
270. Schröck A, Göke F, Wagner P, Bode M, Franzen A, Braun M, Huss S, Agaimy A, Ihrler S, Menon R, Kirsten 
R, Kristiansen G, Bootz F, Lengerke C, Perner S: Sex determining region Y-box 2 (SOX2) amplification is an 
independent indicator of disease recurrence in sinonasal cancer. PLoS One 2013, 8:e59201. 
271. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower E a, Guan Y, Shin J, 
Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman 
V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, 
Illei PB, et al.: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-
cell lung cancer. Nat Genet 2012, 44:1111–6. 
272. Hütz K, Mejías-Luque R, Farkasova K, Ogris M, Krebs S, Anton M, Vieth M, Schüller U, Schneider MR, Blum 
H, Wagner E, Jung A, Gerhard M, Farsakova K: The stem cell factor SOX2 regulates the tumorigenic 
potential in human gastric cancer cells. Carcinogenesis 2014, 35:942–50. 
273. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de 
Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate 
M a, Lang FF, Fueyo J, Gomez-Manzano C: Genetic and epigenetic modifications of Sox2 contribute to the 
invasive phenotype of malignant gliomas. PLoS One 2011, 6:e26740. 
274. Yang N, Hui L, Wang Y, Yang H, Jiang X: SOX2 promotes the migration and invasion of laryngeal 
cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep 2014, 31:2651–9. 
275. Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, Liu Y, Li X, Xiang R, Li N: SOX2 promotes tumor metastasis by 
stimulating epithelial-to-mesenchymal transition via regulation of WNT/β-catenin signal network. Cancer 
Lett 2013, 336:379–89. 
276. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K: Autocrine TGF-beta signaling 
maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 
2009, 5:504–14. 
277. Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM, Suo Z: Oct3/4 and Sox2 are 
significantly associated with an unfavorable clinical outcome in human esophageal squamous cell 
carcinoma. Anticancer Res 2009, 29:1233–41. 
278. Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di 
Tommaso L, Infante M, Alloisio M, Roncalli M, Scorsetti M, Jänne P a, Santoro A, Varella-Garcia M: Increased 
SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung 
Cancer and Predicts Improved Survival in Early Stage Disease. PLoS One 2014, 9:e95303. 
279. Harris ML, Baxter LL, Loftus SK, Pavan WJ: Sox proteins in melanocyte development and melanoma. 
Pigment Cell Melanoma Res 2010, 23:496–513. 
280. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, Claudinot S, Okoniewski M, Beermann F, 
Mihic-Probst D, Moch H, Wegner M, Dummer R, Barrandon Y, Cinelli P, Sommer L: Sox10 promotes the 
formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012, 14:882–90. 
281. Laga AC, Lai C-Y, Zhan Q, Huang SJ, Velazquez EF, Yang Q, Hsu M-Y, Murphy GF: Expression of the 
embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell 
biology. Am J Pathol 2010, 176:903–13. 
282. Laga A, Zhan Q, Weishaupt C: SOX2 and nestin expression in human melanoma: an 
immunohistochemical and experimental study. Exp Dermatol 2011, 20:339–345. 
283. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B: Embryonic stem cell markers 
expression in cancers. Biochem Biophys Res Commun 2009, 383:157–62. 
284. Girouard SD, Laga AC, Mihm MC, Scolyer R a, Thompson JF, Zhan Q, Widlund HR, Lee C-W, Murphy GF: 
SOX2 contributes to melanoma cell invasion. Lab Invest 2012, 92:362–70. 
References 
126 
285. Cimadamore F, Shah M, Amador-Arjona A, Navarro-Peran E, Chen C, Huang C-T, Terskikh A V: SOX2 
modulates levels of MITF in normal human melanocytes, and melanoma lines in vitro. Pigment Cell 
Melanoma Res 2012, 25:533–6. 
286. Santini R, Pietrobono S, Pandolfi S, Montagnani V, D’Amico M, Penachioni JY, Vinci MC, Borgognoni L, 
Stecca B: SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene 
2014(August 2013):1–12. 
287. Hsu M, Rovinsky S, Penmatcha S, Herlyn M, Murihead D: Bone morphogenetic proteins in melanoma: 
angel or devil?. Cancer Metastasis Rev 2005, 24:251–263. 
288. Webster MR, Weeraratna AT: A Wnt-er migration: the confusing role of β-catenin in melanoma 
metastasis. Sci Signal 2013, 6:pe11. 
289. Weeraratna A: A Wnt-er wonderland—the complexity of Wnt signaling in melanoma. Cancer Metastasis 
Rev 2005, 24:237–250. 
290. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJP, Tahan SR: Increased expression of stem cell 
markers in malignant melanoma. Mod Pathol 2007, 20:102–7. 
291. Sommer C a, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G: Induced pluripotent 
stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2008, 27:543–9. 
292. Nissan X, Larribere L, Saidani M, Hurbain I, Delevoye C, Feteira J, Lemaitre G, Peschanski M, Baldeschi C: 
Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis. 
PNAS 2011, 108:14861–14866. 
293. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to 
multiple testing. J R Stat Soc 1995, 57:289–300. 
294. Raposo G, Marks MS: Melanosomes--dark organelles enlighten endosomal membrane transport. Nat 
Rev Mol Cell Biol 2007, 8:786–97. 
295. Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler 
Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G: CEACAM1 promotes melanoma cell growth 
through Sox-2. Neoplasia 2014, 16:451–60. 
296. Hothorn T, Lausen B: On the exact distribution of maximally selected rank statistics. Comput Stat Data 
Anal 2003, 43:121–137. 
297. Adameyko I, Lallemend F, Furlan A, Zinin N, Aranda S, Kitambi SS, Blanchart A, Favaro R, Nicolis S, Lübke 
M, Müller T, Birchmeier C, Suter U, Zaitoun I, Takahashi Y, Ernfors P: Sox2 and Mitf cross-regulatory 
interactions consolidate progenitor and melanocyte lineages in the cranial neural crest. Development 
2012, 139:397–410. 
298. Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B: JASPAR: an open-access database for 
eukaryotic transcription factor binding profiles. Nucleic Acids Res 2004, 32(Database issue):D91–4. 
299. Hallsson JH, Haflidadóttir BS, Schepsky A, Arnheiter H, Steingrímsson E: Evolutionary sequence 
comparison of the Mitf gene reveals novel conserved domains. Pigment Cell Res 2007, 20:185–200. 
300. Khaled M, Larribere L, Bille K, Ortonne J-P, Ballotti R, Bertolotto C: Microphthalmia associated 
transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol 2003, 
121:831–836. 
301. Gabbert H, Wagner R, Moll R, Gerharz CD: Tumor dedifferentiation: an important step in tumor 
invasion. Clin Exp Metastasis 1985, 3:257–79. 
302. Benito JM, López M, Lozano S, Ballesteros C, González-Lahoz J, Soriano V: Hydroxyurea exerts an anti-
proliferative effect on T cells but has no direct impact on cellular activation. Clin Exp Immunol 2007, 
149:171–177. 
References 
127 
303. De la Rocha AMA, Sampron N, Alonso MM, Matheu A: Role of SOX family of transcription factors in 
central nervous system tumors. Am J Cancer Res 2014, 4:312–24. 
304. Hoek KS, Goding CR: Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell 
Melanoma Res 2010, 23:746–59. 
305. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a 
potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like 
kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65–74. 
306. Callahan J, Burgress J, Fornwald J, Gaster L, Harling J, Harrington F, Heer J, Kwon C, Lehr R, Mathur A, 
Olson B, Weinstock J, Laping N: Indentification of novel inhibitors of the transforming growth factor B1 
(TGFB1) type 1 receptor (ALK5). J Med Chem  2002, 45:999–1001. 
307. Weinberg RA: The Biology of Cancer. 2006:864. 
308. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF mutations arise early during 
melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003, 9:6483–
6488. 
309. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin A, Zeuthen J, Bartek J: The p16-cyclin D/Cdk4-pRb 
pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996, 56:5475–
5483. 
310. Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003, 
3:559–570. 
311. Guenou H, Nissan X, Larcher F, Feteira J, Lemaitre G, Saidani M, Del Rio M, Barrault CC, Bernard F-X, 
Peschanski M, Baldeschi C, Waksman G: Human embryonic stem-cell derivatives for full reconstruction of 
the pluristratified epidermis: a preclinical study. Lancet 2009, 374:1745–53. 
312. Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N, Khaner H, Smith Y, 
Wiser O, Gropp M, Cohen M a, Even-Ram S, Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B: 
Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. 
Cell Stem Cell 2009, 5:396–408. 
313. Wakamatsu Y, Endo Y, Osumi N, Weston J a: Multiple roles of Sox2, an HMG-box transcription factor in 
avian neural crest development. Dev Dyn 2004, 229:74–86. 
314. Bondurand N, Kobetz A, Pingault V, Lemort N, Encha-Razavi F, Couly G, Goerich DE, Wegner M, Abitbol M, 
Goossens M: Expression of the SOX10 gene during human development. FEBS Lett 1998, 432:168–172. 
315. Cheng Y-C, Cheung M, Abu-Elmagd MM, Orme A, Scotting PJ: Chick Sox10, a transcription factor 
expressed in both early neural crest cells and central nervous system. Dev Brain Res 2000, 121:233–241. 
316. Paratore C, Goerich DE, Suter U, Wegner M, Sommer L: Survival and glial fate acquisition of neural 
crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic 
combinatorial signaling. Development 2001, 128:3949–61. 
317. Bernhardt M, Galach M, Novak D, Utikal J: Mediators of induced pluripotency and their role in cancer 
cells – current scientific knowledge and future perspectives. Biotechnol J 2012, 7:810–821. 
318. Chen P-L, Chen W-S, Li J, Lind AC, Lu D: Diagnostic utility of neural stem and progenitor cell markers 
nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas. Mod Pathol 2013, 
26:44–53. 
319. Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner 
C, Moch H, Kakies C, Protzel C, Bauer J, Soltermann A, Fend F, Staebler A, Lengerke C, Perner S: SOX2 
amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol 2011, 
42:1078–88. 
References 
128 
320. Kraehn G, Utikal J, Udart M: Extra c-myc oncogene copies in high risk cutaneous malignant melanoma 
and melanoma metastases. Br J Cancer 2001, 84:72–79. 
321. Bishop R: Applications of fluorescence in situ hybridization (FISH) in detecting genetic aberrations of 
medical significance. Biosci Horizons 2010, 3:85–95. 
322. Kemper K, de Goeje PL, Peeper DS, van Amerongen R: Phenotype Switching: Tumor Cell Plasticity as a 
Resistance Mechanism and Target for Therapy. Cancer Res 2014:5937–5941. 
323. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, 
Tüting T: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. 
Nature 2012, 490:412–6. 
324. Talmadge JE, Fidler IJ: AACR centennial series: The biology of cancer metastasis: Historical 
perspective. Cancer Res 2010, 70:5649–5669. 
325. Fidler I: The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev 
Cancer 2003, 3:453–458. 
326. Han X, Fang X, Lou X, Hua D, Ding W, Foltz G, Hood L, Yuan Y, Lin B: Silencing SOX2 induced 
mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC 
patients. PLoS One 2012, 7:e41335. 
327. Herreros-Villanueva M, Zhang J-S, Koenig a, Abel E V, Smyrk TC, Bamlet WR, de Narvajas a a-M, Gomez 
TS, Simeone DM, Bujanda L, Billadeau DD: SOX2 promotes dedifferentiation and imparts stem cell-like 
features to pancreatic cancer cells. Oncogenesis 2013, 2:e61. 
328. Derynck R, Akhurst R: Differentiation plasticity regulated by TGF-beta family proteins in development 
and disease. Nat Cell Biol 2007, 9:1000–1004. 
329. Thiery JP: Epithelial–mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 
2003, 15:740–746. 
330. Aomatsu K, Arao T, Sugioka K, Matsumoto K, Tamura D, Kudo K, Kaneda H, Tanaka K, Fujita Y, 
Shimomura Y, Nishio K: TGF-β induces sustained upregulation of SNAI1 and SNAI2 through Smad and 
non-Smad pathways in a human corneal epithelial cell line. Invest Ophthalmol Vis Sci 2011, 52:2437–43. 
331. Javelaud D, Delmas V, Möller M, Sextius P, André J, Menashi S, Larue L, Mauviel A: Stable 
overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. 
Oncogene 2005, 24:7624–7629. 
332. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen C-R, Manova-Todorova K, Blasberg R, Gerald WL, 
Massagué J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl 
Acad Sci U S A 2005, 102:13909–13914. 
333. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise T a.: 
TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases 
development. J Clin Invest 1999, 103:197–206. 
334. Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A: The SOX2-interactome in brain 
cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One 
2013, 8:e62857. 
335. Boyer LA, Lee TI, Cole MF, Johnstone SE, Stuart S., Zucker JP, Guenther MG, Kumar RM, Murray HL, 
Jenner RG, Gifford DK, Melton D a, Jaenisch R, Young RA: Core Transcriptional Regulatory Circuitry in 
Human Embryonic Stem Cells. Cell 2005, 122:947–956. 
336. Kerppola T: Design and implementation of bimolecular fluorescence complementation (BiFC) assays 
for the visualization of protein interactions in living cells. Nat Protoc 2006, 1:1278–1286. 
References 
129 
337. Papanayotou C, Mey A, Birot A-M, Saka Y, Boast S, Smith JC, Samarut J, Stern CD: A mechanism 
regulating the onset of Sox2 expression in the embryonic neural plate. PLoS Biol 2008, 6:e2. 
338. Lang D, Lu MM, Huang L, Engleka K a, Zhang M, Chu EY, Lipner S, Skoultchi A, Millar SE, Epstein J a: 
Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 2005, 433:884–7. 
339. Medic S, Ziman M: PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and 
melanomas). PLoS One 2010, 5:e9977. 
340. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. 
Cell 2008, 132:567–582. 
341. Rolland T, Taşan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, Yi S, Lemmens I, Fontanillo C, Mosca 
R, Kamburov A, Ghiassian SD, Yang X, Ghamsari L, Balcha D, Begg BE, Braun P, Brehme M, Broly MP, 
Carvunis A-R, Convery-Zupan D, Corominas R, Coulombe-Huntington J, Dann E, Dreze M, Dricot A, Fan C, 
Franzosa E, Gebreab F, Gutierrez BJ, et al.: A Proteome-Scale Map of the Human Interactome Network. Cell 
2014, 159:1212–1226. 
342. Forghanifard MM, Ardalan Khales S, Javdani-Mallak A, Rad A, Farshchian M, Abbaszadegan MR: 
Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal 
squamous cell carcinoma. Med Oncol 2014, 31:922. 
343. Favaro R, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E, Pisati F, Ottolenghi S, Foti M, 
Finocchiaro G, Malatesta P, Nicolis SK: Sox2 is required to maintain cancer stem cells in a mouse model of 
high-grade oligodendroglioma. Cancer Res 2014, 74:1833–44. 
344. Polakova I, Duskova M, Smahel M: Antitumor DNA vaccination against the Sox2 transcription factor. 
Int J Oncol 2014, 45:139–46. 
345. Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis P a: SOX2 
expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of 
a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer 2014. 
346. Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, 
Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN: Directed phenotype 
switching as an effective antimelanoma strategy. Cancer Cell 2013, 24:105–19. 
347. Connolly EC, Freimuth J, Akhurst RJ: Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012, 
8:964–78. 
348. De Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. PNAS 1978, 
75:4001–4005. 
349. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB: New class of transforming growth factors 
potentiated by epidermal growth factor: isolation from non-neoplastic tissues. PNAS 1981, 78:5339–5343. 
350. Seydin S, Thompson A, Bentz H: Cartilage-inducing factor-A: Apparent identity to transforming growth 
factor-beta. J Biol Chem  1986, 261:5693–5695. 
351. Moses H, Branum E, Proper J, Robinson R: Transforming growth factor production by chemically 
transformed cells. Cancer Res 1981, 41:2842–2848. 
352. Siegel P, Massagué J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat 
Rev Cancer 2003, 3:807–820. 
353. Muraoka-Cook R, Kurokawa H, Koh Y, Forbes J, Roebuck L, Barcellos-Hoff M, Moody S, Chodosh L, 
Arteaga C: Conditional overexpression of active transforming growth factor β1 in vivo accelerates 
metastases of transgenic mammary tumors. Cancer Res 2004, 64:9002–9011. 
References 
130 
354. Muraoka R, Dumont N, Ritter C, Dugger T, Brantley D, Chen J, Easterly E, Roebuck L, Ryan S, Gotwals P, 
Koteliansky V, Arteaga C: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and 
metastases. J clini 2002, 109:1533–1536. 
355. Bennett C, Swayze E: RNA Targeting Therapeutics: Molecular Mechanisms of Antisense 
Oligonucleotides as a Therapeutic Platform. Annu Rev Pharmacol Toxicol 2010, 50:259–293. 
356. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ: Outgrowth of 
drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase 
inhibition with LY2109761. Cancer Res 2011, 71:2339–49. 
357. Mead A, Wong T, Cordeiro M, Anderson I, Khaw P: Evaluation of Anti-TGF- 2 Antibody as a New 
Postoperative Anti-scarring Agent in Glaucoma Surgery. Invest Ophthalmol Vis Sci 2003, 44:3394–3401. 
358. Thompson JE, Vaughan TJ, Williams AJ, Wilton J, Johnson KS, Bacon L, Green JA, Field R, Ruddock S, 
Martins M, Pope AR, Tempest PR, Jackson RH: A fully human antibody neutralising biologically active 
human TGFβ2 for use in therapy. J Immunol Methods 1999, 227:17–29. 
359. Cordeiro M, Gay J, Khaw P: Human anti-transforming growth factor-β2 antibody: a new glaucoma anti-
scarring agent. Invest Ophthalmol Vis Sci 1999, 40:2225–2234. 
360. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky J a, Lawrence DP: 
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) 
monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 
2014, 9:e90353. 
361. Mohammad KS, Javelaud D, Fournier PGJ, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, 
Mauviel A, Guise T a: TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of 
melanoma bone metastases. Cancer Res 2011, 71:175–84. 
362. Li R, Chung a C, Dong Y, Yang W, Zhong X, Lan HY: The microRNA miR-433 promotes renal fibrosis by 
amplifying the TGF-beta/Smad3-Azin1 pathway. Kidney Int 2013, 84:1129–1144. 
363. Bertolotto C, Abbe P, Bille K: Different cis-acting elements are involved in the regulation of TRP1 and 
TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of. Mol Cell Biol 1998, 
18:694–702.  
 
 
 
  
Acknowledgements 
131 
10 Acknowledgements 
I would first like to thank Prof. Dr. Jochen Utikal for giving me this opportunity to perform my 
doctoral thesis work in his laboratory. Also, I would like to thank Prof. Dr. Viktor Umansky 
for being my first supervisor and giving me guidance throughout this doctoral work. 
Moreover, I want to thank my TAC members, Dr. Martin Sprick and Prof. Dr. Stefan 
Schneider, for their critical input throughout the duration of my work. Additionally, I want to 
thank Dr. Christoffer Gebhardt for his input into my project and assistance with the tissue 
microarray. 
This work would have not been possible without the constant help, laughs and dedication 
from the Utikal lab. I would especially like to thank Daniel Roth for his great technician work 
and undeniable joy he brought to the lab every day. The scientific help from Maike Reith, 
Mathias Bernhardt and Kathrin Taranidis allowed me to push my project further than I ever 
imagined. Also, I want to thank Dr. Lionel Larribere for his supervision in the beginning of 
my PhD that laid the groundwork for my doctoral work. I would like to give a special thank 
you to Dr. Daniel Novak for providing me with tons of cloning assistance and daily doses of 
happiness.  
This work would not have been possible without the constant support from my dear friend, 
Dr. Janet Lei. She taught me how to survive the entire PhD process and was with me every 
step of the way. The endless lessons we both learned and taught each other in parallel 
guided us to thesis completion. 
I want to give a special thanks to Nathalie Knappe for everything she has done for me over 
the past three years. She has put continual effort in my doctoral work from the beginning and 
has helped me through the good and the bad days. Thank you for giving me strength when I 
needed it, input when it was lacking and most of all laughs and joy every single day.  
This doctoral work was supported constantly by my loving friends and family here and back 
home: I want to thank my parents for their support and love sent across the ocean and also 
Uli and Ilona Zellmann for their overwhelming amounts of reassurance and love. Also, I 
want thank my best friend Emily Sanfilippo for her continual jokes, encouragement and 
optimism. Lastly, I want to thank Asma Fikri for her endless motivation and kindness no 
matter where we meet in the world.  
Finally, I would like to thank Jan who has been my biggest supporter from the beginning. 
Thank you for believing in me when I didn’t, listening to me when no one else would and 
always making me smile when I thought I couldn’t. I would not have been able to do this 
without you and for that I am forever grateful. 
